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ethanol-fed rats. The concentrations of dopamine and DOPAC
were increased two-fold in the frontal cortex, ventral
pallidum, and ventral tegmental area, while the levels were
unchanged in the striatum and globus pallidus. In the
substantia nigra, the dopamine level was decreased and the
level of DOPAC was increased. Although the dopamine level in
the nucleus accumbens was normal, the level of DOPAC was
decreased. An analysis of the G proteins, Gs and Go,
demonstrated minimal, if any, changes in either protein
content and mRNA levels in brain regions analyzed.
Concerning the inhibitory G proteins, the mRNA levels of Gi 1
and Gi 2 were unchanged in all brain regions examined.
However, there was a trend towards an increase in the mRNA
levels of Gi 3 in all regions except the substantia nigra. In
the frontal cortex and striatum, no change was seen in
dopamine-sensitive adenylate cyclase activity. Adenylate
cyclase activity in the presence of dopamine was
significantly increased in the nucleus accumbens of
ethanol-treated rats. In comparison to control animals,
there was an increase in cholesterol levels, while the
levels of phospholipids were not significantly different.
There was also an increase in the ratio of cholesterol to
phospholipid.
These results suggest a selective ethanol effect on
several components of the dopamine system in three-month-old
Fisher 344 rats following one month of ethanol consumption.
iv

Those brain regions which are affected are associated with
the mesolimbic dopamine pathway. The changes in the brain
regions of the mesolimbic dopamine pathway are notable
because this pathway is involved with the reward circuitry.
It is possible that the mesolimbic dopamine neurons may be
involved in the rewarding effects of ethanol. Alterations in
the brain regions associated with this pathway may
contribute to the reinforcing effects of ethanol.

v
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CHAPTER I

INTRODUCTION
Alcohol abuse and alcoholism represent serious health
problems in the United States. Approximately 18 million
adults exhibit some form of alcoholism, alcohol dependence,
or alcohol abuse, and at least 3 out of 100 deaths in the
United States can be attributed to alcohol use (Van Natta et
al. 1984).
Several central nervous system (CNS) neurotransmitter
systems appear to be sensitive to alcohol administration.
These include: the gamma-aminobutyric acid (GABA) system,
the glutamate system, the dopamine system, the
norepinephrine system, and the serotonin system (Greenberg
et al. 1986; Valverius et al. 1987; Celetano et al. 1988;
Murphy et al. 1988; Lovinger et al. 1989). Of particular
interest is the dopaminergic system because both the
nigrostriatal dopamine pathway, which is involved with
locomotor activity (Fibiger et al. 1974; Liljequist et al.
1981), and the mesolimbic dopamine pathway, which has been
implicated in the reinforcement of several drugs of abuse
(Lyness et al. 1979; Bozarth and Wise 1981; Matthews and
German 1984), appear to be sensitive to the effects

1

2

of ethanol exposure (Mereu et al. 1984; Gessa et al. 1985).
In light of ethanol's reported actions on locomotor activity
and its apparent reinforcing properties, it was hypothesized
that chronic ethanol consumption either alters the ability
of the dopamine signal to effect cellular changes through
signal transduction or alters the level of dopamine itself.
In order to test this hypothesis, I proposed to examine the
effects of chronic ethanol consumption on the level of
dopamine as well as several membrane components involved
with signal transduction. This is important because of the
substantial amount of evidence for ethanol's effects on CNS
membranes and membrane components (Hoffman and Tabakof f
1979; Rabin and Molinoff 1981; Sun and Sun 1985; Hruska
1988).The membrane components which were examined include
the 01 and 02 dopamine receptors, the stimulatory (s) and
inhibitory (i) guanine nucleotide binding proteins
(G proteins) which couple the dopamine receptors to
adenylate cyclase, and the activity of dopamine-stimulated
and dopamine-inhibited adenylate cyclase. These components
were measured in brain regions which are associated either
with the nigrostriatal system or mesolimbic dopamine system.
Changes in the level of one or more of the membrane
components (receptors, G proteins, or adenylate cyclase
activity) could result in alterations in cellular activity.
Changes in dopamine or in these membrane components could
contribute to ethanol-induced changes in motor activity and

3

to the reinforcing effects of ethanol.

CHAPTER I I
LITERATURE REVIEW

The Dopaminergic System
In the central nervous system, dopamine has been
identified in several brain regions including the striatum,
the nucleus accumbens, and the cortex (Hokfelt et al. 1976;
Arliuson et al. 1984; Seguela et al. 1988). There are two
major dopaminergic pathways: the nigrostriatal pathway and
the mesolimbic dopamine pathway. The nigrostriatal pathway
originates in the substantia nigra which sends projections
to the striatum and collaterals to the globus pallidus
(Fibiger et al. 1974; Lindvall and Bjorkland 1979). This
pathway is a major component of the extrapyramidal motor
system (Fibiger et al. 1974). The mesolimbic dopamine
pathway consisting of projections from the ventral tegmental
area to the nucleus accumbens (Lindvall et al. 1978; Nauta
et al. 1978) is recognized as an important component of the
reward circuitry (Phillips and Fibiger 1978).
Dopamine, a catecholamine, is synthesized from its
amino acid precursor tyrosine by the action of the enzymes
tyrosine hydroxylase and aromatic amino acid decarboxylase
Tyrosine is converted to 3,4-dihydroxyphenylalanine (DOPA)
4

5

by the enzyme tyrosine hydroxylase. This enzyme is
stereospecific and requires molecular oxygen (02 }, ferrous
ion (Fe+ 2 ) , and the

cofactor tetrahydropteridine. It serves

as the rate limiting step in the biosynthesis of dopamine.
The second enzyme involved in catecholamine synthesis is
aromatic amino acid decarboxylase. This enzyme catalyzes the
conversion of DOPA to dopamine.
The major enzymes in metabolic degradation of the
catecholamines are monoamine oxidase (MAO} and catechol-0methyltransferase (COMT). Monoamine oxidase converts
catecholamines to their corresponding aldehydes. Dopamine is
converted to 3,4-dihydroxyphenylacetaldehyde. This aldehyde
intermediate is rapidly oxidized by the enzyme aldehyde
dehydrogenase. The aldehyde,
3,4-dihydroxyphenylacetaldehyde, is

converted to

3,4-dihydroxyphenylacetic acid (DOPAC) which in turn is
converted to homovanillic acid (HVA) by the enzyme
catechol-0-methyltransferase (Cooper et al. 1986).
There are two types of dopamine receptors (Kebabian and
Calne 1979}, originally defined by either an ability to
stimulate adenylate cyclase activity (the Dl receptor)
(Iversen 1975} or an inability to stimulate adenylate
cyclase activity (the D2 receptor). In addition to the
stimulation of adenylate cyclase, the Dl receptor may be
coupled to inositol phosphate production and calcium (Ca+2}
mobilization (Mahan et al. 1990). The 02 receptors are

6

characterized functionally by their ability to inhibit
adenylate cyclase activity (Enjalbert and Bockaert 1983).
The D2 receptor appears to couple selectively with the Gi2
subtype (Jones and Reed 1987) of the G proteins (Senogles et
al. 1990). Activation of 02 receptors also inhibits calcium
channels, increases potassium conduction, and may inhibit
accumulation of inositol phosphate (Simmonds and Strange
1985; Malgaroli et al. 1987; Lacey et al. 1987).
The Dl and 02 dopamine receptors exist in two forms: a
high

affinity state and a low affinity state with respect

to agonists (Sibley et al. 1982; Leff et al. 1985). The
state of these receptors is modulated by the guanine
nucleotide binding proteins (G proteins) which couple the
receptors to adenylate cyclase (Delean et al. 1982). The
binding of an agonist to the receptor promotes a
receptor-G protein interaction. The agonist is bound with
higher affinity to the receptor of the resulting ternary
complex (agonist-receptor-G protein)

(Boeynaems and Dumont

1975). When guanosine triphosphate (GTP) binds to this
complex, the receptor dissociates from the G protein and is
converted to the low affinity state. The GTP-G protein
complex is the active intermediate which interacts with
adenylate cyclase (Katada et al. 1984).
In order to study the dopamine receptors, a variety of
pharmacological ligands have been developed. Some examples
of the Dl agonists include SKF 38393 and SKF 82526 (Setler

7
et al. 1978;

Flaim et al. 1985). Examples of D2 agonists

include LY 141865, RU

24213, and propylnorapomorphine (NPA)

(Miller et al. 1976; Euvrard et al. 1980; Titus et al.
1983). Dopamine antagonists have also been developed. These
include the Dl antagonists SCH 23390 and SKF 83566 (Hyttel
1983; O'Boyle and Waddington 1984) and the D2 antagonists
spiperone, haloperidol, and YM 09151-2 (Hyttel 1978; Grewe
et al. 1982).
Antagonist binding exhibits different characteristics
than agonist binding. Combined use of agonist and antagonist
binding exhibits competition curves that can be resolved
into the high affinity component and the low affinity
component. Most agonists bind to a receptor population
representing the high affinity component. In the presence of
guanine nucleotides (i.e. GTP and
5'-guanylylimidodiphosphate), agonist/antagonist curves
represent a single affinity state similar to the low
affinity component. Guanine nucleotides bind to the
agonist-receptor-G protein complex resulting in the
conversion of the receptor to its low affinity state.
Agonist binding is decreased in the presence of guanine
nucleotides, whereas antagonist binding which measures both
the agonist high affinity component and the low affinity
component is not altered.

(Boeynaems and Dumont 1975;

Jacobs and Cuatrecasas 1976; Limbird 1981; Hess and Creese
1987). Antagonist and agonist binding assays can be used to

8

measure receptor conversion.
several different functions have been associated with
the dopamine Dl receptor; these functions may vary with the
tissue localization of the receptor. The prototype Dl
receptor is located in the parathyroid gland and mediates
the release of parathyroid hormone (Niznik et al. 1988).
Peripheral Dl receptors promote renal vasodilatory responses
(Kohli and Goldberg 1987) and appear to modulate gap
junction permeability in the retina (Lasater and Dowling
1985). In the central nervous system, Dl receptors may exert
a modulatory influence on the activity of the D2 receptor
(Clark and White 1987). Presynaptic Dl receptors are located
on GABAergic terminals in the substantia nigra, possibly
regulating the release of GABA (Filloux et al. 1987). During
development, central nervous system Dl receptor stimulation
may be involved with regulation of neuron growth and
differentiation (Lankford et al. 1988).
The neuronal Dl receptor is a glycoprotein (Niznik et
al.

1986). A polypeptide of apparent Mr=72,000/74,000

represents the major ligand binding subunit (Niznik et al.
1988). The polypeptide is sialylated and has terminal
mannose residues. However, the neuronal receptor and the
parathyroid receptor are differentially glycosylated. Upon
complete deglycosylation, the Dl receptor (neuronal and
parathyroid) is a single polypeptide Mr=46000. This
polypeptide probably represents the protein backbone of

9

central and peripheral Dl receptors (Jarvie et al. 1989;
Niznik et al. 1989).
Recently, four laboratories cloned a cDNA encoding the
Dl dopamine receptor coupled to the stimulation of adenylate
cyclase (Dearry et al. 1990; Monsma et al. 1990; Sunahara et
al. 1990; Zhou et al. 1990). A Dl clone was used to isolate
and characterize the gene encoding the human Dl dopamine
receptor. This gene is located on an intronless region of
the long arm of chromosome 5 and encodes a protein of 446
amino acids with a predicted molecular mass of 49,300. The
protein sequence of this receptor indicates the presence of
seven transmembrane segments which is characteristic of
G protein-coupled receptors (Dixon et al. 1986; Kubo et al
1986; Kobilka et al. 1987; Bonner et al. 1989). There are
several potential sites for post-translational modification
including a cysteine residue in the carboxy terminus that is
conserved in most G protein-coupled receptors and two
consensus sequences for cAMP-dependent protein kinase
phosphorylation. The cloning of the gene for a Dl dopamine
receptor will provide a valuable tool to study the
regulation and function of this receptor.
DARPP-32 (gopamine- and gdenosine 3 1 :5'-monophosphate~egulated

RhosphoRrotein; molecular weight:32 kD) is a

cytosolic protein enriched in dopaEinoceptive neurons of the
brain (Hemmings and Greengard 1986). Its distribution
correlates with the

distribution of the 01 receptors

10
coupled to adenylate cyclase (Schalling et al. 1990).
Dopamine increases the state of phosphorylation of OARPP-32.
upon phosphorylation, OARPP-32 is converted to a very potent
inhibitor of protein phosphatase-1 (Hemmings et al. 1984).
Protein phosphatase-1 dephosphorylates phosphoproteins that
are substrates for a variety of protein kinases. Thus, one
mechanism by which dopamine may modulate the phosphorylation
state of substrates is through the phosphorylation and
activation of OARPP-32 (Hemmings et al. 1989).
The 02 dopamine receptor is also associated with a
variety of functions. The prototype 02 receptor is located
in the anterior pituitary and inhibits prolactin release
(Weiner and Gangong 1978). Dopamine somatodendritic
autoreceptors appear to be of the 02 receptor subtype
(Lehmann et al. 1983; Brown et al. 1985). 02 receptors are
also localized to the terminals of the cholinergic
interneurons of the striatum. Stimulation of these 02
receptors leads to the decreased release of acetylcholine.
(Joyce and Marshall 1985, 1987; Stoof et al. 1987).
The 02 receptor is a glycoprotein and the major ligand
binding subunit is a polypeptide (Mr=94,000). This subunit
contains acetylglucosamine chains and terminal sialic acid
(Grigoriadis et al. 1988). After complete deglycosylation,
the binding subunit is a polypeptide (Mr=44,000). It is not
known whether this subunit represents the functional 02
receptor moiety (Jarvie et al. 1988).
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A full-length cONA clone of the rat 02 receptor has
been

isolated (Bunzow et al. 1988). This cDNA clone was

used to clone a human genomic fragment (ThD2Gl) which
contains the last coding exon of the D2 receptor gene. The
human 02 receptor is encoded by a gene located at the
q22-q23 junction of chromosome 11. The 02 gene locus
contains a frequent two allele Tagl RFLP (restriction
fragment length polymorphism)

(Grandy et al. 1989).

Two transcripts exist for the D2 receptor which differ
only by the presence of an 87-bp insert (Rao et al. 1990).
The 02 receptor is thought to be an integral membrane
protein of seven transmembrane spanning regions similar to
other G protein-coupled receptors (Lefkowitz and Caron
1988). The 87-nucleotide insert is within the region coding
for the third cytoplasmic loop. It is suggested the two
forms of the 02 receptor represent alternately spliced
transcripts. This hypothesis is consistent with the evidence
of intrans in the rat 02 receptor gene (Bunzow et al. 1988).
O'Malley and colleagues (1990) suggest there must be at
least two genes that produce 02 receptor subtypes designated
D2A and 02B. The 02A gene contains 8 exons and spans at
least 50 kb with exons 2-7 clustered in approximately 13 kb
of the genome. The 02A gene undergoes alternate RNA
processing within intron

s,

resulting in an insertion of 29

amino acids to the predicted 415 amino acid sequence of the
D2A protein. The authors suggest the presence of
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tissue-specific factors that control not only D2A gene
transcription but also alternate splicing of the pre-mRNA.
The dopamine Dl and D2 receptor sites are
differentially distributed throughout the brain. The
localization of these dopamine sites has been examined
utilizing receptor autoradiography and in situ hybridization
techniques (Boyson et al. 1986; Charuchinda et al. 1987;
Mansour et al. 1990). The Dl sites are located in the basal
ganglia, cortical regions, amygdala, and hippocampus and
high concentrations of D2 sites are confined primarily to
the olfactory bulb, basal ganglia, and pituitary. Lesion
studies have demonstrated that both receptor subtypes are
localized on presynaptic and postsynaptic membranes
(Porceddu et al. 1986; Joyce and Marshall 1987; Filloux et
al. 1987, 1988). In most brain regions, the 01 receptors,
found predominately in the low affinity state, are present
in greater density than the D2 receptors, found
predominately in the high affinity agonist state (Huff and
Molinoff 1984; Boyson et al. 1986; Richfield et al. 1989).
Guanine nucleotide-sensitive and -insensitive Dl and 02
receptors have been identified in several brain regions (De
Keyser et al. 1989). A regional heterogeneity

based on this

guanine nucleotide effect has been proposed. These unique
distributions of the Dl and 02 receptors suggest complex
interactions resulting in dopamine-mediated behaviors.
A complex functional interaction exists between the 01 and
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D2

receptors which is involved in the generation of some

motor behaviors. The 01 receptor exerts its greatest
behavioral effects when the D2 receptor is stimulated
simultaneously. (Barone et al. 1986). Braun (1986) has
suggested that 01 receptor activation provides a "tonic"
background which allows the "phasic" component of the D2
receptor to be effective. Stimulation of the 02 receptor can
initiate motor behavior optimally when there is a specific
level of 01 receptor activation. The Dl receptor may control
the

qualitative changes in D2 stimulated behaviors.
Dopamine has two general classes of behavioral action:

motor activation and reward-mediated learning (Beninger et
al. 1989; Miller et al. 1990; Wickens 1990). Dopamine
stimulates motor activity (Beninger 1983j Starr and Starr
1986; Johansson et al. 1987) and dopamine antagonists
prevent locomotor stimulation by dopamine agonists (Hoffman
and Beninger 1985; Molloy and Waddington 1985). Dopamine
agonists facilitate, while dopamine antagonists impair, the
effects of reward on learning (Zarevics and Setler 1979;
Gallistel and Karras 1984; Mazurki and Beninger 1986).
The neuronal model for reward-mediated learning
suggests

this learning process consists of the selection

and strengthening of specific synaptic connections (Miller
et al. 1990; Wickens 1990). The paradigm for synaptic
strengthening involves two sequential processes. First,
there is the selection of synapses (possibly corticostriatal
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synapses). These synapses would have been activated as a
result of a specific stimuli. The synapse must be effective
in firing a striatal neuron. When this has taken place, a
temporary "state of readiness" is established and the
synapses are eligible for modification. Second, if the
behavior which follows the neuronal discharge has
motivationally favorable consequences, reward pathways (i.e.
the mesolimbic dopamine pathway) are activated and the
efficacy of synaptic transmission is enhanced in synapses in
the "state of readiness". Subsequent encounters with these
stimuli result in easier activation of the neuron by these
synapses (synaptic enhancement).
This synaptic enhancement may occur in
dopamine-mediated

motor activation as well as

reward-mediated learning. Dopamine acting on 02 receptors of
the striatal cholinergic terminals exerts an inhibitory
effect on acetylcholine release (Stoof et

al. 1987). Lower

levels of acetylcholine reduce membrane resistance and the
excitatory postsynaptic potential {EPSP) amplitude (Dodt and
Misgeld 1986). This effect may lead to an

enhancement of

the synapses. Dopamine acting on the Dl receptors located on
striatal projection neurons (Ariano 1987) may bring about
the enhancement of selected corticostriatal synapses. These
dopamine effects may in turn link dopamine-mediated motor
activation to reward-mediated learning (Wickens 1990).
Modulation of motivational processes and organization
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and initiation of goal-directed behaviors are associated
with the ascending projections of the ventral tegmental area
(Fibiger et al. 1987; Phillips et al. 1982,1987). One of the
largest projections is to the nucleus accumbens.
Approximately 90% of nucleus accumbens dopamine derives from
this projection (Nauta et al. 1978). The nucleus accumbens
is a major component of the ventral striatum which provides
a ventral pathway by which the limbic system and prefrontal
areas can influence the initiation of voluntary motor
behaviors (Nauta 1986). The ventral pallidum receives a
dopamine projection from the ventral tegmental area (Nauta
et al. 1978). This projection may modulate information
related to motor function (Depue and Iacono 1989). It is
also well established that the ventral tegmental area
dopamine pathway mediates reward, specifically the incentive
type of reward that activates goal acquisition (Stein 1983;
Bozarth 1987; Fibiger and Phillips 1987). It has been
suggested that the nucleus accumbens may serve as an
interface between the limbic and motor systems. Dopamine
activity in the nucleus accumbens appears to modulate the
flow of motivational information from the limbic system to
the motor system; thereby contributing to the processes of
locomotor activity initiation, incentive, and goal-directed
behaviors (Oades and Halliday 1987i Taghzouti et al. 1985;
Depue and Iacono 1989).
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G proteins
G proteins are membrane-associated heterotrimeric
proteins composed of a,

p,

and T subunits. The a subunit has

a guanine nucleotide binding site. In a nonactivated state,
GDP is bound to the a subunit. A stimulated receptor
activates the G protein by catalyzing the exchange of GDP
for GTP which leads to the dissociation of the

Pr subunits

from the a subunit. The GTP-bound a subunit is free to
regulate the activity of various enzymes and ion channels
(Breitweiser and Szabo 1985; Cockroft and Gompert 1985;
Pfaffinger et al. 1985; Yatani et al. 1987, 1988).
Molecular cloning techniques have allowed the isolation
and characterization of cDNA clones for several G protein
subunits. Four a 1 subunits have been identified which appear
to arise from alternate splicing Eechanisms (Bray et al.
1986). Other a subunits (i.e. ail, ai2, ail, a 0 , az, and a 1 ) are
products of unique genes (Lochrie et al. 1985; Medynski et
al. 1985; Jones and Reed 1987; Itoh et al. 1988).
The guanine nucleotide binding proteins (G proteins)
serve as signal transducers linking neurotransmitter and
hormone receptors to membrane bound effectors (Chang and
Bourne 1987;

Stiles 1989; Birnbaurner 1990) .The G8 protein

is linked to the activation of adenylate cyclase and to
calcium (ca+ 2 ) channels (Gilman 1987j Yatani et al. 1987).
The

~

protein is linked to the inhibition of adenylate

cyclase and the activation of potassium (K+) channels
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(Yatani et al. 1988). The G0 protein is the most abundant G
protein in the brain and may be involved in the regulation
of calcium (ca+ 2 ) and potassium (K+) channels (Birnbaumer et
al. 1987). The Gi protein is coupled to rod and cone opsins
and to the regulation of cGMP phosphodiesterase (Medynski et
al. 1985).
The a subunit amino acid sequences are highly
conserved. The greatest variability among the sequences
occurs at the amino (NH2 ) and carboxyl (COOH) terminals
(Strathman et al. 1989). The

ai

and a subunits are post0

translationally modified by the addition of myristic acid
(Buss et al. 1987). In the proposed tertiary structure, the
amino and carboxyl terminals are spatially close to each
other and face the plasma membrane. The guanine nucleotide
binding site is on the cytoplasmic face of the protein
(Holbrook and Kim 1989). The amino terminus may regulate the
interaction of the

Pr subunit complex with the a subunit

(Navon and Fung 1987). The carboxyl terminus may have a
receptor contact site and regulate receptor binding and
activation of the G protein (Deretic and Hanun 1987; Sullivan
et al. 1987; Weiss et al. 1988). It is proposed that the
proximity of the receptor binding domain (carboxyl terminus)
and the

Pr interaction site (amino terminus) would provide

the structural basis for conformational changes within the
subunits which induce guanine nucleotide exchange and
subunit dissociation.
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several

P

and

T

subunits have been identified and there

is heterogeneity among these subunits (Gierschek et al.
!985;

Hildebrandt et al. 1985; Gao et al. 1987). This

heterogeneity may account for altered a subunit regulation
and specific receptor recognition. The T subunit of the Gt
protein is particularly distinct and may account for this G
protein being an extrinsic membrane protein whereas the
other G proteins are intrinsic membrane proteins. It is
hypothesized that the

PT

complex is required for the

efficient interaction of the a subunit with the receptor and
activation of the guanine nucleotide exchange. This complex
may also serve to anchor the G protein to the membrane
(Weiss et al. 1988).
The primary sequence has been determined for many of
the receptors which are coupled to G proteins (e.g. dopamine
receptors, adrenergic receptors, serotonin receptors, and
muscarinic receptors)

(Dixon et al. 1986; Kubo et al. 1986;

Kobilka et al. 1987; Bonner et al. 1989). These receptors
are predicted to have a tertiary structure of seven membrane
spanning regions, three cytoplasmic loops and the carboxyl
terminus on the cytoplasmic side of the membrane. The
receptor-G protein interaction occurs within the cytoplasmic
domains. The amino acid sequences of cytoplasmic loops I-II
and III-IV are conserved, but the sequence of cytoplasmic
loop V-VI is highly variable (Dahlman et al. 1987). The V-VI
loop may contain the recognition sites for G protein binding
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(Strader et al. 1987; Kobilka et al. 1988). The third
cytoplasmic loop and the carboxyl terminal may influence
receptor selectivity and G protein activation (O'Dowd et al.
1988) •
Receptor activation of the G proteins is described as a
catalytic exchange requiring the dissociation of GDP before
the binding of GTP (Wessling-Resnick et al. 1987). The
molecular interactions during activation are allosteric and
display positive cooperation (Wessling-Resnick and Johnson
1987). It is proposed that agonist binding to the receptor
induces conformational changes which increase binding
affinity and efficiency in the interaction with the G
protein (Wessling-Resnick et al. 1987).

Adenylate cyclase
Adenylate cyclase is one of the membrane effectors
regulated by the G proteins. This enzyme is an integral
membrane protein which catalyzes the synthesis of adenosine
3',S'-monophosphate (cAMP), a second messenger for many
hormones and neurotransmitters (Johnson and Dhanasekaran
1989; Birnbaumer 1990). There are two species of this
enzyme, and a cDNA encoding one form has been cloned
(Graziano and Gilman 1987). The primary amino acid sequence
consists of 1134 residues which represent two alternating
sets of hydrophobic and hydrophilic regions. A proposed
model suggests each hydrophobic domain contains six
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transmembrane segments (Krupinski et al. 1989). The overall
topology of adenylate cyclase resembles structures of
various membrane channels and transporters (Gilman 1989).
Gilman (1989} has suggested that adenylate cyclase may be a
multifunctional molecule, serving as both an enzyme of cAMP
synthesis and a transporter that exports cAMP from the cell.
In the nervous system, hoanones and neurotransmitters
affect the cellular content of cAMP. The cAMP levels are
determined by the rate of synthesis from ATP by adenylate
cyclase and the rate of hydrolysis to 5'-AMP by
phosphodiesterase (Nathanson and Greengard 1981). The
effects of cAMP are mediated by its activation of
cAMP-dependent protein kinases. These protein kinases
consist of two regulatory subunits and two catalytic
subunits. The binding of cAMP to the regulatory subunits
leads to the dissociation of the complex and the activated
catalytic subunits are free to phosphorylate cellular
proteins. This phosphorylation usually occurs on serine
residues of the substrate, resulting in alterations in
cellular function (Spiegel et al. 1985; Gilman 1989).

Ethanol Effects on Dopamine Metabolism
In animal studies, acute administration of ethanol has
a biphasic effect on neural function. Low doses of ethanol
cause behavioral stimulation whereas higher doses cause
sedation (Hunt 1981; Majchrowicz 1981; Engel and Liljequist
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l983; Di Chiara and Imperato 1985). Some of these behavioral
changes may be attributed to the effects of ethanol on
dopamine metabolism. Low doses result in increased dopamine
synthesis, utilization, and release (Carlsson and Lindquist
1973; Darden and Hunt 1977; Fadda et

al. 1980). However, at

higher doses there is a decrease in dopamine utilization and
release with a greater increase in synthesis (Carlsson and
Lindquist 1973; Darden and Hunt 1977j Bacapoulous et al.
1978; Fadda et al. 1980). After chronic treatment with
ethanol, dopamine synthesis and release are reduced (Hunt
and Majchrowicz 1983) and the dopaminergic neurons exhibit a
hyposensitivity to haloperidol and apomorphine (Tabakoff and
Hoffman 1978; Tabakoff et al. 1978; Black et al. 1980).
The mesolimbic dopamine neurons which originate in the
ventral tegmental area (VTA) and project to the nucleus
accumbens (Lindvall et al. 1978) appear to be more sensitive
to ethanol than those of the nigrostriatal pathway. Low
doses of ethanol produced a dose-dependent increase in the
firing rate of dopaminergic neurons in the VTA (Gessa et al.
1985; Brodie et al. 1990). Higher doses (approximately
5-f old) were required to produce comparable responses in the
dopamine neurons of the substantia nigra (Mereu et al.
1984). Doses of ethanol which enhanced dopamine release in
the nucleus accumbens of freely moving rats did not modify
dopamine release in the striatum (Imperato and Di Chiara
1986; Di Chiara and Imperato 1988).
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The mesolimbic dopamine neurons have been implicated in
the mediation of the reinforcing properties of drugs of
abuse such as cocaine (Lyness et al. 1979; Roberts and Koob
1983), heroin (Bozarth and Wise 1981), and morphine
(Matthews and German 1984). It is possible these neurons may
be involved in mediating the rewarding effects of ethanol
(Koob and Weiss 1990; Lewis and June 1990; McBride et al.
1990; Samson et al. 1990).
The voluntary intake of ethanol by laboratory animals
and humans may be influenced by genetic factors which in
turn may be manifested in differences in specific
neurotransmitter systems {Goodwin 1979; Deitrich and
McClearn 1981; Schuckit et al. 1985). Animal models
exhibiting alcohol preferring behaviors have been
established to study the genetic and biological basis for
alcohol abuse {Crabbe et al. 1985,1987). Neurochemical
differences have been found between alcohol-preferring (P)
and alcohol-nonpreferring (NP) rats. The differences appear
to be genetic because they exist even in animals never
exposed to alcohol. The levels of dopamine and its
metabolites are lower in the nucleus accumbens of
alcohol-preferring rats as compared with alcoholnonpreferring rats. In contrast, the dopamine content in the
striatum and frontal cortex were not significantly different
in these animal lines {Murphy et al. 1987,1988; McBride et
al. 1990.
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~thanol

Effects on the Dopamine Receptors

When reviewing the literature related to the effects of
alcohol on dopamine receptors, it is important to consider
differences among each laboratory's experimental protocols.
Ethanol dose, route of administration, duration of
treatment, animal species, and assay conditions may account
for discrepancies in results obtained from different
laboratories. Furthermore, most earlier studies concentrated
on ethanol's effect on the dopamine 02 receptor due to the
unavailability of a specific dopamine Dl receptor ligand
until recently and many of these studies were limited to the
striatal receptors.
Ethanol treatment appears to affect dopamine receptors.
However, the effects seem to vary with brain region analyzed
and duration of treatment. Nevertheless, some
generalizations can be made. 1) Short term ethanol exposure
(7 days or less) does not alter the number or affinity of
dopamine receptors (Hoffman and Tabakoff 1979). 2) Various
studies report an increase, decrease, and no change in Dl
and 02 receptor number in the mesolimbic area, striatum, and
cortex after long term exposure in mice and rats (two weeks
to thirty-two weeks) (Lai et al. 1980, Muller et al. 1980,
Lucchi et al. 1983, 1988; Hruska 1988j Syvalahti et al.
1988; Hietala et al. 1990). 3) An ethanol-associated effect

in one brain region may not be present in all brain regions.
For example, Muller at al. (1980) reported a significant
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decrease in

02 receptors in the mesolimbic area, while

there was no difference in striatal 02 receptors after long
term ethanol exposure. 4) Ethanol does not consistently
alter the affinity of dopamine receptors. That is, the
majority of studies report ethanol exposure has no effect on
the affinity of 01 and 02 receptors (Lai et al. 1980; Muller
et al. 1980; Hruska 1988; Lucchi et al. 1988; Syvalahti et
al. 1988; Hietala et al. 1990).
A portion of ethanol's effects may relate to its action
as a nonspecific membrane perturbant, altering the physical
properties of the lipid components of cell membranes which
may lead to changes in optimal membrane fluidity (Chin and
Goldstein 1977; Sun and Sun 1985), for protein function.
Neural membranes become more fluid with acute ethanol
intoxication (Chin and Goldstein 1977). After chronic
ethanol exposure, the membranes are resistant to the
fluidizing effects of ethanol (Lyon and Goldstein 1983).
This response may serve as an adaptive mechanism to
compensate for the fluidizing effects of ethanol. Changes in
membrane cholesterol content may be part of this adaptive
mechanism because cholesterol can maintain the order of
membrane phospholipids by hindering their movement (Stockton
and Smith 1976; Crews et al. 1983j

~eagle

1985). Changes in

memebrane composition and fluidity may alter receptor-ligand
interactions, receptor-effector coupling, and enzyme
activity (Guerri and Grisola 1983; Yeagle 1985).
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g_thanol Effects on Adenylate Cyclase and G proteins
Guanine nucleotide binding proteins (G proteins) are
important components in signal transduction, coupling
hormone and neurotransmitter receptors to second messenger
pathways (e.g. adenylate cyclase pathway, ion channels,
phosphoinositide pathway)

(Sternweis et al. 1981; Cockcroft

1987; Codina et al. 1987; Hescheler et al. 1987). The
G proteins are heterotrimers, consisting of a,

p,

and T

subunits. The a subunit contains a guanine nucleotide
binding site and displays GTPase activity (Northup et al.
1983).
In the adenylate cyclase system, an agonist interacts
with a receptor resulting in the association of the
agonist-receptor complex with the Gs protein which has GDP
bound to the a subunit. This interaction promotes the
displacement of GDP allowing the binding of GTP to the a
subunit. When GTP binds, the agonist-receptor-G protein
complex dissociates. The a subunit bound to GTP dissociates
from the

PT

subunits of the G protein and in turn interacts

with adenylate cyclase. The activation of adenylate cyclase
by the a subunit is terminated by hydrolysis of GTP and
reassociation of the a subunit with the

~r

subunit (Gilman

1987, 1989; Freissmuth et al. 1989; Johnson and Dhanasekaran
1989).
Protein-protein interactions within the cell membrane,
such as those involving G proteins, may be susceptible to
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the actions of ethanol. Under acute conditions, some studies
have demonstrated a selective effect of ethanol on Gs, the
stimulatory guanine nucleotide binding protein, rather than
on the adenylate cyclase enzYllle or the receptor linked to
the G protein. In studies with homogenates of mouse
striatum, ethanol in vitro elicited an increase in basal
adenylate cyclase activity. This effect was enhanced in the
presence of dopamine and guanine nucleotides (Rabin and
Molinoff 1981; Luthin and Tabakoff 1984). A similar effect
was observed in cerebral cortex. Ethanol increased guanine
nucleotide-stimulated and isoproterenol-stimulated adenylate
cyclase activity {Saito et al. 1985).
Studies of ethanol-adenylate cyclase interactions in
cultured cells have supported the findings in brain membrane
preparations. In several cultured cell lines, including the
NlE-115, NG 108-15, and S49 1Y111phoma lines, acute ethanol
exposure increased basal, and to a greater extent,
agonist-stimulated, guanine nucleotide-stimulated, and
fluoride-stimulated adenylate cyclase activity (Rabin and
Molinoff 1983; Gordon et al. 1986). It has been postulated
that acutely, ethanol appears to alter the rate of
activation of Gs and to enhance the interaction of a 1 with
guanine nucleotides (Rabin and Molinoff 1981, 1983; Luthin
and Tabakoff 1984).
Since ethanol increases the stiEulation of adenylate
cyclase under acute conditions, it is possible that there
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would be an adaptive change in adenylate cyclase activity
after chronic ethanol exposure. Dopamine-stimulated
adenylate cyclase activity is reduced after chronic ethanol
treatment in striatal membranes of mice and rats (Tabakoff
and Hoffman 1979; Lucchi et al. 1983; Saffey et al. 1988).
In vitro addition of ethanol to striatal membranes restored
dopamine-stimulated adenylate cyclase activity to normal
levels, indicating that membranes from ethanol-tolerant rats
require the presence of ethanol for normal activity
(Tabakoff and Hoffman 1979). In contrast, another study
reported an

increase in dopamine-stimulated,

GTP-stimulated, and sodium

fluoride-stimulated adenylate

cyclase activities in the striatum of chronically
ethanol-treated rats (Rabin 1987). The discrepancies may be
related to different strains of rat, mode and duration of
ethanol administration, or time of assessment relative to
ethanol withdrawal.
Norepinephrine-stimulated adenylate cyclase activity in
the cerebral cortex is affected by withdrawal from chronic
ethanol exposure. During ethanol withdrawal, there was a
decrease in this activity in the cerebral cortices of mice
and rats {French et al. 1975; Saito et al. 1987}. Also, at
the time of withdrawal, the stimulation of adenylate cyclase
by guanine nucleotides, isoproterenol, vasoactive intestinal
peptide, and forskolin was decreased (Saito et al. 1987).
The effect of chronic ethanol exposure on adenylate
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cyclase activity has also been examined in cultured cells.
The neuroblastoma cell lines, NlE-115 and NG 108-15,
displayed a decrease in the response of adenylate cyclase to
prostaglandin El stimulation after chronic ethanol
treatment. The addition of ethanol restored the response to
control values (Richelson et al. 1986). Chronic ethanol
treatment of primary cerebellar cultures resulted in a
reduction in isoproterenol-stimulated and
adenosine-stimulated adenylate cyclase activity (Rabin
1990) .
It has been hypothesized that changes in adenylate
cyclase activity after chronic ethanol treatment are
indicative of an uncoupled receptor-adenylate cyclase system
(Hoffman and Tabakoff 1990).
Alternatively, the changes in adenylate cyclase
activity

following chronic ethanol exposure may also

reflect qualitative or quantitative changes in the a subunit
of the Gs protein. Mochly-Rosen and colleagues (1988)
demonstrated a decrease in :mRNA levels and protein content
of the a subunit of the Gs protein after chronic ethanol
treatment using the neuroblastoma cell line NG 108-15.
Charness and colleagues (1988) also reported changes in G
protein content in several ethanol-treated neuroblastoma
cell lines. This group reported a decrease in the content of
the Gs a subunit in the NG 108-15 and NlE-115 cell lines,
but not in the N18TG2 cell line. They also found a
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dose-dependent increase in the Gi a subunit in the NlE-115
cell line, with no change in the NG108-15 and N18TG2 cell
lines. Although the content of G proteins is altered in
neural cell lines, no significant alteration in the content
of the Gs a subunit was found in cerebral cortical tissue
from chronically treated mice (Hoffman and Tabakoff 1990).
Nonetheless, it has been suggested that in vivo chronic
ethanol exposure may cause posttranslational modification of
the a subunit which may alter its interaction with the
receptor and adenylate cyclase (Hoffman and Tabakoff 1990).

Possible Genetic Basis of Alcoholism
The development of alcoholism may be determined by
genetic as well as environmental factors (Tarter et al.
1985; Zucker and Gomberg 1986; Cloninger 1987). Studies,
particularly twin and adoption studies, have demonstrated
there is a likely genetic predisposition to alcoholism
(Cotton 1979; Cloninger et al. 1981;

Hrubec and Omenn 1981;

Kaprio et al. 1987). Several genes are probably involved in
determining susceptibility to alcoholism.
Two human studies suggest that alterations in platelet
and lymphocyte adenylate cyclase may serve as markers for a
genetic predisposition to alcoholism. 1) A reduction in the
stimulation of adenylate cyclase activity by guanine
nucleotides (36%), fluoride (26%), and prostaglandin El
(35%) was observed in platelets from human alcoholic
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patients (Tabakoff et al. 1988).

Alcoholics with the

greatest number of alcoholic first degree relatives had the
largest reduction in stimulated adenylate cyclase activity.
The reduced activity was also found in patients who had
abstained for 1-4 years. It is possible the persistent
reduction in platelet adenylate cyclase activity is an
inherent characteristic of alcoholics (Tabakoff et al.
1988). 2) Lower cAMP levels (a 75% decrease) were observed
in lymphocytes obtained from alcoholic patients (Diamond et
al. 1987). These cells were maintained in culture in the
absence of alcohol for 4-6 generations. The differences in
cAMP levels were still observed and these cells were more
sensitive to ethanol's effects (Nagy et al. 1988). Thus,
genetic factors may influence ethanol's effect on adenylate
cyclase activity.
Blum et al.

(1990) recently reported an allelic

association of the dopamine 02 receptor gene with
alcoholism. In their patient population, the "Al" allele of
the 02 receptor was found in 77% of the alcoholic patients
and it was absent in 72% of the nonalcoholic patients. The
authors suggest that an abnonaality in the gene coding for
the 02 receptor may cause susceptibility to a subtype of
alcoholism. The authors also suggest that the gene for the
02 receptor may eventually be used as a diagnostic marker

for the risk of alcoholism. In contrast to Blum's study of
an association of the Al allele of the D2 receptor in
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alcohol-related disease in humans, a study comparing
alcohol-sensitive and alcohol-insensitive rat lines, Korpi
et al. (1987) find no association of the striatal
dopaminergic 02 receptors with sensitivity to alcohol.
Although, Blum and colleagues (1990) have provided a
candidate probe with potential promise in the research on
the genetics of alcoholism, future genetic studies must
include a broader living human sample as well as extended
families of alcoholics. Furthermore, the classification of
alcohol abusers should be done by a single, cooperative
group, rather than by reviewing medical records of deceased
patients.

Proposed Studies
Alcoholism and alcohol abuse constitute a major health
problem in the United States. However, the biochemical
mechanisms by which this disease manifest itself have not
been fully investigated. Among the studies which have
attempted to delineate these mechanisms are those which have
demonstrated that several central nervous system
neurotransmitters are sensitive to alcohol consumption
(Greenberg et al. 1986; Valverius et al. 1987; Celetano et
al. 1988; Murphy et al. 1988; Lovinger et al. 1989). Among
the neurotransmitter systems which are sensitive to ethanol
is the dopamine system. The dopaminergic system is involved
with locomotor activity and is recognized as a component of
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the reward circuitry (Fibiger et al. 1974; Phillips and
Fibiger 1978). Since

ethanol does have an effect on

locomotor activity and displays reinforcing properties, it
is hypothesized that chronic ethanol consumption may alter
dopamine signal transduction or dopamine levels. It is the
objective of the research described in this dissertation to
specifically examine the biochemical changes in the
dopaminergic system.
This dissertation examined the effects of chronic
ethanol exposure on several membrane components of the
dopaminergic system, as well as the level of dopamine. The
membrane components include the Dl and D2 receptors, the
stimulatory and inhibitory guanine nucleotide binding
proteins (G proteins), and adenylate cyclase activity. These
components were measured in brain regions associated with
the dopaminergic system. All studies were done on adult male
Fisher 344 rats pair fed a control or 6.6% (v/v) ethanol
liquid diet for one month prior to sacrifice at three months
of age. This study is important because changes in dopamine
levels or membrane components could result in alterations in
cellular activity which could contribute to ethanol-induced
changes in motor activity or to the reinforcing properties
of ethanol.

CHAPTER I I I

METHODS

Animal Model
Male Fisher 344 rats (2 months) were used in these
experiments. The animals were pair-fed using a 6.6% (v/v)
ethanol liquid diet or control diet for 4-5 weeks (Noronha
and Druse 1982). The caloric content of the control diet
consisted of 21% protein, 29% fat 1 and 50% carbohydrate, the
ethanol diet consisted of 21% protein, 29% fat, 15%
carbohydrate, and 35% ethanol. Animals were maintained on a
12:12 hour light/dark cycle. The animals were weighed weekly
to ensure equal weight gain.

Blood Ethanol Determination
Blood ethanol levels were measured using an enzymatic
kit {Sigma #330-1; St. Louis, MO). This kit accurately
measures ethanol levels by measuring the nicotinamide
adenine dinucleotide (NADH) formed when ethanol is converted
to acetaldehyde via alcohol dehydrogenase (ADH) and reduced
nicotinamide adenine dinucleotide (NAD) . An increase in
absorbance at 340 nm occurs when HAD is converted to NADH.
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Ethanol + NAO

ADH
---------->

Acetaldehyde + NADH

The procedure required the deproteinization of blood
samples by the addition of trichloroacetic acid (6.25%,
w/v). The sample was allowed to stand at room temperature
for 5 minutes, followed by a slow speed centrifugation
(International Clinical Centrifuge, Model CL; International
Equipment Co., Boston, MA) to obtain a clear supernatant. To
each NAD-ADH assay vial, 2.9 ml glycine buffer (0.5 mol/L,
pH 9.0) was added, and the vial was capped and inverted
gently to dissolve contents. The sample (100 µl) was added
to the vial, mixed by inversion, and incubated at 37°C for
10 minutes. The sample was transferred to a cuvette and
covered to exclude contamination and evaporation from air.
The absorbance was recorded at 340 nm. Blood samples were
collected at the time of sacrifice after an overnight fast.

Dissection Technique
The animals were decapitated between 7 a.m. and 10
a.m •• The brains were quickly removed and dissected on a
chilled glass plate. The frontal cortex, striatum, and
nucleus accumbens were dissected. Other brain regions were
dissected using the punch technique as described by
Palkovits and Brownstein (1988). In the latter method brain
samples were fixed to a specimen holder with the embedding
medium Tissue-Tek (Miles; Elkart, IN).
The mounted brains were sectioned using a cryostat set
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at -15°C. Sections of 300-500 µm thickness were sliced and
placed on ice-cold slides for punching. Punching tools with
1.0 and 2.0 mm diameters were used to remove brain regions
of interest. Punched areas included: globus pallidus,
substantia nigra, ventral tegmental area, and ventral
pallidum. Samples were stored at -80°C. All experiments were
performed on frozen tissue.

Dopamine Antagonist Binding Assay
The dopamine (Dl and 02) binding sites in control and
ethanol-treated animals were analyzed using a modified
method of Hess and colleagues (1986). An antagonist binding
assay measures total receptor number (high and low affinity
state receptors). The 01 antagonist [ 3H]-SCH 23390 (New
England Nuclear; Boston, MA) was used to measure total Dl
sites and the 02 antagonist [ 3H)-spiperone (New England
Nuclear; Boston, MA} was used to measure total D2 sites.
Brain tissue was homogenized in 40 volumes of cold
50 mM Tris-HCl buffer (pH 7.4) using a motorized teflon
homogenizer (6 up and down strokes, setting 9) (Caframo
RZR3; Warton, Ontario). The tissue was incubated for 15
minutes at 37°C to remove endogenous dopamine, followed by
centrifugation (SS34 rotor, Sorvall RC-SB centrifuge) at
30,900 x g (16,000 rpm} for 20 minutes at 4°C. The pellet
was resuspended in Tris-HCl buffer and centrifuged again as
described above. This wash was repeated. The final pellet

36

was suspended in assay buffer containing: 50 mM Tris-HCl,
5 mM MgS04 , 0.5 mM EDTA, and 0.02% (w/v) ascorbic acid
(pH 7.4).
The Dl binding assay was performed using a saturationcompeti tion assay containing 0.0-0.5 nM [ 3H]-SCH 23390 and
o.o-5.0 nM SCH 23390. Nonspecific binding was determined by
the dopamine antagonist,

(+)-butaclamol. The 02 binding

assay was performed using 0-1.0 nM [ 3H]-spiperone in the
presence of 40 nM ketanserin to block serotonin sites (5-HT2
sites). Nonspecific binding was determined using 1 µM
(+)-butaclamol.
The reaction was initiated with the addition of tissue
homogenates (O.l to 0.3 mg protein/assay tube)

(triplicate

samples) and incubated for 30 minutes at 37°C. The reaction
was terminated by vacuum filtration using a Brandel Cell
Harvester (Gaithersburg, MD) with Whatman GF/C filters
followed by three 5 milliliter (ml) washes with cold
Tris-HCl buffer. Filters were placed in scintillation vials
containing 10 ml Bio-Safe II (RPii

Mt. Prospect, IL). The

radioactivity on the filters was determined by liquid
scintillation counting by the Beckman LS 7500 counter
(Beckman, Fullerton, CA).
The kinetic parameters (Kd and Bmax) were calculated by
computer-assisted Scatchard analysis developed in this
laboratory. The Scatchard plot is a linear transformation of
the

saturation isotherm. The x-axis is represented by bound
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values and the y-axis is represented by the bound/free
values. From this plot, the Bmax (receptor number) is the
x-intercept and the Kd (affinity) is -1/slope.

Dopamine Agonist Binding Assay
The agonist binding assays were performed using a
modification of the methods of Hess et al. (1986) and Sibley
et al. (1982). Agonist binding was used to measure the
percentage of receptors in the high affinity state and the
ability of guanine nucleotides to convert the receptors from
the high affinity state to the low affinity state. The 02
receptors were measured using the 02 agonist,
[3

H]-N-n-propylnorapomorphine (NPA)

(New England Nuclear;

Boston, MA). The assay conditions were similar to that
described previously for the antagonist binding assay,
however, the assay buffer for the NPA studies also contained
120 mM NaCl to stabilize the high affinity state. In order
to measure the conversion of the

D2

receptor from the high

affinity state to the low affinity state, assays were
performed in the absence and presence of 300 µM GTP.

Adenylate Cyclase Assay
Basal and dopamine-sensitive adenylate cyclase activity
of brain regions obtained from control and ethanol-treated
animals were assessed by a modification of the methods of
Tabakoff and Hoffman (1979) and Battaglia et al. (1986).
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Adenylate cyclase activity was measured in the striatum,
nucleus accumbens, and frontal cortex. Samples were
homogenized in 50 volumes of ice-cold homogenization buff er
using a Tekmar Tissumizer (Cincinnati,OH)

(setting 6, 10

seconds). The homogenization buffer contained 10 mM
Tris-maleate (pH 7.4) and 2.0 mM EGTA. The samples were
centrifuged (SS34 rotor, Sorvall RC-SB centrifuge) at
30,900 x g (16,000 rpm) for 10 minutes (4°C). The pellet was
washed with homogenization buffer and centrifuged as
described above. The final pellet was resuspended in the
homogenization buffer.
The assay buffer contained BO mM Tris-maleate (pH 7.4),
0.4 mM EGTA, 4.0 mM MgS04 , 1.0 mM isobutylmethylxanthine
(IBMX), 5.0 mM phosphocreatine, 0.02% (w/v) ascorbic acid,
and 50 U/ml creatine kinase. Triplicate samples were
preincubated in assay buffer for 5 minutes at 37°C in the
presence (dopamine-stimulated/dopamine-inhibited) or absence
(basal) of 100 µM dopamine. To measure Dl-stimulated
adenylate cyclase activity, 50 nM spiperone was added to
block 02 sites, while 100 nM SCH 23390 was used to block 01
sites in assays of 02-inhibited adenylate cyclase activity.
Basal adenylate cyclase activity was also measured in the
presence of 100 µM forskolin, 10 mM NaF (sodium fluoride),
or 100 µM GTP to determine the site of any ethanol effect.
The reaction was initiated with the addition of 1 mM ATP
(adenosine triphosphate) and allowed to proceed for
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5 minutes at 37°C. The reaction was terminated by the
addition of 50 nM sodium acetate buffer (pH 6.2) and
iIIII1lersion in boiling water for 3 minutes. Precipitated
protein was removed by centrifugation (SE12 rotor, Sorvall
RC-SB centrifuge) at 21,800 x g (16,000 rpm) for 15 minutes
(4°C). The supernatant was collected and stored at -80°C

for

measurement of cAMP levels by radioimmunoassay (RIA).

cAMP Radioimmunoassay
The cAMP radioimmunoassay was a modified method of
steiner (1972). Samples and standards were acetylated to
resemble the antigen used to generate the antibody for cAMP
and to increase the sensitivity of the assay. Samples and
standards were acetylated with the addition of triethylamine
(20 µl) and acetic anhydride (10 µl). Duplicate acetylated
standards (O to 500 fmoles of cAMP) and samples were
transferred to 12 x 75 mm glass test tubes and [ 1llI]-cAMP
(0.01 µCi) in 50 mM sodium acetate (pH 6.2) was added to
each sample. The reaction was initiated with the addition of
anti-cAMP antibody in sodium acetate buffer. The samples
were incubated overnight (20°C). The assay was terminated
with the addition of 1% (w/v) ga:mma globulin (50 µl) and 95%
(v/v) isopropanol (2 ml). The samples were centrifuged for
30 minutes at 1,623 x g (2800 rpm) in a Jouan GR4.11
centrifuge (4°C). The supernatant was decanted and the
radioactivity was measured by a LKB Wallac 1272 CliniGamma
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gamma counter .

~ransf ormation/Plasmid

Preparation

Lyophilized samples containing the cDNA probes for the

a subunits of the G proteins (in the pGEM-2 plasmid) were
obtained from Dr. Randall Reed (Jones and Reed 1987). The
samples were diluted in Tris-EDTA buffer (10 mM Tris, 2.0 mM
EDTA) and incubated for 5 minutes at 65°C. The samples were
diluted again to a 1:20 dilution and used for
transformation.
The transformation procedure was the method of Chung et
al.

(1989). Microcentrifuge tubes were chilled on ice and

100 µl of cells [E.coli HBlOl/F+;{F+=Tn lO:Kan recK) from
Dr. Mark

Kelley) and 1 µl of cDNA were added. Samples were

mixed gently and incubated for 30 minutes at 4°C. After the
incubation, LB broth (5 g NaCl, 10 g tryptone, 5 g yeast
extract/lL) was added and the cells were incubated for
30 minutes at 37°C. The cells were plated onto ampicillin
plates and incubated at 37°C overnight. A single colony from
the transformation plate was streaked onto a new ampicillin
plate. The plate was incubated at 37°C overnight and served
as the master plate. A single colony from the transformation
plate was added to culture tubes containing LB broth and
ampicillin. The cells were incubated at 37°C overnight. This
preparation was used in the plasma preparation.
The plasmid preparation (Morelle 1989) extracts the
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plasmid DNA from the bacterial cells. The cells in the LB
broth were aliquoted into microcentrifuge tubes and
centrifuged for 1 minute at 10,000 x g (10,000 rpm) in a
tabletop centrifuge (mc15, Hill

Scientific, Derby, CT). The

supernatant was removed by aspiration. The pellet was
suspended in 250 µl of Tris-EDTA buffer (50 mM Tris, 100 mM
EDTA) and 250 µl of NaOH/SDS buffer (200 mM NaOH, 1% (w/v)
SDS) was added. After incubation for 5 minutes at room
temperature, 250 µl of potassium acetate (2.55 M) buffer was
added and the sample was centrifuged for 15 minutes at 4°C.
The supernatant was transferred to another microcentrifuge
tube and 400 µl of isopropanol (60%, v/v) was added. After 5
minutes at room temperature, the sample was centrifuged for
15 minutes at 10,000 x g (10,000 rpm) in a tabletop
centrifuge (mc15; Hill Scientific). The supernatant was
removed by aspiration and the pellet was washed with
70% (v/v) ethanol by inversion. Following aspiration of
ethanol, the pellet was incubated in a heat block (65°C) to
evaporate the remaining ethanol. The pellet was suspended in
Tris-EDTA (10 mM Tris, 1.0 mM EDTA) buffer. The cDNA probes
were subjected to a DNA digest by Eco RI and separated on a
0.7% (w/v) agarose gel to ensure purity. These samples of
the cDNA probes for the G proteins were used for
hybridization.
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ENA Extraction and

Analysis

Total RNA was extracted from brain regions of control
and ethanol-treated animals using the modified method of
chomczynski and Sacchi (1987). The tissue was homogenized in
guanidine isothiocyanate buffer (4.0 M guanidine
isothiocyanate, 25 mM sodium citrate, 0.1 M
2-mercaptoethanol, and 0.5% (w/v) sarcosyl) and allowed to
stand for 5 minutes. The samples were transferred to
microcentrifuge tubes. To these samples, 50 µl of 2 M sodium
acetate (pH 4.0), 500 µl phenol, and 100 µl
chloroform:isoamyl alcohol (49:1, v/v) were added. Samples
were placed on ice for 15 minutes and then centrifuged for
20 minutes at 10,000 x g (10,000 rpm) in a tabletop
centrifuge (mc15, Hill Scientific). The aqueous layer was
transferred to a new microcentrifuqe tube and an equal
volume of isopropanol was added. The sample was then placed
in a dry ice/methanol bath (-70DC) for one hour. The sample
was centrifuged as described above. Following aspiration of
isopropanol, the pellet was resuspended in guanidine
isothiocyanate buffer. The sample was incubated in a heat
block (65°C) for 5 minutes. To this sample, 10 µl 3.0 M
sodium acetate (pH 5.2) and 100 µl isopropanol were added,
prior to cooling on dry ice for 10 minutes. The sample was
centrifuged as described and the supernatant was removed by
aspiration. The pellet was washed with 70% (v/v) ethanol and
centrifuged for 10 minutes at 10,000 x g (10,000 rpm) in a
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tabletop centrifuge (mc15, Hill Scientific). The pellet was
resuspended in diethyl pyrocarbonate (DEPC)-treated water
and incubated in a heat block (65°C) for 5 minutes. Samples
were stored at -20°c. The amount of RNA extracted was
determined by a spectrophotometer (Spectronic 21D, Milton
Roy co.) reading (260 nm).
Equal amounts of RNA in DEPC-treated water were diluted
to 1:10 and 1:1000 in microcentrifuge tubes. Formaldehyde
(37%, v/v) in a 3.0 M sodium chloride/0.3 M sodium citrate
(20X SSC) buffer (1:1) was added to each sample and the
samples were incubated in a heat block (65°C) for 15
minutes. The samples were loaded into the wells of the
Manifold II with Nytran filter (0.45 µm)

(Scheicher &

Schuell; Keene, NH) and vacuum filtered. The wells were
washed with lOX SSC buffer to remove the formaldehyde. The
RNA was cross-linked to the Nytran using the UV Stratalinker
(Stratagene; La Jolla, CA).

Hybridization Procedure
The levels of G protein mRNA from control and ethanoltreated animals were measured using cDNA probes for the a
subunits of the G proteins (Jones and Reed 1987). The Nytran
filter was prehybridized for 2 hours under high stringency
conditions in a buffer containing: 50% (v/v) formamide, lOOx
Denhardt's solution [2% (w/v) polyvinylpyrrolide, 2% (w/v)
bovine serum albumin, and 2% (w/v) Ficoll 400], 20% (v/v)
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salmon sperm DNA (lOmg/ml), and a Na/P04 (5.0 M NaCl, 50 mM
Na2po4 , and 0.5% (w/v) pyrophosphate) buffer. The cDNA probes
isolated in the plasmid preparation were labeled with
[32p]-CTP by random priming (Feinberg and Vogelstein 1983).
The cDNA (2 µl) was diluted in 28 µl sterile distilled water
and denatured at 100°C for 3 minutes. The sample was chilled
on ice for 5 minutes. To the sample, 10 µl labeling buffer
(250 mM Tris, 25 mM MgC1 2, 10 mM DTT, and 1 mM HEPES), 2 µl
nonlabeling dNTP's (1.5 mM each ATP, GTP, TTP), 2 µl
acetylated BSA (1 mg/ml), 1 µl Klenow (5 U), and 5 µl
a-[ 32P]-dCTP were added and the sample was incubated at room
temperature for one hour. The sample was heated to 100°c for
2 minutes, chilled on ice, and 2 µl 0.5 M EDTA and 48 µl
sterile distilled water were added. The sample was added to
a Sephadex G50 column and centrifuged for 5 minutes at
1000 x g (2000 rpm)

(Beckman TJ-6 centrifuge). The

32 P-labeled cDNA was added to the prehybridization buffer and
the filter was incubated overnight at 42°C on a rotator.
After hybridization, the filter was washed three times
(65°C) to remove excess labeled probe with a buffer
containing 0.5% (v/v)

sos

and 0.2x SSC (high stringency).

The filter was blotted dry and exposed on film at

-ao

0

c

(Kodak XAR-5; Eastman Kodak Co., Rochester, N.Y.). The
filters were stripped to remove all labeled probe. The
stripping buffer contained 3.0 M sodium chloride, 0.2 M
sodium phosphate, and 0.02 M EDTA (20X SSPE) and

sos.

The
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filters were washed three times in boiling stripping buffer
and exposed on film at -80°C. The filters were reprobed with
cDNA probes for other G proteins and actin. Actin served as
a control.

western Analysis
G protein content in control and ethanol-treated
animals was measured by Western analysis. Tissue samples
were homogenized in a TSA (0.01 M Tris (pH 8.0), 0.14 M
NaCl, and 0.025% (w/v) NaN3 ) buffer containing: 0.5% (v/v)
Triton X-100, 1 mM

phenylmethylsulfonyl fluoride (PMSF), 5

mM iodoacetamide, and 0.2 U/ml aprotinin. The samples were
diluted 1:1 in a loading buffer (40 mM Tris, 4% (v/v)
mercaptoethanol, 1% (w/v) SOS, 40% (v/v) glycerol, and
Bromophenol Blue). The samples were boiled for 5

minutes

and then centrifuged for 5 minutes in a tabletop centrifuge
(mc15; Hill Scientific). The samples (20 µg protein) and
molecular weight markers (Bio-Rad; Richmond, CA) were loaded
onto a 10% (w/v) acrylamide gel (30% (w/v) acrylamide, 8%
(w/v) N,N'-methylene-bisacrylamide, 4x Tris/SOS (pH 8.8),
10% (v/v) ammonium

persulfate, and TEMED) using the Bio-Rad

Protein II gel apparatus (Laemmli 1970) . The gel was run at
150 volts (constant voltage) in an electrophoresis buffer
(0.125 M Tris base, 0.950 M glycine, and 0.05% (w/v) SDS).
The proteins were either stained with Coomassie Blue (0.05%
(w/v) Coomassie Blue, 20% (v/v) methanol, 10% (v/v) acetic
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acid) or transferred to a nitrocellulose filter (0.2 µm)
(Schleicher & Schuell; Keene, NH) by a Bio-Rad Mini
Trans-Blot electrophoretic transfer cell. Prior to transfer,
gels and nitrocellulose filters were equilibrated in
transfer buffer (25 mM Tris base, 192 1llM glycine, 20%
methanol) for 20 minutes. Protein transfer was completed by
45 minutes at 150 mA (constant current). The filter was
washed in TBST (100 mM Tris base, l.5M

NaCl, and 5 ml Tween

20) buffer for 5 minutes, followed by a one hour incubation
in blot buffer (1% (v/v) TBST, 5% (w/v) powdered milk, 2 ml
Nonidet P-40, 0.02% (w/v) SDS). After blot incubation, the
primary antibody (anti-Ga8 or anti-Ga 0 , Dupont; Boston, MA),
diluted 1:1000 in blot buffer, was added to the filter and
the filter was incubated overnight on a rotator at 4°C. The
filter was washed three times for 15 minutes in TEST buffer.
The second antibody ([ 1 ~I]-anti-rabbit IgG, Amersham;
Arlington Heights,IL), diluted to 0.1 µCi/ml in blot buffer,
was added to the filter and the filter was incubated for
3 hours at room temperature on a rotator. The filter was
washed three times for 15 minutes in TBST buffer. The filter
was blotted dry and placed on film (Kodak XAR-5) and exposed
at -80°C. Actin also served as the control in Western
analysis. Actin monoclonal antibody (ICN; Costa Mesa, CA)
was used as the primary antibody and ( 1 ~I]-anti-mouse IgG
(ICN; Costa Mesa, CA) was used as the second antibody.
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High Performance Liquid Chromatography
Dopamine and DOPAC (3,4-dihydroxyphenylacetic acid)
levels were measured in control and ethanol-treated animals
by high performance liquid chromatography (HPLC) . Tissue
samples were extracted in 0.1 M perchloric acid. The larger
brain regions were homogenized by the Tekmar Tissumizer
(setting 6, 10 seconds)

(Tek.mar Co., Cinncinnati, OH). The

other brain regions were homogenized by a motorized teflon
homogenizer (Deltaware, Kimble Science Products) . The
samples were centrifuged at 21,800 x g (16,000 rpm) for 20
minutes at 4°C (SE12 rotor, Sorvall RC-SB centrifuge).
Samples were separated by reverse phase HPLC using a C-18
microbondapak column (3.9 mm x 30 cm)

(Waters; Milford, MA).

The mobile phase contained 0.1 M sodium phosphate-citric
acid (pH 4.0), 1.0 mM disodium EDTA, 1 mM heptanesulfonic
acid, and 7% (v/v) acetonitrile (Hortnagal et al. 1989). The
internal standard 3,4-dihydroxybenzylamine (DHBA) was
included in each sample. The flow rate was 0.7 ml/min and
the sample run time was approximately 35 minutes. Six to
eight individual samples were measured for each brain
region. The HPLC system consisted of a Bio-Rad (Richmond,CA)
pump, BAS (West Lafayette, IN) Amperometric detector LC-4B,
and a Hewlett Packard (Avondale, PA) 3390A integrator.

Synaptic Plasma Membrane Preparation
Synaptic plasma membranes (SPM) were prepared from

48
whole brain from control and ethanol-treated animals by the
method of Cotman and Matthews (i971). The preparation was
maintained at 4°C. The brains were removed and homogenized
(20%, w/v) in ice cold 0.32 M sucrose, 5.0 mM Tris (pH 7.0)
buffer (sucrose buffer) using a motorized teflon homogenizer
(Caframo RZR3; Warton, Ontario)

(6 up and down strokes,

setting 9). The homogenate was diluted to 10% (w/v) and
centrifuged at 1100 x g (3000 rpm) for 5 minutes (SS34
rotor, Sorvall RC-SB centrifuge). The supernatant was
decanted into another centrifuge tube and pelleted at
17,000 x g (13,700 rpm) for 10 minutes. The pellet was
resuspended in sucrose buffer (10%, w/v) using a round
bottom glass homogenizer and centrifuged for 20 minutes at
11,000 x g (11,000 rpm). The pellet was suspended in 5 ml of
sucrose buffer and layered onto a discontinuous
Ficoll-sucrose gradient consisting of i3 ml of
7.5% (w/v) Ficoll 400 in sucrose buffer and 13 ml of 13.0%
Ficoll 400 in sucrose buffer. The gradient was centrifuged
at 63,581 x g (22,000 rpm) for 45 minutes (SW-28 rotor,
Beckman L8-M ultracentrifuge). The synaptosomal material,
found at the 7.5% /13.0% Ficoll-sucrose interface, was
removed and diluted with 4 voluDes of sucrose buffer,
followed by centrifugation at 106,000 x g (24,000 rpm) for
30 minutes. This synaptosomal pellet was suspended in a
small volume of sucrose buffer, osmotically shocked in 6
volumes of 6.0 mM Tris, pH 8.1 for i.5 hours, and
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centrifuged for 15 minutes at 54,500 x g (20,000 rpm). The
resulting pellet was resuspended in 5 ml of sucrose buffer
and layered onto a discontinuous sucrose gradient consisting
of the following concentrations in ascending order: 38.0%
(w/v)

(7.5 ml), 35.0% (w/v)

and 25% (w/v)

(7.5 ml), 32.5% (w/v)

(7.5 ml),

(7.5 ml}. This gradient was centrifuged for

1.5 hours at 106,000 x g (24,250 rpm). The synaptic plasma
membranes (SPM) were found at the 25% /32.5% interface. This
layer was removed, diluted with 4 volumes of sucrose buffer,
and centrifuged at 106,000 x g {24,250 rpm) for 30 minutes.
The final pellet was suspended in sucrose buff er and stored
at -80°C. Cholesterol and phospholipid content was measured
in the SPM preparation.

Phosphorus Assay
The SPM lipids were extracted with chloroform:methanol
(2:1, v/v) and dried under nitrogen (Felch et al. 1957)
before measuring the phosphorus content by a modification of
the method of Fiske and Subbarrow {1925). To each triplicate
sample, 100 µl of perchloric acid (70%, v/v) was added. The
samples were heated by a heat block to 170°C until
colorless. After cooling, 1 ml of distilled water was added
to each sample. Standards (0 to 40 µg phosphorus) were
prepared from a stock solution of 1.3 mM KH2P04 (1 ml equals
40 µg phosphorus). Perchloric acid (100 µl) and distilled
water (1 ml} were also added to each standard. To each
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sample and standard were added 250 µl of 2.5% (w/v) ammonium
molybdate, 100 µl of reducer {3 g Na 2S03 ·anhydrous, 60 g
NaHS03 , and 1 g 1-amino-2-naphthol-4-sulphonic acid in 500
ml distilled

water), and distilled water (to a final volume

of 2.5 ml). Samples and standards were allowed to stand at
room temperature for 10 minutes. The 0.0. of the samples and
standards was determined at 625 nm.

Cholesterol Assay
Cholesterol levels in the SPM preparations were assayed
using the Sigma Diagnostic Kit (#351, st. Louis, MO). The
Sigma procedure involves a series of enzymatic reactions
coupled with the p-hydroxybenzenesulfonate and
4-aminoantipyrine chromogenic system. In the last step of
the reaction series, hydrogen peroxide reacts with
4-aminoantipyrine and p-hydroxybenzenesulfonate in the
presence of peroxidase to yield a quinoneimine dye, which
has a maximum absorbance at 500 nm.
The micro method (1 ml reaction volume) was used to
measure total cholesterol in the synaptic plasma membrane
(SPM) preparations from control and ethanol-treated animals.
To each cuvette, 100 µl of SPM sample (in triplicate) and
1 ml of cholesterol assay solution were added. The cuvettes
were covered immediately and mixed by inversion. The
cuvettes were incubated for 10 minutes at 37°C. The
absorbance at 500 nm was recorded iI1llllediately after the
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incubation. Sample values were calculated based on the
absorbance of the cholesterol standard (200 mg/dL).

protein Determination
Protein levels were assayed following the method of
Lowry et al. (1951). Human serum albumin (1 mg/ml) served as
the protein standard. The standard curve consisted of
concentrations of 0-50 µg protein. Standards and samples
were incubated in 100 µl of 1.0 N NaOH for 30 minutes at
room temperature to solubilize membrane bound proteins. To
each sample and standard 1 ml of a solution (0.1:0.1:10,
v/v/v) containing 1% (w/v) cupric sulfate, 2% (w/v) K+-Na+
tartrate, and 2% (w/v) sodium carbonate. After a 10 minute
incubation, 100 µl of 1.0 N Falin phenol reagent was added.
After a 30 minute incubation, the O.D. of the standards and
samples was determined at 700 nm.

Statistical Analysis
The values reported for dopamine and DOPAC
concentrations, adenylate cyclase activity, G protein
content, and cholesterol and phospholipid levels represent
the mean value ± the standard deviation of several samples.
student's 't' test was used to determine statistical
significance. P values of <0.05 represent significant
differences.
Certain types of experiments yield day to day
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variability in control values. Nonetheless, a comparison of
multiple studies of paired analyses of experimental and
control animals may consistently show the same effect (e.g.
an increase or decrease). To compensate for the day to day
variability in control values, a pair of samples for control
and ethanol-treated rats were assayed on the same day with
the same assay conditions. Multiple paired samples were
statistically analyzed utilizing the t-test for paired
comparisons. This type of analysis was used for the dopamine
Dl and 02 binding assays and for the slot blot analysis
G protein mRNA levels.

of
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chemicals

Source

Acetic anhydride

Sigma

Acrylamide

BioRad

Agarose

IBI

1-Amino-2-napthol-4-sulphonic acid

Sigma

Ammonium molybdate

Mallinckrodt

Ammonium persulf ate

BioRad

Aprotinin

Sigma

Ascorbic acid

Mallinckrodt

ATP

Sigma

Anti-actin antibody

ICN

Anti-cAMP antibody

RPI/BT!

1
[ 25!

ICN

[

125

J -anti mouse IgG

1 J -anti rabbit IgG

Amersham

Blood ethanol kit

Sigma

Bio-Safe II

RPI

Bovine serum albumin

Siqma

Bromophenol blue

Sigma

(+)-Butaclamol

RBI

[

125

! ] -cAMP

BTI

Chloroform

J.T. Baker

Cholesterol assay kit

Sigma

Citric acid

Sigma

Coomassie blue

Bio Rad

Cooper sulfate

Mallinckrodt

Creatine kinase

Sigma
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[32p]-CTP

Amer sham

Dextran sulfate

Sigma

DHBA

RBI

Diethyl pyrocarbonate

Sigma

Dithiothreitol

Sigma

DMSO

Sigma

DO PAC

RBI

Dopamine

RBI

EDTA

Sigma

EGTA

Sigma

Ethanol

Quantum

Ethidium bromide

IBI

Ficoll

Sigma

Ficoll 400

Pharmacia

Formaldehyde

Sigma

Formamide

IBI/BRL

Forskolin

Calbiochem

G protein antibodies

Dupont

'f-Globulin

Sigma

Glycerol

Sigma

Glycine

Sigma

GTP

Sigma
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suppliers
Amer sham

Arlington Heights, IL.

J.T. Baker

Jackson, TN.

Baxter

Muskegon, MI.

BioRad

Richmond, CA.
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Gaithersburg, MD.

BRL

Gaithersburg, MD.
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Stoughton, MA.

calbiochem

LaJolle, CA.

carnation

Los Angeles, CA.
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Detroit, MI.
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Boston, MA.
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St. Louis, MO.
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Boston, MA.

Pharmacia
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Anaheim, CA.
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Natick, MA.
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Keene, NH.

Sigma

St. Louis, MO.

CHAPTER IV
RESULTS
Animal Model
This study examined Fisher 344 male rats that were
pair-fed a control or ethanol liquid diet for 4-5 weeks
(chronic exposure) prior to sacrifice at three months. The
animals consumed 80-100 ml/day which corresponds to 20-25 g
ethanol/kg weight for the ethanol-treated animals. The
initial weights of the two-month old rats were 172.2 + 30.6
grams for the control animals and 174.4 ± 31.0 grams for the
ethanol-fed animals. After diet consumption for 4-5 weeks,
the weights of the control animals were 238.1

±

31.0 grams

and the weights of the ethanol-treated animals were 233.8 +
31.3 grams, reflecting comparable weight gain (Figure 1).
The final weights were significantly greater than the
initial weights (p<0.05). Blood ethanol levels of the
ethanol-fed animals ranged between 80-130 mg/dL following a
90 minute exposure to ethanol. Ethanol was undetectable in
the control animals.

Dopamine Dl Receptors
The Dl receptors were assessed using the radioligand
SCH 23390, a Dl antagonist which binds to both the high and
59
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Figure 1.

Weights of control and ethanol-treated animals.

weights of control and ethanol-treated animals are shown.
This

data represents the mean weight + the standard

deviation obtained from 130 ethanol-treated animals and 120
control animals. The initial (two months of age) and final
weights {12 to 13 weeks of age) of control and experimental
animals were compared using Student's ' t ' test. There was no
significant difference in the initial weights between
control and ethanol-treated rats before diet consumption nor
after 4-5 weeks of pair-feeding (p>0.05).
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low affinity sites of the Dl receptor, in several brain
regions of control and ethanol-treated animals. The regions
analyzed include the frontal cortex, the striatum, the
nucleus accumbens, and the globus pallidus.
Typical binding assays for each brain region are
depicted in Figures 2 to 5. The figures represent saturation
curves. The x-axis represents ligand concentration (nM),
while the y-axis indicates specific binding (pmol/mg
protein). Scatchard plots are shown in the inset. In
Scatchard plots, the x- and y-axes stand for bound and
bound/free, respectively. Nonspecific binding of SCH 23390,
determined in the presence of 1

uM

(+)-butaclamol, accounted

for 10-15% of the total bound radioactivity in the striatum
and nucleus accumbens. Nonspecific binding was approximately
25% in the globus pallidus and 25-30% in the frontal cortex.
Under the assay conditions established in this laboratory,
the Kd values ranged from 0.3 nM in the globus pallidus to
2.0 nM in the frontal cortex. For a typical assay, an
attempt was made to assess binding at ligand concentrations
ranging from 1/8-1/10

Kd to 8-10 Kd. For the SCH 23390

binding assays, several ligand concentrations between 0.05
nM to 5.0 nM were selected. These concentrations were
generally sufficient to establish saturation. In the frontal
cortex, an apparent second site was detected at ligand
concentrations greater than 6.0 nM. However, saturation was
established at ligand concentrations of 4.0 to 5.5 nM. A
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Figure 2. Binding of SCH 23390 to membranes from the nucleus
accumbens of control and ethanol-treated animals.

This figure represents a typical study of SCH 23390 binding
to Dl receptors in membranes from the nucleus accumbens. The
saturation curve depicts the binding of

o.o

nM

to 0.5 nM

[3H]-SCH 23390 and the binding of 0.5 nM [ 3H]-SCH 23390 in

the presence of several concentrations (O.O nM to 5.0 nM) of
unlabelled SCH 23390. Membranes from three control or
ethanol-treated animals were pooled prior to analysis. The
nonspecific binding, determined in the presence of 1

uM

(+)-butaclamol, accounted for 10-15% of the total binding at
each ligand concentration. The Kd and Bmax values ± the
standard deviation, derived from the linear regression of
the data points, were:
Kd: 0.802 ± .088 nM (control)
0.601 ± .055 nM (ethanol)
Bmax: 0.788 ± .051 pmol/mg protein (control)
0.476 ± .024 pmol/mg protein (ethanol)
The differences in the Kd and Bmax values obtained from six
similar paired experiments were statistically analyzed using
the t-test for paired comparisons. It was found that the
Bmax for Dl

binding sites was significantly decreased

(p<0.05) in the nucleus

accumbens of ethanol-treated

animals. There were no significant differences in the Kd
values (p>0.05).
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Figure 3.

Binding of SCH 23390 to cortical membranes
from control and ethanol-treated

animals.

This figure represents a typical study of SCH 23390 binding
to Dl receptors in membranes of the frontal cortex. The
saturation curve depicts the binding of
[ 3H]-SCH

o.o

nM to 0.5 nM

23390 and the binding of O. 5 nM [ 3HJ-SCH 23390 in

the presence of several concentrations (O.O nM to 5.0 nM) of
unlabelled SCH 23390. Membranes from three control or
ethanol-treated animals were pooled prior to analysis. The
nonspecific binding, determined in the presence of 1 µM
(+)-butaclamol, accounted for 25-30% of the total binding at
each ligand concentration. The Kd and Bmax values ± the
standard deviation, derived from the linear regression of
the data points, were:
Kd: 2.422 ± .257 nM (control)
2.282 ± .461 nM (ethanol)
Bmax: 0.251 ± .017 pmollmg protein (control)
0.209 ± .022 pmoltmg protein (ethanol)
The differences in the Kd and Bmax values obtained from six
similar paired experiments were statistically analyzed using
the t-test for paired comparisons. It was found that the
Bmax for Dl binding sites was significantly decreased
(p<0.05) in the frontal cortex of ethanol-treated animals.
There were no significant differences in the Kd values
(p>0.05).
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Figure 4.

Binding of SCH 23390 to striatal membranes of
control and ethanol-treated animals.

This figure represents a typical study of SCH 23390 binding
to Dl receptors in striatal membranes. The saturation curve
depicts the specific binding of

o.o

nM to 0.5 nM [ 3H]-SCH

23390 and the binding of 0.5 nM [ 3H]-SCH 23390 in the
presence of several concentrations (O.O nM to 5.0 nM) of
unlabelled SCH 23390. Membranes from three control or
ethanol-treated animals were pooled prior to analysis. The
nonspecific binding, determined in the presence of 1

uM

(+)-butaclamol, accounted for 10-15% of the total binding at
each ligand concentration. The Kd and Bmax values ± the
standard deviation, derived from the linear regression of
the data points, were:
Kd: 0.681 ± .029 nM (control)
0.708 ± .025 nM (ethanol)
Bmax: 0.420 ± .009 pmol/mg protein (control)
0.398 ± .007 pmol/mg protein (ethanol)
The differences in the Kd and Bmax values obtained from six
similar paired experiments were statistically analyzed using
the t-test for paired comparisons. It was found that neither
the Kd nor the Bmax were significantly different in striatal
membranes of ethanol-treated animals (p>0.05).
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Figure 5. Binding of SCH 2339a to membranes from the globus
pallidus of control and ethanol-treated animals.

This figure represents a typical study of SCH 23390 binding
to Dl receptors in membranes from the globus pallidus. The
binding of SCH 23390 to membranes isolated from the globus
pallidus was assayed in duplicate at each ligand
concentration. The saturation curve depicts the binding of
a.a nM to 1.a nM of [ 3H]-SCH 23390. Membranes from five
control or ethanol-treated animals were pooled prior to
analysis. The nonspecific binding, determined in the
presence of 1 µM (+)-butaclamol, accounted for 25% of the
total binding at each ligand concentration. The Kd and Bmax
values ± the

standard deviation, derived from the linear

regression of the

data points, were:
Kd: 0.277 ± .048 nM (control)
0.295 ± .043 nM (ethanol)

Bmax: 0.306 ± .a2s pmol/mg protein (control)
0.318 ± .a25 pmol/mg protein (ethanol)
The differences in Kd and Bmax values obtained from four
similar paired studies were statistically analyzed using the
t-test for paired comparisons. It was found that neither the
Kd nor the Bmax were significantly different in membranes of
ethanol-treated animals (p>a.05).
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component of SCH 23390 binding in the frontal cortex may be
the serotonin (5-HT2 ) receptor (Hess et al. 1986). Binding
assays for the frontal cortex were repeated in the presence
of 40 nM ketanserin, a 5-HT2 antagonist, to discriminate
multiple binding sites (Figure 6). For all binding assays,
the Kd values were calculated from the slope and Bmax values
from the x-intercept of the Scatchard plot utilizing linear
regression. The linear fit of the Scatchard plots represent
correlation coefficients of at least 0.9.
Dopamine Dl binding sites were measured at multiple
ligand concentrations when sufficient tissue was available.
However, in quantitatively small regions, binding was
initially examined using five three-point analyses. The
three concentrations of [ 3H]-SCH 23390 represented
approximately 1/5 Kd, Kd, and 5 Kd values. Four saturation
analyses were performed to confirm the observations made
using the three point analyses. The t-test for paired
comparisons demonstrated that the Bmax was decreased
approximately 40% in the nucleus accumbens and 25% in the
frontal cortex (p<0.05). Figure 13

demonstrates that the

ketanserin competition for [ 3H]-SCH 23390 binding in the
frontal cortex represents a single binding site; therefore,
the loss of Dl receptors in the frontal cortex appears to be
only a loss of the Dl sites, not the serotonin sites. In
contrast, there were no significant differences in either
the Kd or Bmax for SCH 23390 binding to membranes from the
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Figure 6. Binding of SCH 23390 in the presence of
ketanserin to cortical membranes from control
and ethanol-treated rats.

This figure represents the binding of SCH 23390 in the
presence of 40 nM ketanserin, a 5-HT2 antagonist, to the Dl
receptors in membranes from the frontal cortex. The
saturation curve depicts the binding of 0.0 nM to 0.5 nM
[ 3H]-SCH

23390 and the binding of 0.5 nM [ 3H]-SCH 23390 in

the presence of several concentrations (O.O nM to 5.0 nM) of
unlabelled SCH 23390. The nonspecific binding, determined in
the presence of 1 µM (+)-butaclamol, accounted for 35-40% of
the total binding at each ligand concentration. The Kd and
Bmax values ± the standard deviation, derived from the
linear regression of the data points, were:
Kd: 2.078 ± .140 nM (control)
1.966 ± .164 nM (ethanol)
Bmax: 0.216 ± .010 pmol/mg protein (control)
0.175 ± .010 pmol/mg protein (ethanol)

This experiment demonstrates that the ketanserin competition
for SCH 23390 binding in the frontal cortex represents a
single binding site. It was found that the Bmax for Dl
binding sites in the presence of ketanserin was decreased
(20%) in the frontal cortex of ethanol-treated animals, as
observed in previous experiments.
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striatum or globus pallidus of three-month old
ethanol-treated rats (p>0.05). In addition, there was a
nonsignif icant trend towards increased affinity (decreased
Kd) in the nucleus accumbens in all experiments. Under the
assay conditions described, binding sites for SCH 23390 were
not detectable in the substantia nigra, ventral pallidum,
and ventral tegmental area. Others have detected 01 sites in
these areas
et al. 1986;

utilizing quantitative autoradiography (Boyson
Mansour et al. 1990).

This analysis has demonstrated that three-month old
Fisher 344 rats, fed an ethanol liquid diet on a chronic
basis, had a significant decrease in the Bmax for SCH 23390
binding in the nucleus accumbens and frontal cortex
(p<0.05).

Dopamine D2 Binding Assay
The radioligand [ 3H]-spiperone was used to measure
total dopamine D2 sites in the striatum and nucleus
accumbens of control and ethanol-treated animals. Figures 7
and 8 represent typical binding assays in which 02 binding
sites were measured in the striatum and nucleus accumbens,
respectively. The D2 sites were labeled with [ 3H]-spiperone
in the presence of 40 nM ketanserin to block 5-HT2 sites.
Nonspecific binding, determined by 1 µM (+)-butaclamol,
accounted for 15% to 35% of the total binding at the lowest
to the highest concentration in the striatum and 25% to 40%
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Figure 7.

Binding of spiperone to striatal membranes of
control and ethanol-treated animals.

This figure represents a typical study of spiperone binding
to 02

receptors in striatal membranes. The saturation curve

depicts the binding of

o.o

nM to 0.9 nM [ 3H]-spiperone.

Membranes from three control or ethanol-treated animals were
pooled prior to analysis. The nonspecific binding,
determined in the presence of 1

~M

(+)-butaclamol,

represented 20% of the total binding. The Kd and Bmax values
± the standard deviation, derived from the linear regression

of the data points, were:
Kd: 0.154 ± .012 nM (control)
0.121 ± .014 nM (ethanol)

Bmax: 0.248 ± .009 pmol/mg protein (control)
0.252 ± .016 pmol/mg protein (ethanol)

The differences in the Kd and Bmax values obtained from six
similar paired experiments were statistically analyzed using
the t-test for paired comparisons. It was found that neither
the Kd nor the Bmax were significantly different in striatal
membranes of three-month-old ethanol-treated animals
{p>0.05).
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Figure 8. Binding of spiperone to membranes from the
nucleus accumbens of control and ethanol-treated
animals.

This figure represents a typical study of spiperone binding
to 02 receptors in membranes of the nucleus accumbens. The
saturation curve depicts the binding of

o.o

nM to 0.8 nM

[3H]-spiperone. Membranes from three control or
ethanol-treated animals were pooled prior to analysis. The
nonspecific binding, determined in the presence of 1 µM
(+)-butaclamol, represented 30% of the total binding. The Kd
and Bmax ± values the standard deviation, derived from the
linear regression of the data points, were:
Kd: 0.083 ± .012 nM (control)
0.082 ± .006 nM (ethanol)
Bmax: 0.129 ± .009 pmol/mg protein (control)
0.112 ± .004 pmol/mg protein (ethanol)
The differences in the Kd and Bmax values obtained from six
similar paired experiments were statistically analyzed using
the t-test for paired comparisons. It was found that neither
the Kd nor the Bmax were significantly different in
membranes from the nucleus accumbens of three-month-old
ethanol-treated animals (p>0.05).
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of that in the nucleus accumbens. The Kd values ranged
from o.08 nM in the nucleus accumbens to 0.15 nM in the
striatum. For the kinetic assays, several ligand
concentrations between 0.0 nM and 1.0 nM were selected to
establish saturation. The Kd values were calculated from the
slope and Bmax values from the x-intercept of the Scatchard
plots utilizing linear regression. The linear fit of the
scatchard plots represent correlation coefficients of at
least 0.9.
The t-test for paired comparisons demonstrated there
were no significant differences in either the Kd or Bmax for
[ 3H]-spiperone

binding to membranes from the striatum or the

nucleus accumbens. This analysis indicates that neither the
number nor the affinity of spiperone binding sites are
altered in these brain regions of three-month-old Fisher 344
rats fed an ethanol-containing liquid diet for one month
prior to sacrifice.
Using the binding techniques described,

[ 3H]-spiperone

labeled 02 receptors were below the level of detectability
in the

frontal cortex and globus pallidus. The nonspecific

binding was at least 90% at ligand concentrations greater
than 0.2 nM in these regions. As described for the Dl
binding assay, three point surveys were also performed on
quantitatively small regions. Spiperone binding sites were
not measurable in the substantia nigra, ventral pallidum,
and ventral tegmental area.
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Dopamine 02 Agonist Binding Assay
The dopamine receptors exist in two states: a high
affinity state and a low affinity state. The radioligand
propylnorapomorphine, a selective 02 agonist, was used to
measure the high affinity state of the 02 receptor in brain
regions of three-month-old control and ethanol-treated rats.
The assay was also performed in the presence of GTP to
measure the ability of these receptors to be converted to
the low affinity state, which would indicate alterations in
the functionality of the G proteins. The regions analyzed
include the striatum and the nucleus accumbens, areas where
spiperone binding was measurable using the described ligand
binding technique.
Both three point surveys and saturation assays were
performed to assess [ 3H]-propylnorapomorphine binding and
conversion of the 02 high affinity sites. In the three point
assays, the concentrations of [ 3H]-propylnorapomorphine
represented approximately 1/5 Kd, Kd, and 5 Kd values.
Typical binding assays for each brain region are depicted in
Figures 9 and 10. Binding assays reflecting conversion of
the high affinity state to the low affinity state are shown
in Figures 11 and 12. The figures represent saturation
curves and Scatchard plots. Nonspecific binding, determined
in the presence of 1 µM (+)-butaclamol, accounted for
approximately 20% of the total radioactivity at the lowest
ligand concentration and 50 % of the total radioactivity at
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Figure 9. Binding of propylnorapomorphine to striatal
membranes of control and ethanol-treated animals.

The binding of [ 3H]-propylnorapomorphine to striatal
membranes was assayed in duplicate at each ligand
concentration. The saturation curve depicts the binding of

o.o

nM to 1.6 nM [ 3H]-propylnorapomorphine. Membranes from

four control or ethanol-treated animals were pooled prior to
analysis. The nonspecific binding, determined in the
presence of 1 µM (+)-butaclamol, ranged from 20% to 50% of
the total binding. The Kd and Bmax values ± the standard
deviation, derived from the linear regression of the data
points, were:
Kd: 0.167 ± .030 nM (control)
0.164 ± .024 nM (ethanol)
Bmax: 0.208 ± .014 pmol/mg protein (control)
0.201 ± .010 pmol/mg protein (ethanol)

The differences in the Kd and Bmax values obtained from four
similar paired experiments were statistically analyzed using
the

t-test for paired comparisons. It was found that

neither the Kd

nor the Bmax were significantly different in

striatal membranes from three-month-old ethanol-treated
Fisher 344 rats (p>0.05).
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Figure 10. Binding of propylnorapomorphine to membranes from
the nucleus accumbens of control and
ethanol-treated rats.

The binding of [ 3H]-propylnorapomorphine to membranes from
the nucleus accumbens was assayed in duplicate at each
ligand concentration. The saturation curve depicts the
binding of

o.o

nM to 1.7 nM [ 3H]-propylnorapomorphine.

Membranes from four control or ethanol-treated animals were
pooled prior to analysis. The nonspecific binding,
determined in the presence of 1 µM (+)-butaclamol, ranged
from 20% to 50% of the total binding. The Kd and Bmax values
± the standard deviation, derived from the linear regression
of the data points, were:
Kd: 0.373 ± .052 nM (control)
0.494 ± .090 nM (ethanol)
Bmax: 0.103 ± .008 pmol/mg protein (control)
0.109 ± .012 pmol/mg protein (ethanol)

The differences in the Kd and Bmax values obtained from four
paired similar experiments were statistically analyzed using
the t-test for paired comparisons. It was found that neither
the Kd nor the Bmax were significantly different in
membranes from the nucleus accumbens ethanol-treated Fisher
344 rats (p>0.05).
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Figure 11. Binding of propylnorapomorphine in the presence
of GTP to striatal membranes in control and
ethanol-treated rats.
Figures a and b represent the conversion of the high
affinity state of the 02 receptor to its low affinity state
in ethanol-treated and control animals, respectively. The
saturation curves depict the binding of 0.05 nM to 1.6 nM
[ 3H]-propylnorapomorphine

in the absence and presence of

300 µM GTP. The Kd and Bmax values ± the standard deviation,
derived from the linear regression of the data points, were:
Ethanol-treated:

Kd: 0.164 ± .024 nM
0.234 ± .044 nm (300 µM GTP)

Bmax: 0.201 ± .010 pmol/mg protein
0.111 ± .008 prnol/mg protein (300 µM GTP)
Kd: 0.167 ± .030 nM

Control:

0.244 ± .019 nM (300 µM GTP)
Bmax: 0.208 ± .014 prnol/rng protein
0.111 ± .004 pmol/rng protein (300 µM GTP)

In the ethanol-treated animals approximately 45% of the 02
high affinity sites were converted to the low affinity state
and in the control animals, approximately 47% of the sites
were

converted. It was found that the proportion of

striatal 02 sites converted from high affinity state to the
low affinity state was not significantly altered by ethanol
treatment (p>0.05).
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Figure 12. Binding of propylnorapomorphine in the presence
of GTP to the nucleus accumbens of control and
ethanol-treated rats.
Figure a and b represent the conversion of the high affinity
state of the D2 receptor to the low affinity state in
ethanol-treated and control animals, respectively. The
saturation curves depict the binding of
[ 3HJ-propylnorapomorphine

o.o

nM to 1.7

nM

in the absence and presence of

300 µM GTP. The Kd and Bmax values ± the standard deviation,
derived from the linear regression of the data points, were:
Ethanol-treated:

Kd: 0.494 ± .090 nM
0.813 ± .123 nm (300 µM GTP)

Bmax: 0.109 ± .012 pmol/mg protein
0.075 ± .008 pmol/mg protein (300 µM GTP}
Control:

Kd: 0.373 ± .052 nM
0.735 ± .125 nM (300 µM GTP)
Bmax: 0.103 ± .008 pmol/mg protein
0.066 ± .007 pmol/mg protein (300 µM GTP)

In the ethanol-treated animals approximately 31% of the D2
high affinity sites were converted to the low affinity state
and in the control animals, approximately 36% of the sites
were converted. It was found that the proportion of the D2
sites converted from the high affinity state to the low
affinity state in the nucleus accumbens was not
significantly altered by ethanol treatment (p>0.05).
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the highest ligand concentration in the striatum and the
nucleus accumbens. The Kd values ranged from 0.15 nM in the
striatum to 0.40 nM in the nucleus accumbens; with the
addition of GTP, there was approximately a two-fold increase
in the Kd values. Several ligand concentrations between
0.02 nM

to 2.0 nM were selected to establish saturation.

The Kd and Bmax values were calculated from the Scatchard
plots utilizing linear regression analysis. The linear fit
of the Scatchard plots represent correlation coefficients of
at least 0.9.
In membranes from both control and ethanol-fed rats,
300 µM GTP stimulated the conversion of the high affinity
binding state to the low affinity state. In the striatum, an
average 50% of the high affinity sites were converted to the
low affinity state, while in the nucleus accumbens, an
average 35% of the high affinity sites were converted to the
low affinity state.
The t-test for paired comparisons demonstrated that
there

were no significant differences in either the Kd or

Bmax for propylnorapomorphine binding to membranes from the
striatum or nucleus accumbens (p>0.05). In addition, in the
presence of GTP, the conversion of the high affinity state
to the low affinity state was similar in membranes from
control and ethanol-treated animals (p>0.05). The percent
conversion for all experiments was statistically analyzed by
Student's ' t ' test. The results of these studies demonstrate
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that consumption of an ethanol-containing diet for one month
does not alter the high affinity state of the D2 site or the
ability of this site to convert to the low affinity state in
three-month-old Fisher 344 rats.

Determination of Dopamine and DOPAC Concentrations
This study determined dopamine and
3,4-dihydroxyphenylacetic acid (DOPAC) concentrations (ng/mg
protein) in several brain regions of control and
ethanol-treated animals. The regions analyzed include: the
striatum, globus pallidus, and substantia nigra which are
components of the nigrostriatal pathway and the nucleus
accumbens, ventral pallidum, frontal cortex, and ventral
tegmentum which are components of the mesolimbic dopamine
pathway. The results of these studies, presented as the mean

±

the standard deviation, were compared for statistical

significance using Student's ' t ' test •
The results of these studies are depicted in Figures 13
to 16. Six to eight individual samples from control rats and
six to eight samples from ethanol-treated rats were examined
for each brain region. In comparison to control animals,
there was a 2- to 3-fold increase in dopamine and DOPAC
concentrations in the frontal cortex, ventral tegmentum, and
ventral pallidum, a 2-fold increase in DOPAC concentration
in the substantia nigra (p<0.01), and approximately a 30%
decrease in dopamine concentration in the substantia nigra
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Figure 13.

Concentration of dopamine and DOPAC in the
frontal cortex and nucleus accumbens.

Figure a depicts the concentration (ng/mg protein) of
dopamine and DOPAC in the frontal cortex.
Ethanol

Control

Dopamine

5.33 ± 1.87 ..

DOPAC

4.14 ±

i.oa·

2.23 ± 1.16
2.61 ± 1.01

Figure b depicts the concentration (ng/mg protein) of
dopamine and DOPAC in the nucleus accumbens.
Ethanol
Dopamine

Control

180.3 ± 49.1

DOPAC

95.6 ±

s1.s·

194.3 ± 45.6
233.5 ± 94.3

Each value represents the mean ± the standard deviation of
values obtained from six to eight individual animals. The
symbols • and •• indicate that values from control and
ethanol-treated animals differ significantly at p<0.05 and
p<0.01, respectively.
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Figure 14. Concentration of dopamine and DOPAC in the
ventral pallidum and the ventral tegmental area.

Figure a depicts the concentration (ng/mg protein) of
dopamine and DOPAC in the ventral pallidum.
Ethanol

io.a··

Dopamine

31.5 ±

DO PAC

55.5 ± 35_5•

Control
14.0 ± 7.9
17.9 ± 12.9

Figure b depicts the concentration (ng/mg protein) of
dopamine and DOPAC in the ventral tegmental area.
Ethanol
Dopamine
DOPAC

50.3 ± 11.a164.8 ±

60.a··

Control
19.1 ± 5.8
77.2 ± 16.9

Each value represents the mean ± the standard deviation of
values obtained from six to eight individual animals. The
symbols • and •• indicate that values from control and
ethanol-treated animals differ significantly at p<0.05 and
p<0.01, respectively.
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Figure 15. Concentration of dopamine and DOPAC in the
striatum and the globus pallidus.

Figure a depicts the concentration (ng/mg protein) of
dopamine and DOPAC in the striatum.
Ethanol
Dopamine

Control

265.5 ± 137.6

278.4 ± 77.2

87.4 ± 51.0

125.7 ± 51.2

DOPAC

Figure b depicts the concentration (ng/mg protein) of
dopamine and DOPAC in the globus pallidus.
Ethanol
Dopamine

347.8 ± 96.2

DOPAC

37.3 ± 8.7

Control
241.9 ± 88.8
31.4 ± 11.8

Each value represents the mean ± the standard deviation of
values obtained from six to eight individual animals. The
symbols • and •• indicate that values from control and
ethanol-treated animals differ significantly at p<0.05 and
p<0.01, respectively.
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Figure 16. Concentration (ng/mg protein) of dopamine and
DOPAC in the substantia nigra.

Ethanol

Control

Dopamine

26.6 ± 4,9•

38.6 ± 9.7

DOPAC

21.2 ± 9,2··

8.2 ± 1.7

Each value represents the mean ± the standard deviation of
values obtained from six to eight individual animals. The
symbols • and •• indicate that values from control and
ethanol-treated animals differ significantly at p<0.05 and
p<0.01, respectively.
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FIGURE 16
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(p<0.05). Although DOPAC was 60% below control values in
the nucleus accumbens (p<0.01), the dopamine
concentration was not significantly altered (p>0.05). In the
striatum and globus pallidus, dopamine and DOPAC
concentrations were not significantly different (p>0.05).
The findings of this

study demonstrate that consumption of

an ethanol liquid diet for one month results in significant
changes in the concentration of dopamine and DOPAC in
specific brain areas of three-month-old Fisher 344 rats.

Adenylate Cyclase Activity
Basal and dopamine-sensitive adenylate cyclase activity
were measured in several brain regions of control and
ethanol-treated animals. The brain regions analyzed include
the striatum, nucleus accumbens, and frontal cortex.
Adenylate cyclase activity also was assessed in the presence
of forskolin, GTP, and sodium fluoride in order to identify
the site of any observed change. Forskolin directly
activates adenylate cyclase whereas GTP and sodium fluoride
directly stimulate the G protein. The levels of cAMP
(nmoles/mg protein/5 min) measured by radioi11UI1unoassay were
used as an assessment of adenylate cyclase activity.
Table 1 demonstrates the stiEulation or inhibition of
adenylate cyclase by these drugs. There was a significant
increase in adenylate cyclase activity in the presence of
forskolin, GTP, and sodium fluoride in all brain regions
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Table 1

Adenylate Cyclase Activity
(nmoles c'AMP/mg protein)

Stria tum

Accumbens

0.14 + .03

0.08

+ Forskolin

42.5 ± 1. 3••

27.0 ± 1. 4 ••

6.72 ± . 25 ..

+ NaF

4.46 ± . 4 3••

2.24 ±

• 3g••

2.05 ± • 33••

+ GTP

1.12 ± .05 ..

0.63 ± . 21··

0.88 ± . 05••

Basal

±

.01

Cortex
0.16 + .02

Dopamine
-stimulated

1.94 ± .23°

-inhibited

0. 92 ± • 09°

1.19

±
ND

,27•

1.01 ±

.os·

ND

Each value represents the mean ± the standard deviation of
three individual experiments for each brain region. Basal
adenylate cyclase activity was measured in the absence or
presence of either 100 µM forskolin, 100 µM GTP, or 10 mM
NaF. The data also depicts the mean ± the standard deviation
of three individual experiments of the stimulation (+ 50 nM
spiperone) or inhibition (100 nM SCH 23390) of adenylate
cyclase activity by 100 µM dopamine. The symbols • and ••
indicate the values that differ siqnificantly at p<0.05 and
p<0.01, respectively, as compared to basal values or basal
values in the presence of GTP.
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analyzed (p<0.01). Compared to basal adenylate cyclase
activity in the presence of GTP, there was a significant
increase in dopamine-stimulated adenylate cyclase activity
(in the presence of 50

nM

spiperone) in all regions and a

significant decrease in dopamine-inhibited adenylate cyclase
activity (in the presence of 100 nM SCH 23390) in the
striatum (p<0.05). These results indicate that there was a
true stimulation of the Dl receptors in the striatum,
nucleus accumbens, and frontal cortex, and a true inhibition
of the D2 receptors in the striatum.
The results of this study are depicted in Figures 17 to
19. Figure 17 represents the basal and dopamine-sensitive
adenylate cyclase activity in the striatum and the effects
of forskolin, GTP, and sodium fluoride on striatal adenylate
cyclase activity. Similarly, Figures 18 and 19 depict the
adenylate cyclase activity of the nucleus accumbens and the
frontal cortex, respectively. The activity is defined as
nmoles cAMP formed per mg protein per 5 minutes. The
nonspecific binding determined by bovine serum albumin (BSA)
was an average 3% of total binding and the cAMP antibody
accounted for an average 30% of the total binding. Each
value represents the mean ± the standard deviation of three
individual experiments. Student's 't' test was used to
determine significant differences.
The results of this study of adenylate cyclase activity
demonstrate that consumption of an ethanol liquid diet for
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Figure 17. The effect of chronic ethanol treatment on
adenylate cyclase activity in the striatum of
three-month-old rats.

Figures 17a, 17b, 17c, and 17d depict striatal basal
adenylate cyclase activity in the absence of stimulatory
chemicals (a), or in the presence of 100 µM GTP (b), 100 µM
forskolin (c), or 10 nM sodium fluoride (NaF)

(d). Figure

17b also depicts 01-stimulated and D2-inhibited adenylate
cyclase activity in the presence of GTP. The activity is
defined as nmoles cAMP/mg protein.

Each value represents the mean ± the standard deviation of
three individual experiments. The symbols • and .. indicate
that values from control and ethanol-treated animals differ
significantly at p<0.05 and p<0.01, respectively.
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Figure 18. The effect of chronic ethanol treatment on
adenylate cyclase activity in the nucleus
accumbens of three-month-old rats.

Figures 18a, lSb, 18c, and 18d depict basal adenylate
cyclase activity of the nucleus accumbens in the absence of
stimulatory chemicals (a), or in the presence of
100 µM GTP (b), 100 µM forskolin (c), or 10 nM sodium
fluoride

(NaF)

(d). Figure 18b also depicts DI-stimulated

adenylate cyclase activity in the presence og GTP. The
activity is defined as nrnoles cAMP/mg protein.

Each value represents the mean ± the standard deviation of
three individual experiments. The symbols • and •• indicate
that values from control and ethanol-treated animals differ
significantly at p<0.05 and p<0.01, respectively.
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Figure 19. The effect of chronic ethanol treatment on
adenylate cyclase activity in the frontal cortex
of three-month-old rats.

Figures 19a, 19b, 19c, and 19d depict basal adenylate
cyclase activity of the frontal cortex in the absence of
stimulatory chemicals (a), or in the presence of 100 µM GTP
(b), 100 µM forskolin (c), or 10 nM sodium fluoride (NaF)
(d). Figure 19b also depicts D-1 stimulated adenylate
cyclase activity in the presence of GTP. The activity is
defined as nmoles cAMP/mg protein.

Each value represents the mean ± the standard deviation of
three individual experiments. The symbols • and

**

indicate

that values from control and ethanol-treated animals differ
significantly at p<0.05 and p<0.01, respectively.
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one month results in significant alteration in adenylate
cyclase activity in the nucleus accumbens of three-month-old
Fisher 344 rats, although the adenylate cyclase activity of
the striatum and the frontal cortex was not affected by
ethanol treatment.
Basal, Dl-stimulated, and D2-inhibited adenylate
cyclase activities in the striatwn. were not significantly
altered by chronic ethanol treatment (p>0.05). Striatal
adenylate cyclase activity in the presence of forskolin,
GTP, and sodium fluoride was not effected by ethanol
treatment (p>0.05).
In the nucleus accumbens, although basal adenylate
cyclase activity was not significantly different in
ethanol-treated animals (p>0.05), adenylate cyclase activity
in the presence of 100 µM dopamine was significantly
increased (70%) in ethanol-treated animals (p<0.05).
Dl-stimulated adenylate cyclase activity was not
significantly altered in the nucleus accumbens of
ethanol-treated animals (p>0.05). Adenylate cyclase activity
in the presence of forskolin, GTP, and sodium fluoride was
not effected by ethanol treatment (p>0.05). Dopamine
02-inhibited adenylate cyclase activity was not measurable
in the nucleus accumbens. This finding concurs with the
observations of Stoof and Verheijden (1986) and Kelly and
Naharski (1987).
Basal and Dl-stimulated adenylate cyclase activity was
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not significantly altered in the frontal cortex of
ethanol-treated animals (p>0.05). Since 02 sites were not
measurable in the frontal cortex, 02-inhibited adenylate
cyclase activity was not analyzed. Adenylate cyclase
activity of the frontal cortex in the presence of forskolin,
GTP, and sodium fluoride was not significantly altered in
ethanol-treated animals (p>0.05).

Analysis of G Proteins
This study analyzed the effects of chronic ethanol
treatment on the content of the G proteins in several brain
regions. The a subunits of Gs and Go were measured using
monoclonal antibodies directed against these subunits, Gia
was not analyzed due to the unavailability of specific
antibodies to this protein. The brain regions studied
include the striatum, globus pallidus, and substantia nigra
of the nigrostriatal pathway and the frontal cortex, nucleus
accumbens, ventral pallidum, and the ventral tegmentum of
the mesolimbic dopamine pathway.

~-Actin

was analyzed as a

control to monitor for equivalency for protein loading.
The samples were separated on a 10% (v/v)

sos-

polyacrylamide gel and the separated proteins were
transferred to nitrocellulose filters. The filters were
incubated with the antibody for the G proteins or actin
(primary antibody), followed by incubation with [ 1 ~I)-IgG
(secondary antibody). The filters were then exposed on film.
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The autoradiograms for Gs, Go, and actin were scanned
by a densitometer. Optical density (O.D.) values were
assigned to each sample and these values were used to
calculate ratios for Gs and Go relative to actin. Actin
served as a control for differences in the loading of gel
lanes. This allowed for a correction factor due to unequal
protein loading onto the gel. The ratios were defined as
arbitrary densitometer units (ADU). Three individual samples
(control and ethanol) from each brain region were separated
on a gel. Three additional individual samples were similarly
analyzed. Thus, a total of six samples were analyzed for
each brain region.
The results of this study are shown in Figures 20 and
21. Figure 20 depicts the ratio of ADU for Gs/actin in each
brain region, while Figure 21 depicts the ratio of ADU for
Go/actin. The values represent the mean ± the standard
deviation of three individual samples separated on the same
gel. Similar results were obtained from gels containing
additional samples. In all brain regions analyzed, neither
the Gs protein nor the Go protein were significantly altered
{p>0.05). The results indicate that chronic ethanol exposure
does not alter the protein content of the Gs or Go proteins
in the striatum, globus pallidus, substantia nigra, nucleus
accumbens, frontal cortex, ventral pallidum, and ventral
tegmental area from three-month-old rats which consumed
ethanol for one month prior to sacrifice.
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Figure 20. The effects of chronic ethanol exposure on the
protein content of Gs in three-month-old rats.

Control

Ethanol
Brain Region
Frontal Cortex

0.84 ± 0.14

0.80 ± 0.06

Nucleus Accumbens

3.10 ± 0.49

3.13 ± 0.32

Ventral Pallidum

4.55 ± 1.82

4.29 ± 1.80

Ventral Tegmentum

2.79 ± 0.66

2.91 ± 0.08

Stria tum

1.30 ± 0.51

1.28 ± 0.54

Globus Pallidus

2.42 ± 0.99

2.66 ± 1.38

Substantia Nigra

1.01 ± 0.05

1.07 ± 0.14

-----------------------------------------------------------Each value represents the mean ± the standard deviation
of the Gs/actin ratio in arbitrary densitometer units
(ADU) obtained from three individual samples separated
on the same gel. These results are similar to the
results obtained from other gels. There was no
significant difference in the protein content in
similar samples of Gs from control and ethanol-treated
rats in all brain regions analyzed (p>0.05).
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FIGURE 20
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Figure 21. The effects of chronic ethanol exposure on the
protein content of Go in three-month-old rats.

Control

Ethanol
Brain Region
Frontal Cortex

3.33 ± 1.27

3.49 ± 1.16

Nucleus Accumbens

8.44 ± 1.17

8.89 ± 1.59

Ventral Pallidum

4.22 ± 0.45

4.11 ± 1. 02

Ventral Tegmentum

4.85 ± 2.18

5.27 ± 2.61

Stria tum

0.82 ± 0.17

0.88 ± 0.23

Globus Pallidus

0.98 ± 0.03

0.94 ± 0.06

Substantia Nigra

0.53 ± 0.23

0.51 ± 0.11

-----------------------------------------------------------Each value represents the mean ± the standard deviation
of the Go/actin ratio in arbitrary densitometer units
{ADU) obtained from three individual samples separated
on the same gel. These results are similar to the
results obtained from other gels. There was no
significant difference in the protein content in
similar samples of Go from control and ethanol-treated
rats in all brain regions analyzed {p>0.05).
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Assessment of mRNA Levels of G Protein
The mRNA levels of several G proteins were measured in
brain regions of control and ethanol-treated animals. The
cDNA probes for the a subunits of Gs, Go, Gi 11 Gi 2 , and Gi3
(obtained from Dr. Randall Reed; Jones and Reed 1987) were
used to analyze the mRNA levels of brain areas of the
nigrostriatal and mesolimbic dopamine pathways.
Total RNA was loaded onto Nytran filters utilizing a
slot blot apparatus. The cDNA probes isolated from plasmids
were subjected to a DNA digest and separated on a 0.7% (w/v)
agarose gel to screen for purity (Figure 22). The cDNA
probes were labeled with [ 32 P]-CTP by random priming and
hybridized to the filters. The filters were exposed to film
to generate autoradiograms.
The autoradiograms for the G proteins and actin were
scanned by densitometer and ratios were calculated for each
G protein (G protein/actin). These values were defined as
arbitrary densitometer units (ADU). Slot blot analyses were
repeated 3-5 times and G protein/actin ratios, obtained from
scanning individual autoradiograms, were analyzed by the
t-test for paired comparison to account for day to day
differences in control ADU values.
Typical slot blots for each G protein and actin are
shown in Figures 23 to 27. The values listed in the legend
represent the ratio of G protein to actin for each blot.
There was a 20% decrease in mRNA levels for Go in the
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Figure 22. Analysis of DNA fragments after enzymatic
cleavage.

The DNA probes for the G proteins were extracted from the
plasmid, pGEM-2, and digested with the restriction enzyme,
Eco RI. The DNA fragments were separated on a 0.7% (v/v)
agarose gel to estimate the size of the cleavage products
in order to determine the purity of preparation.
Lane 1: Gi 3 (3.1 kb)
Lane 2: Gi 2 (1. 8 kb)
Lane 3: Gi 1 (2. 0 kb)
Lane 4: Go

(2 .1 kb)

Lane 5: Gs

(0.7 and 1.1 kb)

Lane 6: Size markers from HindIII and BamHI digest
of phage T.
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Figure 23. Ratio of mRNA for Gs/actin in 3-month-old control
and ethanol-treated rats.

Ethanol

Control

Brain Region
Frontal Cortex

1. 84

1.63

stria tum

0.89

0.94

Nucleus Accumbens

1. 00

0.85

Globus Pallidus

1.32

1.19

Substantia Nigra

1.24

1.33

Ventral Tegmentum

0.60

0.57

Ventral Pallidum

1.17

1.30

Each value represents the ratio of G protein/actin in
arbitrary densitometer units (ADU) from a typical slot
blot analysis. The differences in ratio values obtained
from 3-5 paired experiments were statistically analyzed
using the t-test for paired comparisons. There were no
significant differences in Gs content in all brain
regions analyzed (p>0.05). This figure represents a
typical slot blot for Gs. Equal amounts of RNA were
diluted to 1:10 and 1:1000 and all three dilutions
were loaded onto the Nytran filter. The first sample of
each set represents an ethanol-treated animal.
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Figure 24. Ratio of mRNA for Go/actin in 3-month-old control
and ethanol-treated animals.

Ethanol

Control

Brain Region
Frontal Cortex

1.05

1.05

stria tum

1.21

1.19

Nucleus Accumbens

1.07

1.11

Globus Pallidus

1.22

1.44

Substantia Nigra

0.92 ..

Ventral Tegmentum

1.00

0.96

Ventral Pallidum

1.05

1.08

1.14

Each value represents the ratio of G protein/actin in
arbitrary densitometer units (ADU) from a typical slot
blot analysis. The differences in ratio values obtained
from 3-5 paired experiments were statistically analyzed
using the t-test for paired comparisons. There was a
significant decrease in the Go content of the
substantia nigra (p<0.01)

(**).There were no

significant differences in the other brain regions
analyzed (p>0.05). This figure represents a typical
slot blot for Go. Equal amounts of RNA were diluted to
1:10 and 1:1000 and all three dilutions wereloaded onto
the Nytran filter. The first sample of each set
represents an ethanol-treated animal.
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FIGURE 24

FRONTAL
CORTEX

STRIATUM

NUCLEUS
ACCUMBENS

GLOB US
PALLIDUS

SUBSTANTIA
NIGRA

VENTRAL
PALLIDUM

VENTRAL
TEGMENTUM

--

--

- --

-- --- -

-...

...
--

Go

ETHANOL
CONTROL

•

122
Figure 25.

Ratio of mRNA for Gi 1/actin in 3-month-old
control and ethanol-treated animals.

Ethanol

Control

Brain Region
Frontal Cortex

0.87

0.81

Stria tum

0.59

0.67

Nucleus Accumbens

0.84

0.89

Globus Pallidus

0.38

0.47

Substantia Nigra

0.90

0.97

Ventral Tegmentum

0.50

0.54

Ventral Pallidum

0.70

0.80

Each value represents the ratio of G protein/actin in
arbitrary densitometer units (ADU) from a typical slot
blot analysis. The differences in ratio values obtained
from 3-5 paired experiments were statistically analyzed
using the t-test for paired comparisons. There were no
significant differences in Gi 1 content in all brain
regions analyzed (p>0.05). This figure represnts a
typical slot blot for Gil" Equal amounts of RNA were
diluted to 1:10 and 1:1000 and all three dilutions were
loaded onto the Nytran filter. The first sample of each
set represents an ethanol-treated animal.
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Figure 26.

Ratio of mRNA for Gi 2 /actin in 3-month-old
control and ethanol-treated animals.

Ethanol

Control

Brain Region
Frontal Cortex

0.83

0.87

Striatum

0.88

0.78

Nucleus Accumbens

0.63

0.60

Globus Pallidus

0.84

0.95

Substantia Nigra

1.36

1.10

Ventral Tegmentum

1.40

1.25

Ventral Pallidum

1.20

1.12

Each value represents the ratio of G protein/actin in
arbitrary densitometer units (ADU) from a typical slot
blot analysis. The differences in ratio values obtained
from 3-5 paired experiments were statistically analyzed
using the t-test for paired comparisons. There were no
significant differences in Gi 2 content in all brain
regions analyzed (p>0.05). This figure represents a
typical slot blot for Gi2 • Equal amounts of RNA were
diluted to 1:10 and 1:1000 and all three dilutions were
loaded onto the Nytran filter. The first sample of each
set represents an ethanol-treated animal.
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Figure 27. Ratio of mRNA for Gi 3 /actin in 3-month-old
control and ethanol-treated animals.

Ethanol

Control

Brain Region
Frontal Cortex

0. 71°

Stria tum

0.83

0.67

Nucleus Accumbens

0.62

0.48

Globus Pallidus

0.73

0.56

Substantia Nigra

0.52

0.63

Ventral Tegmentum

1.13

0.86

Ventral Pallidum

0. 31°

0.53

0.22

Each value represents the ratio of G protein/actin in
arbitrary densitometer units (ADU) from slot blot
analysis. The differences in ratio values obtained
from 3-5 paired experiments were statistically analyzed
using the t-test for paired comparisons. There was a
significant increase in Gi3 content in the frontal
cortex and ventral pallidum (p<0.05)

(*).There was no

significant differences in Gi 3 content in the other
brain regions analyzed (p>0.05). This figure
represents a typical slot blot for Gi3 • Equal amounts
of RNA were diluted to 1:10 and 1:1000 and
loaded onto the Nytran filter. The first sample of each
set represents an ethanol-treated animal.
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FIGURE 27
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substantia nigra (p<0.01). In all brain regions except the
substantia nigra, there was a 30-40% increase in Gi3 but
this difference was only significant in the frontal cortex
and ventral pallidum (p<0.05). There were no significant
differences in mRNA levels for Gs, Gi 1 , and Gi 2 in all brain
regions analyzed. The results of this experiment indicate
that three-month-old rats exposed to ethanol for one month
displayed region specific alterations in the mRNA levels of
Go and Gi 3 , while the mRNA levels of Gs, Gi 11 and Gi 2 were
not significantly changed.

Cholesterol and Phospholipid Levels
This study examined the cholesterol and phospholipid
levels in synaptic plasma membranes prepared from whole
brains of control and ethanol-treated rats. The results
presented as the mean ± the standard deviation were compared
for statistical significance using student's ' t ' test (Table
2) •

In comparison to control animals, there was a 42%
increase in cholesterol levels (p<0.01), while the levels of
phospholipid were not significantly different (p>0.05).
There was also a significant increase (31%) in the ratio of
cholesterol to phospholipid (p<0.05). This study
demonstrates that consumption of an ethanol liquid diet for
one month resulted in a significant increase in cholesterol
levels and in the cholesterol/phospholipid ratio of synaptic
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plasma membranes.

Table 2

Effects of Chronic Ethanol Consumption on Cholesterol and Phospholipids
in Synaptic Plasma Membranes from 3-Month-Old Fisher 344 Rats
Cholesterol
(µmol/mg protein)
Ethanol
Control

Phospholipid
(µmol/mg protein)

0.532 ± .068 ..
0.375 ± .102

1.017 ± .150
0.948 ± .129

Cholesterol/
Phospholipid

o. 529 ± • 01a·
0.403 ± .128

Each value represents the mean ± the standard deviation
of values obtained from individual synaptic membrane
preparations from seven rats. The symbols • and .. indicate
that values from control and ethanol-fed rats are
significantly different at p<0.05 or p<0.01, respectively.

I-'

w
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Summary
Tables 3 and 4 represent a summary of the results of
this research.
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Table 3
Components of the Mesolimbie Dopamine Pathway

Frontal
Cortex
Dopamine
DOPAC

t
t

Nucleus
Accumbens
NC
.l.

Dl Site

Ventral
Pallidum

Ventral
Tegmentum

t
t

t
t

ND

ND

NC
NC

NC
NC

G Protein
(Gs)
mRNA
protein

NC
NC

NC
NC

AC
Activity:

NC

t

ND

NC
NC
NC

ND

ND

NC

NC

NC

NC

D2 Site
Spiperone
NPA
Conversion
G Protein
(Gi2)
mRNA
AC
Activity:
G Protein
mRNA
(Go)
(Gil)
(GiJ)
protein
(Go)
NC: no change

ND

NC
NC

NC
NC

i

NC
NC
NC

t

NC
NC
NC

NC

NC

NC

NC

ND: not detected

(-): not determined
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Table 4
Components of the Niqrostriatal Dopamine Pathway

Stria tum

Globus
Pallidus

Dopamine
DOPAC

NC
NC

NC
NC

.J.

Dl Site

NC

NC

ND

G Protein
(Gs)
mRNA
protein

NC
NC

NC
NC

NC
NC

AC
Activity

NC

D2 Site
Spiperone
NPA
Conversion

NC
NC
NC

ND

ND

G Protein
(Gi2)
mRNA

NC

NC

NC

AC
Activity

NC

G Protein
mRNA
(Go)
(Gil)
(Gi3)

NC
NC
NC

NC
NC
NC

NC
NC

protein
(Go)

NC

NC

NC

NC: no change

ND: not detected

Substantia
Ni gr a

t

.J.

(-): not determined

CHAPTER V
DISCUSSION
The objective of this research was to examine the
effect of chronic ethanol exposure on several components of
the dopaminergic system. It was hypothesized that chronic
ethanol consumption either alters the ability of the
dopamine signal to effect cellular changes through signal
transduction or alters the concentration of dopamine itself.
These studies represented a comprehensive examination of the
membrane components of the dopaminergic system.
Specifically, the components analyzed included the dopamine
Dl and 02 receptors, the guanine nucleotide binding proteins
(G proteins),

and adenylate cyclase activity. In addition,

steady-state levels of dopamine and its metabolite,
3,4-dihyroxyphenylacetic acid (DOPAC) were analyzed. These
components were measured in brain regions associated with
the nigrostriatal or mesolimbic dopamine pathways.
Alterations in any of these components could contribute to
ethanol-induced changes in motor activity or to the
reinforcing effects of ethanol.
These studies demonstrated that consumption of a 6.6%
(v/v) ethanol-containing liquid diet for one month affected
several components of the dopamine system in three-month-old
134
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Fisher 344 rats. Specifically, there was a loss of Dl
receptors in the frontal cortex and nucleus accumbens. In
contrast, there was no change in Dl receptor affinity or
density in the striatum and globus pallidus. In addition,
the number and affinity of spiperone binding sites and the
number of propylnorapomorphine high affinity sites, as well
as their conversion from the high affinity state to the low
affinity state in the striatum and nucleus accumbens were
unchanged by chronic ethanol consumption. The concentrations
of dopamine and DOPAC were increased at least two-fold in
the frontal cortex, ventral pallidum, and ventral tegmental
area, while the levels were unchanged in the striatum and
globus pallidus. In the substantia nigra, dopamine
concentration was decreased and that of DOPAC was increased.
The dopamine concentration in the nucleus accumbens was
normal, but that of DOPAC was decreased. An analysis of Gs
and Go proteins demonstrated minimal, if any changes, in
either protein content or mRNA levels in all brain regions
analyzed. Concerning the inhibitory G proteins, the mRNA
levels of Gi 1 and Gi 2 were unchanged in all brain regions,
however, there was a trend towards an increase in the mRNA
levels of Gi 3 in all regions except the substantia nigra.
This increase was only significant in the frontal cortex and
ventral pallidum. In the frontal cortex and striatum, no
change was seen in dopamine-sensitive adenylate cyclase
activity, although Dl-stimulated adenylate cyclase activity
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and Dl-stimulated adenylate cyclase activity in the presence
of forskolin were increased in the nucleus accumbens. These
results suggest a selective ethanol effect on several
components of the dopamine system.

Dopamine and DOPAC Concentrations
This study examined the effects of chronic ethanol
exposure on dopamine and DOPAC content in the striatum,
globus pallidus, and substantia nigra which are components
of the nigrostriatal pathway (Fibiger et al. 1974; Lindvall
and Bjorkland 1979), and in the frontal cortex, nucleus
accumbens, ventral pallidum, and ventral tegmental area
which are components of the mesolimbic dopamine pathway
{Lindvall et al. 1978; Nauta et al. 1978). Although, other
laboratories have assessed dopamine and DOPAC content and
turnover following acute ethanol exposure, this is the first
extensive assessment of the effects of chronic ethanol
consumption on the concentrations of dopamine and DOPAC in
several brain regions. In the present study, the
concentrations of dopamine ranged from 2.2 ng/mg protein in
the frontal cortex to approximately 250 ng/mg protein in the
striatum and globus pallidus in control rats. The
concentrations of DOPAC ranged from 2.6 ng/mg protein in the
frontal cortex to 234 ng/mg protein in the nucleus accumbens
of control rats. Other investigators have reported dopamine
and DOPAC concentrations are highest in the striatum and
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lowest in frontal cortex (Fadda et al. 1980; Westerink 1983;
Ehrenstrom and Johansson 1985; Haikala 1987; Wetherell et
al. 1989). The dopamine concentrations in the nucleus
accumbens and substantia nigra in the present study are
comparable to values reported by Bacopoulous et al.

(1978).

Chronic ethanol consumption had a region-specific
effect on dopamine and DOPAC levels in three-month-old
Fisher 344 rats. In the frontal cortex, ventral pallidum,
and ventral tegmental area, there was a two-fold increase in
dopamine and DOPAC levels in the ethanol-treated animals.
The dopamine content in the substantia nigra was slightly
decreased but the level of DOPAC was increased two-fold. In
the nucleus accumbens, dopamine concentration was not
altered by chronic ethanol treatment, while that of DOPAC
was decreased. Neither the dopamine nor DOPAC levels in the
striatum and globus pallidus were affected by ethanol
consumption. Some of the brain regions associated with the
mesolimbic dopamine pathway

are those affected by chronic

ethanol treatment. In contrast, the content of dopamine and
DOPAC in the striatum and globus pallidus which are
components of the nigrostriatal pathway were not affected by
chronic ethanol treatment.

An increase in dopamine content as observed in the
frontal cortex, ventral pallidum, and ventral tegmental area
may reflect an increase in dopamine synthesis, a decrease in
dopamine release, or a decrease in dopamine turnover.
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Increased dopamine synthesis would occur if there were
increased activity of tyrosine hydroxylase, the
rate-limiting enzyme in the biosynthesis of the
catecholamine neurotransmitters {Cooper et al. 1986). This
enzyme can be activated by phosphorylation by any of at
least three protein kinases: cAMP-dependent protein kinase,
ca+ 2 /calmodulin-dependent protein kinase, and
ca+ 2/diacylglycerol-dependent protein kinase (Nestler and
Greengard 1989). Phosphorylation of tyrosine hydroxylase
increases its catalytic activity by increasing the affinity
of the enzyme for its tetrahydropteridine cofactor and by
decreasing its affinity for its end-product inhibitor
{Cooper et al 1986). Ethanol may activate tyrosine
hydroxylase by activating one or more protein kinase through
an increased activation of second messenger systems (cAMP,
phosphoinositide, ca+ 2 ) (Rabin and Molinoff 1981; Lynch and
Littleton 1983; Hudspith et al. 1985; Saito et al. 1985;
Gonzales et al. 1986; Messing et al. 1986; Dolin et al.
1987). The present studies suggest the cAMP-dependent
phosphorylation and activation of tyrosine hydroxylase may
not occur in the frontal cortex since normal adenylate
cyclase activity was found in this area. However, the
present studies cannot exclude the possibility that ethanol
may have increased tyrosine hydroxylase phosphorylation via
altered phosphoinositide (IP3 ) formation or calcium (Ca+ 2 )
influx.
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Within the ventral tegmental area, 02 receptors are
reportedly autoreceptors on dendrites of dopaminergic
neurons which project to the nucleus accumbens (Wang 1981;
White and Wang 1984). In contrast, D2 receptors are lacking
on ventral tegmental area dopaminergic cell bodies which
project to the frontal cortex (Chiodo et al. 1984). In both
projection areas of the ventral tegmental area (the frontal
cortex and nucleus accumbens), 01 and 02 receptors are found
postsynaptically (White and Wang 1984, 1986; Galloway et al.
1986). In addition, D2 receptors are also found
postsynaptically in the nucleus accumbens (White and Wang
1986) .
With the above receptor localization in mind, an
elevation in ventral tegmental area dopamine and DOPAC may
be indicative of an increase in the dendrodendritic release
of dopamine. The increased release of dopamine, acting on
the D2 autoreceptors, could inhibit firing of the projection
from the ventral tegmental area to the nucleus accumbens. As
a consequence of decreased firing, one would expect
decreased release of dopamine, as suggested by the lower
DOPAC levels in this region. In light of the apparent lack
of a D2 autoreceptor in the ventral tegmental area on cells
which project to the prefrontal cortex (Chiodo et al. 1984)
and the finding of elevated cortical dopamine and DOPAC, a
similar analogy cannot be made with the mesocortical system.
On the other hand, dopamine was decreased in the
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substantia nigra. Dopamine may be decreased if dopamine
synthesis is decreased as a result of decreased activation
(decreased phosphorylation} of tyrosine hydroxylase by the
second messenger systems mentioned above. Alternatively,
dopamine levels may be decreased if dopamine release is
increased. Dopamine release could be increased by an
ethanol-induced activation of second messenger systems which
phosphorylate synapsin I. Synapsin I, a component of the
regulation of neurotransmitter release, is associated with
the synaptic vesicles located in the nerve terminal
(Browning et al. 1985; De Camilli et al. 1986}. Synapsin I
is phosphorylated by cAMP-dependent protein kinase and
ca+ 2 /calmodulin-dependent protein kinase. The
dephosphorylated protein inhibits neurotransmitter release,
whereas the phosphorylated protein facilitates release
(Llinas et al. 1985). Consequently, phosphorylation of
synapsin I could facilitate dopamine release and result in
decreased dopamine levels as seen in the substantia nigra.
If this explanation for a decrease in dopamine levels in the
substantia nigra is valid, it would suggest that
phosphorylation of synapsin I is not similarly affected in
other brain regions which did not demonstrate a decrease in
dopamine levels.
It is also possible that ethanol may inhibit the
enzymes responsible for the metabolic degradation of
catecholamines: monoamine oxidase (MAO) and
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catechol-0-methyltransferase (COMT). Differences in the
concentration of OOPAC in the brain regions of
ethanol-treated animals may reflect an ethanol-induced
alteration in MAO activity. Presently, additional
information is needed to substantiate this interpretation.
In summary, three-month-old Fisher 344 rats fed an
ethanol-containing diet for one month display unique
regional responses. These differential effects for each
brain region may reflect complex regulatory mechanisms
specific for each region.

Dopamine Receptors
The present study provides information concerning the
effects of chronic ethanol exposure on the dopamine Dl and
02

receptors in rat brain. This is the first report that

examines the 01 and D2 receptors in brain regions other than
the striatum in chronically ethanol-treated rats. This is
also the first report of the effects of ethanol on the
conversion of the 0 2 receptor from the high affinity state
to the low affinity state.
Although the present study was unable to detect D2
receptors in the frontal cortex, ventral pallidum, ventral
tegmental area, globus pallidus and the substantia nigra, a
more sensitive method, using quantitative autoradiography,
detected 02 sites in these regions {Boyson et al. 1986;
Charuchinda et al. 1987; Richfield et al. 1989). Similarly,
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quantitative autoradiography has demonstrated 01 receptors
in several brain regions in which these receptors were below
the level of detectability for homogenate binding studies.
These areas include the ventral pallidum, ventral tegmental
area, and the substantia nigra (Richfield et al. 1987;
1989).
Total dopamine 01 sites were measured using the
selective 01 antagonist, SCH 23390 (Billard et al. 1984).
Binding studies indicate that [ 3H]-SCH 23390 binds
stereospecifically with high affinity to a single site, the
01 receptor site (Billard et al. 1984; Schulz et al. 1984).
In the present study, the Kd values of control rats ranged
from 0.3 nM in the globus pallidus to 2.0 nM in the frontal
cortex. The Bmax values ranged from 0.2 pmol/mg protein in
the frontal cortex to 0.8 pmol/mg protein in the nucleus
accumbens. The Kd and Bmax values of this study are
consistent with those in previous reports of Dl binding in
the rat striatum (Billard et al. 1984; Schulz et al. 1985;
Hess et al. 1986; Manik et al. 1988).
The present study demonstrated regional alterations in
dopamine 01 sites in ethanol-treated rats. A decrease in 01
sites was observed in the nucleus accumbens and frontal
cortex, while the 01 sites in the striatum and globus
pallidus were not changed by ethanol treatment. The affinity
of the SCH 23390 for 01 site was not significantly different
in these four regions. Other studies have reported that
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ethanol increases, decreases, or has no effect on striatal
SCH 23390 Dl sites. Hietala et al.

(1990) observed the

number and affinity of Dl receptor sites in the frontal
cortex and striatum were not significantly altered by 5
weeks of ethanol treatment. However, Hruska (1988) reported
a 40% increase in striatal Dl sites after 3 weeks of ethanol
administration, while Lucchi et al.

(1988) reported a 25%

decrease in striatal Dl sites after 25 days of ethanol
treatment. Both investigators observed no significant
differences in the affinity of striatal Dl sites. The
effects of ethanol exposure on Dl sites in other brain
regions have not been reported.
The discrepancies among the present report of striatal
binding sites and previous findings are possibly explained
by

technical differences, specifically species, dose and

mode of

ethanol administration, or assay conditions. For

example, Lucchi et al.

(1988) administered 6% (v/v) ethanol

in the drinking water to Sprague-Dawley rats. The mean daily
intake of ethanol was 2-3 g/kg body weight. Hruska (1988)
used a liquid diet with an ethanol concentration of 6.2%
(v/v). Adult male Sprague-Dawley rats were placed on the
diet for 14 or 21 days and the amount of ethanol consumed
daily ranged from 12-17 g/kg body weight. Hietala et al.
(1990) also used a liquid diet containing 6% (v/v) ethanol.
Wister rats were maintained on the diet for 5 weeks. In the
present study, male Fisher 344 rats were pair-fed a 6.6%
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(v/v) ethanol-containing diet for 4 weeks. The average daily
intake was 20-25 g/kg body weight. It is possible the
different feeding models, length of treatment, daily intake,
or species differences may account for the discrepancies in
these findings. Nevertheless, the present findings
corroborate some findings observed in other binding assays.
Namely, ethanol treatment does not alter the affinity of the
dopamine 01 receptor site and an ethanol effect in one
region does not necessarily define the effect in all
regions.
It is interesting to note the selective decrease in 01
sites in the nucleus accumbens and frontal cortex, brain
areas which are components of the mesolimbic dopamine
pathway (Lindvall et

al. 1978; Nauta et al. 1978). The

mesolimbic dopamine pathway is recognized as an important
component of reward circuitry and has been implicated in the
reinforcement of several drugs of abuse (Phillips and
Fibiger 1978; Lyness et al. 1981; Bozarth and Wise 1981;
Mathews and German 1984). Thus, changes in the dopamine 01
receptors may in some way be associated with rewarding
effects of ethanol and thus may potentially be involved with
the development of ethanol dependence.
Total dopamine 02 sites were measured using the 02
antagonist, spiperone (Leyson et al. 1978). Spiperone binds
specifically and with high affinity to a single class of
dopamine 02 sites (Leslie and Bennett 1987). The Kd values
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in this study ranged from 0.08 nM in the nucleus accumbens
to 0.15 nM in the striatum of control animals. The Bmax
values in the striatum were 0.1 pmol/mg protein. The Kd and
Bmax values in this study are in agreement with reported Kd
values and Bmax values of other binding assays in the rat
striatum (Briley and Langer 1978; Leyson et al. 1978; Owen
et al. 1979;

List & Seeman 1981). Little information is

available about the kinetics of spiperone binding, as
measured by homogenate binding assays in the nucleus
accumbens and frontal cortex.
The density and affinity of dopamine 02 sites in the
nucleus accumbens and striatum were not altered by ethanol
exposure in this study. Similar to the reports of others
regarding ethanol's effect on the 01 sites, various
laboratories have observed an increase, decrease, or no
change in 02 sites after ethanol treatment. Hietala et al.
(1990) demonstrated that the affinity and number of striatal

02 sites, measured by [ 3H]-spiperone, were not significantly
altered by 3 or 5 weeks of ethanol treatment. In addition,
the specific binding of [ 3H]-haloperidol to striatal 02
sites was unaffected in rats treated with ethanol for 11-15
days (Muller et al. 1980). In contrast, Hruska (1988)
reported an increase (15-20%) in striatal D2 sites measured
by spiperone after 3 weeks of ethanol treatment, while
Lucchi et al. (1988) observed a decrease (27%) in these
sites after 25 days of ethanol exposure. Furthermore,
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Syvalahti et al. (1988) found a decrease (38%) in the number
of striatal 02 sites in rats treated with ethanol for 32
weeks. As stated previously, the difference in findings may
be attributed to technical differences including species,
dose and duration of ethanol treatment, and assay
conditions.
The effect of chronic ethanol exposure on the high
affinity state of the dopamine 02 site and its ability to
convert from the high affinity state to the low affinity
state were analyzed with the 02 agonist,
propylnorapomorphine (Creese et al. 1979; Titeler and Seeman
1979). This 02 agonist binds with high affinity to an
apparently homogeneous receptor population, representing the
high affinity agonist binding site {Sibley et al. 1982).
Guanine nucleotides decrease the binding capacity for
[

3

H)-propylnorapomorphine by inducing a conformational

change in the high affinity state of the receptor {Sibley et
al. 1982), a mechanism involving the guanine nucleotide
regulatory proteins {G proteins) {Boeynaems and Dumont
1975).
This is the first report that examines agonist binding
in brain regions of control and ethanol-treated rats. The Kd
values of control animals ranged from 0.1 nM in the striatum
to 0.4 nM in the nucleus accumbens. In the presence of GTP,
the Kd values ranged from 0.2 nM in the striatum to 0.7 nM
in the nucleus accumbens. Reported Kd values range from 0.2
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nM in bovine anterior pituitary to 1.5 nM bovine striatum

{Sibley et al. 1982; Creese et al. 1979). In the presence of
GTP, the Kd value reported in the anterior pituitary was 0.3
nM (Sibley et al. 1982). The Bmax values of control animals

in the present study ranged from 0.1 pmol/mg protein in the
nucleus accumbens to 0.2 pmol/mg protein in the striatum and
in the presence of GTP, the Bmax values ranged from 0.07
pmol/mg protein in the nucleus accumbens to 0.1 pmol/mg
protein in the striatum.
In the present study, approximately 50% of the striatal
02

high affinity sites were converted to the low affinity

state in the presence of GTP; in the nucleus accumbens
approximately 35% of the sites were converted in the
presence of GTP. Sibley et al. {1982) reported a 50%
conversion rate in the anterior pituitary. Chronic ethanol
treatment did not alter the binding of
[

3

H]-propylnorapomorphine to the high affinity site or the

conversion of the 02 high affinity site to the low affinity
site in the striatum and nucleus accumbens.
In summary, this study demonstrated that
three-month-old Fisher 344 rats exposed to ethanol for the
month displayed a selective ethanol effect on the dopamine
receptors. There was a significant decrease in the number of
01 sites in the nucleus accumbens and frontal cortex while
the 01 sites in the striatum and globus pallidus were not
altered. In these four regions, the affinity of SCH 23390
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was not affected by ethanol treatment. The density and
affinity of the dopamine 02 sites in the striatum and
nucleus accumbens were not significantly different in
ethanol-treated rats. Also ethanol exposure did not change
the affinity, number, or conversion of the 02 high affinity
site.
The number of 01 receptors was decreased in both the
nucleus accumbens and frontal cortex of ethanol-fed rats.
Although a decrease in cortical 01 receptor number could be
potentially explained as a compensatory down regulation in
response to the increased dopamine release (increased OOPAC)
in the cortex, this explanation cannot explain the decrease
in 01 receptors in the nucleus accumbens since OOPAC is
decreased in this area. Alternative explanations for the
decreased number of dopamine receptors are: 1) receptor
desensitization, 2) agonist-induced endocytosis, 3)
decreased gene transcription. For example, ethanol may
induce receptor desensitization of the 01 receptor or may
inhibit transcription of the gene for the 01 receptor,
resulting in the loss of 01 receptor sites. It is also
possible that the selective effect of ethanol on 01
receptors in distinct brain areas may reflect a different
cellular localization of the 01 and 02 receptors.
Molecular mechanisms of receptor desensitization have
been described using the
(Sibley et

~-adrenergic

receptor as a model

al. 1987). A similar mechanism may exist for
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other receptor types including the dopamine Dl receptor.
Receptors assume an altered conformation during
desensitization. This conformational change is promoted by
covalent receptor modification. Phosphorylation plays a role
in desensitizing receptors linked to the G proteins (Klein
et al. 1989). Receptors may be phosphorylated by a variety
of protein kinases but a novel cAMP-independent protein
kinase (PARK) appears to be involved in the homologous
desensitization of the P-adrenergic receptor (Benovic et al.
1986). This enzyme only phosphorylates the agonist-occupied
form of the receptor. When a cell is stimulated by a
P-adrenergic agonist, PARK is translocated from the cytosol
to the plasma membrane where it phosphorylates the
agonist-occupied receptor {Strasser et al. 1986). The
phosphorylated receptor is uncoupled from adenylate cyclase
and sequestered within the cell into low density membrane
vesicles. Within the vesicle, the receptor is
dephosphorylated by a phosphoprotein phosphatase and then is
functionally regenerated. When the agonist is removed, the
receptor is redistributed to the plasma membrane. PARK may
serve as a nonspecific adenylate cyclase-coupled receptor
kinase and may play a role in a generalized mechanism for
homologous desensitization for several receptors including
the dopamine receptors.
The loss of dopamine Dl receptors in the nucleus
accumbens and frontal cortex may be explained by an ethanol
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effect on the mechanism described above. Ethanol may promote
receptor phosphorylation via an increased activation of one
or more second messenger pathway, which in turn may activate
one or more protein kinases. An activated protein kinases
would increase the phosphorylation state of the receptor,
maintaining the receptor in an inactive form. on the other
hand, ethanol may inhibit phosphatase activity, thus
maintaining the phosphorylated state of the receptor and in
turn, inhibit the recycling of the receptors into the plasma
membrane resulting in a loss of receptors. Presently,
additional information regarding ethanol's effects on this
mechanism is needed to substantiate this interpretation.
Another mechanism which may account for the down
regulation of receptors is receptor-mediated endocytosis.
Ligand-induced receptor degradation occurs when the
endosomes containing the receptors fuse with lysosomes
(Chuang et al. 1982). It is possible that ethanol mediated
changes in dopamine concentrations or other
neurotransmitters levels may promote agonist-induced
receptor degradation resulting in receptor down-regulation.
Adaptive changes in receptor density may also be
regulated at the level of gene transcription. Ethanol may
alter the activation or inhibition of transcriptional
factors that control the rate of transcription. A decrease
in transcription may result in a decreased receptor number.
The recent availability of cDNA probes for the dopamine
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receptors will provide a means to examine this mechanism of
receptor regulation.
It is interesting to note the selective loss of the Dl
receptors in the nucleus accumbens and frontal cortex. It is
possible the Dl and 02 receptors are differentially
regulated within each brain region or cell type at the level
of gene transcription. It is possible that the genes for the
01 and 02 receptors require at least one tissue specific
transcriptional factor in order for transcription to occur.
Although, the precise pharmacological actions of ethanol are
unknown, however, the differential responses to ethanol
reveal the complex neuronal interactions involved in normal
physiological activity.
Regardless of the cause of the decreased number of 01
receptors in the frontal cortex and nucleus accumbens, it is
doubtful whether this decrease is responsible for altered
cellular function because in the presence of a saturating
concentration of GTP dopamine-stimulated adenylate cyclase
activity was not altered in either region. Additional
components of this signal transduction pathway, namely the
synthesis and concentration of Gsa as well as the basal,
NaF, and forskolin-stimulated adenylate cyclase activity
were unaltered in these regions from ethanol-fed rats.
Consequently, the loss of 01 receptors from the frontal
cortex and nucleus accumbens may represent a loss of spare
receptors.
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Adenylate Cyclase Activity
In the present study, cAMP levels were assessed as an
indicator of adenylate cyclase activity. The response of
adenylate cyclase to stimulation by forskolin, GTP, and
sodium fluoride was also analyzed as a means to define the
site of ethanol's action. Basal, Dl-stimulated, and
02-inhibited adenylate cyclase activity was not altered in
the striatum of ethanol-treated animals. There was no change
in the stimulation of striatal adenylate cyclase activity by
forskolin, GTP, and sodium fluoride. Similarly, adenylate
cyclase activity in the frontal cortex was not altered by
ethanol treatment. In contrast, basal adenylate cyclase
activity in the presence of dopamine was significantly
increased in the nucleus accumbens of ethanol-treated
animals, Dl-stimulated activity and basal adenylate cyclase
activity in the presence of forskolin or sodium fluoride
were unchanged in this region. It is possible that there was
a sufficient amount of GTP in the tissue resulting in the
stimulation of adenylate cyclase by dopaminej however,
further studies will be necessary to determine the site of
this ethanol effect.
In studies by other laboratories, chronic ethanol
treatment generally produced a decrease in adenylate cyclase
activity. Dopamine-stimulated and norepinephrine-stimulated
adenylate cyclase activity was reduced in the striatum and
cerebral cortex, respectively (Tabakoff and Hoffman 1979;
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Lucchi et al. 1983; Saito et al. 1987). The stimulation of
adenylate cyclase by various agonists and agents acting
through Gs or adenylate cyclase also was decreased after
chronic ethanol exposure (Saito et al. 1987). Studies in
cultured cells demonstrated a similar response, a decrease
in agonist-stimulated adenylate cyclase after chronic
ethanol treatment (Richelson et al. 1986; Rabin 1990). In
contrast, Rabin et al.

(1987) reported an increased response

to dopamine-stimulated, GTP-stimulated, and sodium fluoridestimulated adenylate cyclase activity in the striatum of
chronic ethanol-treated rats. The discrepancies among the
present study and other studies may be attributed to
different laboratory protocols. For example, some studies
examined adenylate cyclase activity in ethanol-withdrawn
animals which may not represent the effects of chronic
ethanol exposure. Mode of ethanol administration, dose of
ethanol, or animal species also may contribute to these
different findings.
An increase in cAMP levels may be the result of
increased levels of adenylate cyclase. Ethanol may alter the
activation of one or more transcription factors which
regulate the gene for adenylate cyclase. Alternatively,
ethanol may inhibit the degradation of either the mRNA or
the protein for adenylate cyclase. Such alterations would
result in an increased synthesis of cAMP.
Another possible explanation for increased cAMP levels
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may be decreased phosphodiesterase activity.
Phosphodiesterase hydrolyzes the phosphodiester linkage of
cAMP terminating the biological activity of adenylate
cyclase. As stated previously, ethanol may alter the
activation of the transcription factors regulating the
expression of the gene for phosphodiesterase. Decreased
phosphodiesterase levels may result in increased levels of
cAMP. Phosphodiesterase is regulated by cAMP-dependent
protein kinase (Northup et al. 1989). Phosphorylation of
this enzyme decreases its affinity for calmodulin, thereby
decreasing its activation. Alternately the phosphorylation
state of phosphodiesterase may be modulated via the
dopamine-stimulated phosphorylation and activation of
DARPP-32, potent inhibitor of protein phosphatase-1
(Hemmings et al. 1989). Inhibition of protein phosphatase-1
would maintain phosphodiesterase in its phosphorylated
inactive state.

G Proteins
In the present study, mRNA and protein levels of the a
subunit of several G proteins were assessed by slot blot
analysis and Western analysis. In all brain regions
surveyed, the mRNA levels of the a subunits of Gs, Gi 11 and
Gi 2 were not altered by ethanol exposure. There were
significant differences in the mRNA levels of Go in the
substantia nigra and Gi 3 in the frontal cortex and ventral
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pallidum. The protein levels of the a subunits of Gs and Go
were not affected by ethanol treatment. The 01 stimulation
of adenylate cyclase appears to involve Gs, whereas 02
inhibition of adenylate cyclase may be coupled to Gi 2
(Senogles et al. 1990). Ethanol-induced alterations of
dopamine-sensitive adenylate cyclase activity may not be
mediated through the G proteins since ethanol does not
affect G protein synthesis.

Although there was a decrease

(20%) in the Go mRNA level in the

substantia nigra, the

protein level of Go in the substantia nigra was not altered.
A change in mRNA levels of this magnitude may not result in
differences in protein levels.
The results of this study concur with findings reported
concerning G protein content in the cerebral cortices of
chronically treated mice (Hoffman and Tabakoff 1990). The
investigators observed no significant alterations in the
levels of the a subunits of the Gs and Go proteins. However,
studies of ethanol-treated culture cell lines differ.
Mochley-Rosen and colleagues (1988) demonstrated decreases
in mRNA and protein levels of the a, subunit in chronic
ethanol-treated NG 108-15 cells. Charness and colleagues
(1988) reported a decrease in the content of the a, subunit
in NG 108-15 and NlE-115 cell lines, but not in the N18TG2
cell line. They also found a dose-dependent increase in the
ai

subunit in the NlE-115 cell line with no change in the NG

108-15 and N18TG2 cell lines. In the present study, there

156

was a significant increase in the mRNA levels of Gi 3 in the
frontal cortex and ventral pallidum which may result in an
increase in the protein content as observed by Charness et
al.

(1988).
In theory the presently observed ethanol-induced

changes in

adenylate cyclase activity may involve

alterations of the synthesis of the a subunits of the G
proteins. Mochley-Rosen and colleagues (1988) suggest the
quantity of a, is the rate-limiting step in the activation
of adenylate cyclase. However, this hypothesis is not
supported by the present study because the mRNA and protein
levels of a 1 were not altered by ethanol exposure. Hoffman
and Tabakoff (1990) suggest the possibility that chronic
ethanol exposure causes posttranslational modification of
the a subunit that may alter its interaction with receptors
and effectors. In the present study, this possibilty could
not be tested utilizing the selected experimental procedure.
In summary, three-month-old rats exposed to ethanol for
one month display regional specific changes in G protein
mRNA levels, but protein content of Gs and Go were not
altered. Although there were small changes in the mRNA
levels of Go and Gi3 , these differences may not affect the
overall function of the G proteins. The results of this
study suggest ethanol's action may be at the level of
adenylate cyclase rather than at the level of the G
proteins.
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Cholesterol/Phospholipid Ratio of Synaptic Plasma Membranes
Although a significant increase in the
cholesterol/phospholipid ratio of synaptic plasma membranes
was observed, it is unlikely that this membrane change was
responsible for the observed changes in components of the
dopaminergic system. Whereas the present studies report a
decrease in dopamine Dl receptor number in certain brain
areas, earlier studies from this laboratory have shown that
Dl receptor number is not significantly affected by changing
the cholesterol/phospholipid ratio (Maguire and Druse 1989).
In contrast, artificial elevation of the
cholesterol/phospholipid ratio does inhibit dopaminestimulated adenylate cyclase (Maguire and Druse 1989), while
the ethanol-induced increase in membrane cholesterol did not
inhibit this enzyme in any brain region examined. Thus, the
observed changes in membrane-associated components of the
dopaminergic systems appear to be caused by factors other
than changes in the membrane cholesterol content.

Concluding Remarks
The results of the present studies have demonstrated
that several components of the dopaminergic system in
three-old-month Fisher 344 rats are altered after one month
of chronic ethanol exposure. Those brain areas which are
affected are associated with the mesolimbic dopamine
pathway. There was a loss of the 01 dopamine receptor in the
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nucleus accumbens and frontal cortex of chronic
ethanol-treated rats. Dopamine and DOPAC levels were
increased two-fold in the frontal cortex, ventral pallidum,
and ventral tegmental area, while DOPAC levels were
decreased in the nucleus accumbens of chronic
ethanol-treated rats. In the nucleus accumbens, there was an
increase in basal adenylate cyclase activity in the presence
of dopamine.
These changes in the brain regions of the mesolimbic
dopamine pathway are notable because this pathway is a
component of the reward circuitry (Phillips and Fibiger
1978). Several drug self-stimulation studies suggest that
dopamine neurons in the accumbens and prefrontal cortex play
a critical role in the reinforcement of cocaine (Roberts and
Koob 1980; Goeders and Smith 1986). It is also possible the
mesolimbic dopamine neurons may be involved in the rewarding
effects of ethanol (Koob and Weiss 1990; Lewis and June
1990; McBride et al. 1990; Samson et al. 1990).
In three-month-old Fisher 344 rats fed an
ethanol-containing diet for one month prior to sacrifice,
specific components of the mesolimbic and mesocortical
dopamine systems were significantly altered. Whether these
changes are translated into behavioral abnormalities is not
known. Although, it does not appear that the observed
changes in receptor number contribute to signal transduction
in regards to the adenylate cyclase pathway, we cannot rule
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out the possibilty that other dopamine-sensitive signal
transduction pathways may be altered. Furthermore, it is not
known whether the observed changes are readily reversed upon
withdrawal of the ethanol diet or whether they represent the
first stages of a potential neurotoxicity.
The differential responses of each brain region to
chronic ethanol may reflect different mechanisms of
regulation as discussed previously. In addition, regulation
through other neurotransmitter systems should be considered
as a possible explanation for ethanol's selective effects.
For example, GABA, serotonin, and neurotensin may have a
role in the regulation of the dopamine system (Mereu and
Gessa 1985; Nemeroff and Cain 1985; Erwin and Korte 1988;
Galloway 1990). Thus, alterations in components of the
dopamine system may be secondary to the effects of ethanol
on other neurotransmitter systems. Consequently, ethanol's
unique effect on a given neurotransmitter may reflect the
interaction of effects produced on a number of interrelated
pathways.

CHAPTER VI
BIBLIOGRAPHY
Altar CA, Boyar we, Oei E, and Wood PL. (1987) Dopamine
autoreceptors modulate the in vivo release of dopamine
in the frontal, cingulate, and entorhinal cortices. J.
Pharmacol. Exp. Ther. 242:115-120.
Ariano MA. (1987) Comparison of dopamine binding sites in
rat superior cervical ganglion and caudate nucleus.
Brain Res. 412:245-254.
Arluison M, Dietl M, and Thebault J. (1984) Ultrastructural
morphology of dopaminergic nerve terminals and synapses
in the striatum of the rat using tyrosine hydroxylase
immunocytochemistry: a topographical study. Brain Res.
Bull. 13:269-285.
Bacopoulous NG, Bhetnager RK, and Van Orden LS III. (1978)
The effects of subhypnotic doses of ethanol on regional
catecholamine turnover. J. Pharmacol. Exp. Ther.
204:1-10.
Barone P, Davis TA, Braun AR, and Chase TN. (1986)
Dopaminergic mechanisms and motor function:
characterization of Dl and 02 receptor interactions.
Eur. J. Pharmacol. 123:109-114.
Battaglia G, Norman AB, Hess EJ, and Creese I. (1986}
Forskolin potentiates the stimulation of rat striatal
adenylate cyclase mediated by D-1 dopamine receptors,
guanine nucleotides, and sodium fluoride. J. Neurochem.
46:1180-1185.
Beninger RJ. {1983) The role of dopamine in locomotor
activity and learning. Brain Res. Rev. 6:173-196.
Beninger RJ, Hoffman DC, and Mazurski EJ. (1989) Receptor
subtype-specific dopaminergic agents and conditioned
behavior. Neurosci. Biobehav. Rev. 13:113-122.
Benovic JL, Strasser RH, Caron MG, and Lefkowitz RJ. (1986)
~-Adrenergic receptor kinase: identification of a novel
protein kinase that phosphorylates the agonist-occupied
160

161
form of the receptor. PNAS 83:2797-2801.
Billard W, Ruperto V, Crosby G, Iorio LC, and Barnett A.
(1984) Characterization of the binding of [ 3H]-SCH
23390, a selective D-1 receptor antagonist ligand, in
rat striatum. Life Sci. 35:1885-1893.
Birnbaumer L, Codina J, Mattera R, Yatani A, Sherer NM, Goro
M-J, and Brown AM. (1987) Signal transduction by
G proteins. Kidney Int. 32{Suppl. 23) :S14-37.
Birnbaumer L. (1990) G proteins in signal transduction. Ann.
Rev. Pharmacol. Toxicol. 30:675-705.
Black RF, Hoffman PL, and Tabakoff B. (1980)
Receptor-mediated dopaminergic function after ethanol
withdrawal. Alcoholism: Clin. Exp. Ther. 4:294-297.
Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T,
Jagadeeswaran P, Nogami H, Briggs AH, and Cohn JB.
(1990) Allelic association of human 02 dopamine
receptor gene in alcoholism. JAMA 263:2055-2060.
Boeynaems JM and Dumont JE. (1975) Quantitative analysis to
the binding of ligands to their receptors. J. Cyclic
Nucleotide Res. 1:123-142.
Bonner TI, Young AC, Brann MR, and Buckley NY. (1989)
Cloning and expression of the human and rat ms
muscarinic acetylcholine receptor genes. Neuron
1:403-410.
Boyson SJ, McGonigle P, and Molinoff PB. (1986) Quantitative
autoradiographic localization of the Dl and 02 subtypes
of dopamine receptors in rat brain. J. Neurosci.
6:3177-3188.
Bozarth MA and Wise RA. (1981) Heroin reward is dependent on
a dopaminergic substrate. Life Sci. 29:1881-1886.
Bozarth MA. (1987) Ventral tegmental reward system. Brain
Reward systems and Abuse. Raven Press: New York.
pp. 1-17.
Braun AR, Barone P, and Chase TN. (1986) Interaction of Dl
and 02 receptors in the expression of dopamine agonist
induced behaviors. Neurobiology of Central Dl-Dopamine
Receptors. Raven Press: New York. pp. 151-166.
Bray P, Carter A, Simons C, Guo V, Puckett c, Kamholz J,
Spiegel A, and Nirenberg M. (1986) Human cDNA clones

162

for four species of Ga, signal transduction protein.
PNAS 83:8893-8897.
Breitwiesser GE and Szabo G. (1985) Uncoupling of cardiac
muscarinic and P-adrenergic receptors from ion channels
by guanine nucleotide analogue. Nature 317:538-540.
Brilel M and Langer. (1978) Two binding sites for
H-spiroperidol on rat striatal membranes. Eur. J.
Pharmacol. 50:283-284
Brodie MS, Shefner SA, Dunwiddie TV. (1990) Ethanol
increases the firing rate of dopamine neurons of the
rat ventral tegmental area in vitro. Brain Res.
508:65-69.
Brown F, Campbell W, Mitchell PJ, and Randall K. (1985)
Dopamine autoreceptors and the effects of drugs on
locomotion and dopamine synthesis. Br. J. Pharmacol.
84:853-860.
Browning MD, Huganir R, and Greengard P. (1985) Protein
phosphorylation and neuronal function. J. Neurochem.
45:11-23.
Bunzow JR, Van Tol HHM, Grandy DK, Albert P, Salon J,
Christie M, Machida CA, Neve KA, and civelli O. (1988)
Cloning and expression of a rat 02 dopamine receptor
cDNA. Nature 336:783-787.
Buss JB, Mumby SM, Casey PJ, Gilman AG, and Sefton BM.
(1987) Myristoylated a subunits of guanine
nucleotide-binding regulatory proteins. PNAS
84:7493-7497.
Carlsson A and Lindquist M. (1973) Effect of ethanol on
hydroxylation of tyrosine and tryptophan in rat brain
in vivo. J. Pharm. Pharmacol. 25:437-440.
Celentano JJ, Gibbs TT, and Farb DH. (1988) Ethanol
potentiates GABA- and glycine-induced chloride currents
in chick spinal cord neurons. Brain Res. 455:377-380.
Chang F and Bourne HR. (1987) Dexamethasone increases
adenylyl cyclase activity and expression of the
a-subunit of G1 in GH3 cells. Endocrinology
121:1711-1715.
Charness ME, Querimit LA, and Hinteleff M. (1988) Ethanol
differentially regulates G proteins in neural cells.
Biochim. Biophys. Comm. 155:138-142.

163
Charuchinda c, Supanilai P, Karobath M, and Palacios JM.
{1987) Dopamine 02 receptors in the rat brain:
autoradiographic visualization using a high affinity
selective agonist ligand. J. Neurosci. 7:1352-1360.
Chin JH and Goldstein DB. (1977) Drug tolerance in
biomembranes: a spin label study of the effects of
ethanol. Science 196:684-685.
Chiodo LA, Bannon MJ, Grace AA, Roth RH, and Bunney BS.
{1984) Evidence for the absence of impulse-regulating
somatodendritic and synthesis-modulating nerve terminal
autoreceptors on subpopulations of mesocortical
dopamine neurons. Neurosci. 12:1-16.
Chomczynski P and Sacchi N. (1987) Single-step method of RNA
isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal.
Biochem. 162:156-159.
Chuang OM. (1982) Internalization of a-adrenergic receptor
binding sites: involvement of lysosomal enzymes.
Biochem. Biophys. Res. Comm. 105:1466-72.
Chung CT, Niemela SL, and Miller RH. (1989) One-step
preparation of competent Escherichia
coli:
transformation and storage of bacterial cells in
same solution. PNAS 86:2172-2175.

the

Clark D and White FJ. (1987) Review: Dl dopamine
receptor-the search for a function: a critical
evalution of the Dl/02 dopamine receptor classification
and its functional implications. Synapse 1:347-388.
Cloninger CR, Bohman M, and Sigvardsson s. (1981)
Inheritance of alcohol abuse. Arch. Gen. Pyschiatry
38:861-868.
Cloninger CR. (1987) Neurogenetic adaptive mechanisms in
alcoholism. Science 236:410-416.
Cockcroft S and Gompert BO. (1985) Role of guanine
nucleotide binding protein in the activation of
polyphosphoinositide phosphodiesterase. Nature
314:534-536.
Cockcroft S. (1987) Polyphosphoinositide phosphodiesterase:
regulation by a novel guanine nucleotide binding
protein, Gp. Trends Biochem. Sci. 12:75-81.
Codina J, Yatani A, Grenet D, Brown AM, and Birnbaumer L.
(1987) The alpha subunit of the GTP binding protein Gk

164

opens atrial potassium channels. Science 236:442-445.
Cooper JR, Bloom FE, and Roth RH. (1986) catecholamines I:
General Aspects. The Biochemical Basis of
Neuropharmacology. Oxford University Press:
New York pp. 203-258.
Cotman CW and Matthews DA. (1971) Synaptic plasma membranes
from rat brain synaptosomes: isolation and partial
characterization. Biochim. Biophys. Acta 249:380-394.
Cotton NS. (1979) The familial incidence of alcoholism: a
review. J. stud. Alcohol 40:89-116.
Crabbe JC, Kosobud A, Young ER, Tam BR, and McSwigan JD.
(1985) Bidirectional direction for susceptibility to
ethanol withdrawal seizures in Mus musculus. Behav.
Genet. 15:521-536.
Crabbe JC, Young ER, Deutsch CM, Tam BR, and Kosobud A.
{1987) Mice genetically selected for differences in
open-field activity after ethanol. Pharmacol. Biochem.
Behav. 27:577-581.
Creese I, Padgett L, Fazzini E, and Lopez F. {1979) 3H-N-npropylnorapomorphine: a novel agonist ligand for
central dopamine receptors. Eur. J. Pharmacol. 56:411412.
Crews FT, Majchrowicz E, and Meeks R. (1983) Changes in
cortical synaptosomal plasma membrane fluidity and
composition in ethanol-dependent rats. Psychopharmacol.
81:208-213.
Darden JH and Hunt WA. {1977) Reduction of striatal dopamine
release during an ethanol withdrawal syndrome. J.
Neurochem. 29:1143-1145.
Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Bates MD,
and Caron MA. {1990) Molecular cloning and expression
of the gene for a human 0 1 dopamine receptor. Nature
347:72-76.
De Camilli P and Greengard P. (1986) Synapin I: a synaptic
vesicle-associated neuronal phasphorprotein. Biochem.
Pharmacol. 35:4349-4357.
Deitrich RA and McClearn GE. (1931) Neurobiological and
genetic aspects of the etiology of alcoholism. Fed.
Proc. 40:2051-2055.

165
DeKeyser J, Walraevens H, De Backer J-P, Ebinger G, and
Vauquelin G. (1989) D2 dopamine receptors in the human
brain: heterogeneity based on differences in guanine
nucleotide effect on agonist binding, and their
presence on corticostriatal nerve terminals. Brain Res.
484:36-42.
DeKeyser J, Walraevens H, Ebinger G, and Vauquelin G. (1989)
In human brain two subtypes of D1 dopamine receptors
can be distinguished on the basis of differences in
guanine nucleotide effect on agonist binding. J.
Neurochem. 53:1096-1102.
DeLean A, Kilpatrick BF, and Caron MG. (1982) Dopamine
receptor of the porcine anterior pituitary gland:
evidence for two affinity states discriminated by both
agonists and antagonists. Mol. Pharmacol. 22:290-297.
Depue RA and Iacono WG. (1989) Neurobehavioral aspects of
affective disorders. Ann. Rev. Psychol. 40:457-492.
Deretic D and Hamm EH. (1987) Topographic analysis of
antigenic determinants recognized by monoclonal
antibodies to the photoreceptor guanyl
nucleotide-binding protein, transducin. J. Biol. Chem.
262:10839-10847.
Diamond I, Wrubel B, Estrin W, and Gordon A. (1987) Basal
and adenosine receptor-stimulated levels of cAMP are
reduced in lymphocytes in alcoholic patients. PNAS
84:1413-1416.
Di Chiara G and Imperato A. (1985) Ethanol preferentially
stimulates dopamine release in the nucleus accumbens of
freely moving rats. Eur. J. Pharmacol. 115:131-135.
Di Chiara G and Imperato A. (1988) Drugs abused by humans
preferentially increase synaptic dopamine
concentrations in the mesolimbic system of freely
moving rats. PNAS 85:5274-5278.
Dixon RAF, Kobilka BK, Strader DJ, Benovic JL, Dahlman HG,
Frielle T, Bolanowski MA, Bennett CD, Rands E, Diehl
RE, Mumford RA, Slater EE, Sigal IS, Caron MG,
Lefkowitz RJ, and Strader CD. (1986) Cloning of the
gene and cDNA for mammalian ~-adrenergic receptor and
homology with rhodopsin. Nature 321:75-79.
Dodt HU and Misgeld U. (1986) Muscarinic slow excitation and
muscarinic inhibition of synaptic transmission in the
rat neostriatum. J. Physiol. 380:593-608.

166
Dohlman HG, Caron MD, and Lefkowitz RJ. (1987) A family of
receptors coupled to guanine nucleotide regulatory
proteins. Biochemistry 26:2657-2664.
Dolin s, Little H, Hudspith M, Pagonis C, and Littleton J.
(1987) Increased dihydropyridine-sensitive calcium
channels in rat brain may underlie ethanol physical
dependence. Neuropharmacol. 26:275-279.
Ehrenstrom F and Johansson P. (1985) A method for very rapid
determination of catechols using ion-pairing reverse
phase HPLC with electrochemical detection: effects of
L-DOPA treatment on the catechol content in various rat
brain structures. Life Sci. 36:867-879.
Engel J and Liljequist s. (1983) The involvement of
different central neurotransmitters in mediating
stimulatory and sedative effects of ethanol. Stress and
Alcohol Use. Elsevier: New Vork. pp 153-169.
Enjalbert A and Bockaert J. (1983) Pharmacological
characterization of the D2 dopamine receptor negatively
coupled with adenylate cyclase in rat anterior
pituitary. Mol. Pharmacol. 23:576-584.
Erwin VG and Korte A. (1988) Brain neurotensin receptors in
mice bred for differences in sensitivity to ethanol.
Alcohol 5:195-201.
Euvrard c, Ferland L, Di Paolo T, Beaulieu M, Labrie F,
Oberlander c, Raynaud JP, and Bassier JR. (1980)
Activity of two new potent dopaminergic agonists at the
striatal and pituitary levels. Neuropharmacol.
19:379-386.
Fadda F, Argiolas A, Melis MR, Serra G, and Gessa GL. (1980)
Differential effects of acute and chronic ethanol on
dopamine metabolism in frontal cortex, caudate nucleus,
and substantia nigra. Life Sci. 27:979-986.
Feinberg AP and Vogelstein B. (1983) A technique for
radiolabeling DNA restriction endonuclease fragments to
high specific activity. Anal. Biochem. 132:6-13.
Fibiger HC, Phillips AG, and Zis AP. (1974) Deficits in
instrumental responding after 6-hydroxydopamine lesions
of the nigro-striatal dopaminergic projection.
Pharmacol. Biochem. Behav. 2:87-96.
Fibiger HC and Phillips AG. (1987) Role of catecholamine
transmitters in brain reward systems. Brain Reward
Systems and Abuse. Raven Press: New York. pp. 61-74.

167
Fibiger HC, LePaine FG, Jakubovic A, and Phillips AG. (1987)
The role of dopamine in intracranial self-stimulation
of the ventral tegmental area. J. Neurosci.
7:3888-3896.
Filloux FM, Wamsley JK, and Dawson TM. (1987) Presynaptic
and postsynaptic Dl dopamine receptors in the
nigrostriatal system of rat brain: a quantitative
autoradiografhic study using the selective Dl
antagonist [HJ SCH·23390. Brain Res. 408:205-209.
Filloux FM, Wamsley JK, and Dawson TM. (1987) Dopamine D2
auto- and postsynaptic receptors in the nigrostriatal
system of the rat brain: localization by quantitative
autoradiography with [ 3H]-sulpiride. Eur. J. Pharmacol.
138:61-68.
Filloux FM, Dawson TM, and Wamsley JK. (1988) Localization
of nigrostriatal dopamine receptor subtypes and
adenylate cyclase. Brain Res. Bull. 20:447-459.
Fink JS and Reis DJ. (1981) Genetic variations in midbrain
dopamine cell number: parallel with differences in
responses to dopaminergic agonists and in naturalistic
behaviors mediated by central dopaminergic systems.
Brain Res. 222:335-349.
Fisk CH and Subbarrow Y. (1925) The colorimetric
determination of phosphorous. J. Biol. Chem.
66:375-400.
Flaim KE, Gessner GW, Crooke ST, Saurai HM, and Weinstock J.
(1985) Bindin~ of a novel dopaminergic agonist
radioligand [ H]-fenoldopam (SKF 82526) to Dl receptors
in rat striatum. Life Sci. 36:1427-1436.
Folch J, Lees M, and Sloane-Stanley G. (1957) A simple
method for isolation and purification of total lipids
from animal tissue. J. Biol. Chem. 226:497-509.
Freissmuth M, Casey PJ, and Gilman AG. (1989) G proteins
control diverse pathways of transmembrane signalling.
FASEB J. 3:2125-2131.
French SW, Palmer DS, Narod MF, Reid PF, and Ramey cw.
(1975) Noradrenergic sensitivity and withdrawal. J.
Pharmacol. Exp. Ther. 194:319-326.
Gallistel CR and Karras D. (1984) Pimozide and amphetamine
having opposing effects on reward summation function.
Pharmacol. Biochem. Behav. 20:73-77.

168
Galloway MP, Wolf ME, and Roth RH. (1986) Regulation of
dopamine synthesis in the medial prefrontal cortex is
mediated by release modulating autoreceptors: studies
in vivo. J. Pharmacol. Exp. Ther. 236:689-698.
Galloway MP. (1990) Regulation of dopamine and serotonin
synthesis by acute administration of cocaine. Synapse
6:63-72.
Gao B, Mumby s, and Gilman AG. (1987) The G protein ~2
complementary DNA encodes the P35 subunit. J. Biol.
Chem. 262:17254-17257.
Gessa GL, Muntoni F, Collu M, Vargiu L, and Mereu G. (1985)
Low doses of ethanol activate dopaminergic neurons in
the ventral tegmental area. Brain Res. 348:201-203.
Gierschek P, Codina J, Simons c, Birnbaumer L, and Spiegel
A. (1985) Anti-sera against a guanine nucleotide
binding protein from retina cross-react with the ~
subunit of the adenylyl cyclase associated guanine
nucleotide binding proteins, N1 and Ni. PNAS
82:727-731.
Gilman AG. (1987) G proteins: transducers of
receptor-generated signals. Ann. Rev. Biochem.
56:616-649.
Gilman AG. (1989) G proteins and regulation of adenylyl
cyclase. JAMA 262:1819-1825.
Goeders NE and Smith JE. (1986) Reinforcing properties of
cocaine in the medial prefrontal cortex: primary action
on presynaptic dopaminergic terminals. Pharmacol.
Biochem Behav. 25:191-199.
Goodwin DW. (1979) Alcoholism and heredity:a review and
hypothesis. Arch. Gen. Pyschiatry 36:57-61.
Gonzales RA, Theiss c, and Crews FT. (1986) Effects of
ethanol on stimulated inositol phospholipid hydrolysis
in rat brain. J. Pharmacol. Exp. Ther. 237:92-98.
Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam
H, Reed L, Magenis RE, and Civelli o. (1989) The human
dopamine D2 receptor gene is located on chromosome 11
at q22-q23 and identifies a Tag I RFLP. Am. J. Hum.
Genet. 45:778:785.
Graziano MP and Gilman AG. (1987) Guanine nucleotide-binding
regulatory proteins: mediators of transmembrane

169
signaling. Trends Pharmacol. Sci. 8:478-481.
Greenberg DA, Cooper EC, Gordon A, and Diamond I. (1986)
Ethanol and the gamma-aminobutyric acid-benzodiazepine
receptor complex. J. Neurochem. 42:1062-1068.
Grewe CW, Frey EA, Cote TE, and Kebabian JW. (1982)
YM-09151-2: a potent antagonist for peripheral
D2-dopamine receptor. Eur. J. Pharmacol. 81:149-152.
Grigoriadis DE, Niznik HB, Jarvie KR, and Seeman P. (1988)
Glycoprotein nature of D2 dopamine receptors. FEB.
227:220-224.
Guerri c and Grisolia s. (1983) Chronic ethanol treatment
affects synaptosomal membrane-bound enzymes. Pharmacol.
Biochem. Behav. 18(Suppl. 1):45-50.
Haikala H. (1987) Use of a novel type rotating disc
electrode and a flow cell with laminar flow pattern for
the electrochemical detection of biogenic monoamines
and their metabolites after Sephadex gel
chromatographic purification and high performance
liquid chromatographic isolation from rat brain. J.
Neurochem. 49:1033-1041.
Harden TK. (1983) Agonist-induced desensitization of the
beta-adrenergic receptor-linked adenylate cyclase.
Pharmacol. Rev. 35:5-32.
Hattori T, Fibiger HC, and McGeer PL. (1975} Demonstration
of a pallidonigral projection innervating dopaminergic
neurons. J. Comp. Neurol. 162:487-504.
Hemmings HC, Greengard P, Lim Tung HY, and Cohen P. (1984)
DARPP-32, a dopamine-regulated neuronal phosphoprotein,
is a potent inhibitor of protein phosphatase-1. Nature
310:503-508.
Hemmings HC and Greengard P. (1986) DARPP-32, a dopamine and
adenosine-3':5'-monophosphate-regulated neuronal
phosphoprotein: regional, tissue, and phylogenic
distribution. J. Neurosci. 6:1469-1481.
Hemmings HC, Nairn AC, McGuinness TL, Hugnair RL, and
Greengard P. (1989) Role of protein phosphorylation in
neuronal signal transduction. FASEB J. 3:1583-1592.
Hescheler J, Rosenthal W, Trautwein W, and Schultz G. (1987)
The GTP-binding protein, Go, regulates neuronal calcium
channels. Nature 325:445-447.

170
Hess EJ, Battaglia G, Norman AB, Iorio LC, and Creese I.
(1986) Guanine nucleotide regulation of agonist
interactions at 3H-SCH 23390 labeled Dl dopamine
receptors in rat striatum. Eur. J. Pharmacol.
121:31-38.
Hess EJ and Creese I. (1987) Biochemical Characterization of
Dopamine Receptors. Dopamine Receptors. Alan R.Liss:
New York. pp. 1-27.
Hietala J, Salonen I, Lappalainen J, and Syvalahti E. (1990)
Ethanol administration does not alter dopamine D1 and
D2 receptor characteristics in rat brain. Neurosci.
Lett. 108:289-294.
Hildebrandt JD, Codina J, Rosenthal W, Birnbaumer L, Neer
EJ, Yamagaki A, and Bitensky MW. (1985)
Characterization by two-dimensional peptide mapping of
the subunit composition of the regulatory Ns and Ni
proteins of adenyl cyclase and transducin, the guanine
nucleotide binding protein of retinal rod outer
segments. J. Biol. Chem. 260:14867-14872.
Hoffman DC and Beninger RJ. (1985) The D-1 dopamine receptor
antagonist, SCH 23390 reduces locomotor activity and
rearing in rats. Pharmacol. Biochem. Behav. 22:341-342.
Hoffman PL and Tabakoff B. {1979) Adaptive changes in the
dopamine system produced by chronic ethanol feeding.
Drug Alcohol Depend. 4:255-261.
Hoffman PL and Tabakoff B. {1990) Ethanol and guanine
nucleotide binding proteins: a selective interaction.
FASEB J. 4:2612-2622.
Hokfelt T, Johansson o, Fuxe K, Goldstein M, and Park D.
{1976) Immunohistochemical studies on the localization
and distribution of monoamine neuron systems in the rat
brain. I. Tyrosine hydroxylase in the mes- and
diencephalon. Med. Biol. 54:427-453.
Holbrook SR and Kim SH. {1989) Molecular model of the
G protein a subunit based on the crystal structure of
the HRAS protein. PNAS 86:1751-1755.
Hortnagal H, Potter PE, Kindel G, and Hanin I. (1989)
Noradrenaline depletion protects cholinergic neurons in
rat hippocampus against AF64A-induced damage. J.
Neurosci. Methods 27:103-108.

171
Hrubec Z and Omenn GS. (1981) Evidence of genetic
predisposition to alcoholic cirrhosis and pychosis:twin
concordance for alcoholism and its end points by
zygosity among male veterans. Alcoholism 5:207-215.
Hruska RE. {1988) Effect of ethanol administration on
striatal Dl and D2 dopmine receptors. J. Neurochem.
50:1929-1933.
Hudspith M, John GR, Nhamburo PT, and Littleton JM. (1985)
Effects of ethanol in vitro and in vivo on calcium
activated metabolism of brain phospholipids in rat
synaptosomal and brain slice preparations. Alcohol
2:133-138.
Huff RM and Molinoff PB. (1984) Quantitative assay of
dopamine receptor subtypes. Dopamine Receptor Agonists.
Plenum Press: New York. pp. 65-86.
Hunt WA. (1981) Neurotransmitter function in basal ganglia
after acute and chronic ethanol treatment. Fed. Proc.
40:2077-2081.
Hunt WA and Majchrowicz E. (1983) Studies of
neurotransmitter interactions after acute and chronic
ethanol administration. Pharmacol. Biochem. Behav.
18(1):371-374.
Hyttel J. {1978) Effects of neuroleptics on 3H-haloperidol
and 3H-cis{2)-flupenthixol binding and on adenylate
cyclase activity in vitro. Life Sci. 23:551-556.
Hyttel J. {1983) SCH 23390-the first selective dopamine D-1
antagonist. Eur. J. Pharmacol. 91:153-154.
Imperato A and Di Chiara G. {1986) Preferential stimulation
of dopamine release in the nucleus accumbens of freely
moving rats by ethanol. J. Pharmacol. Exp. Ther.
239:219-228.
Itch H, Toyama R, Kazasa T, Tsukamoto T, Matsuoka M, and
Kaziro Y. {1988) Presence of three distinct molecular
species of Gi protein a subunit: structure of rat cDNAs
and human genomic DNAs. J. Biol. Chem. 263:6656-6664.
Iversen LL. {1975) Dopamine receptors in brain. Science
188:1084-1089.
Jacobs s and Cuatrecasas P. (1976) The mobile receptor
hypothesis and the cooperativity of hormone binding;
application to insulin. Biochim. Biophys. Acta

172
433:482-495.
Jarvie KR, Niznik HB, and Seeman P. (1988) Dopamine 02
receptor binding subunits of Mr=140,000 and 94,000 in
brain: deglycosylation yields a common unit of
Mr=44,000. Mol. Pharmacol. 34:91-97.
Jarvie KR, Booth G, Brown EM, and Niznik HB. (1989)
Glycoprotein nature of dopamine Dl receptors in the
brain and parathyroid gland. Mol. Pharmacol.
36:566-574.
Johansson P, Levin E, Gunnel L, and Ellison G. (1987)
Opposite effects of a D-1 and a D-2 agonist on oral
movements in rat. Eur. J. Pharmacol. 134:83-88.
Johnson GL and Dhanasekaran N. (1989) The G-protein family
and their interactions with receptors. Endocrine Rev.
10:317-331.
Jones DT and Reed RR. (1987) Molecular cloning of five GTPbinding protein cDNA species from rat olfactory
neuroepithelium. J. Biol. Chem. 262:14241-14249.
Joyce JN and Marshall JF. (1985) Striatal topography of D-2
receptors correlates with indexes of cholinergic neuron
localization. Neurosci. Lett. 53:127-131.
Joyce JN and Marshall JF. {1987) Quantitative
autoradiography of dopamine D2 sites in rat
caudate-putamen: localization to intrinsic neurons and
not to neocortical afferents. Neurosci. 20:773-795.
Kaprio J, Koskenvuo M, Langinvainio H, Romanov K, Sarna s,
and Rose RJ. (1987) Genetic influence on use and abuse
of alcohol: a study of 5638 adult Finnish twin
brothers. Alcoholism 11(4):349-356.
Katada T, Bokoch GM, Smigel MD, Ui M, and Gilman AG. (1984)
The inhibitory guanine nucleotide-binding regulatory
component of adenylate cyclase. Subunit dissociation
and the inhibition of adenylate cyclase in S49 lymphoma
eye- and wild type membranes. J. Biol. Chem.
259:3586-3595.
Kelly E and Naharski SR. (1987) Dopamine D-2 receptors
inhibit D-1 stimulated cyclic AMP formation in striatum
but not in limbic forebrain. Naunyn-Schiedeberg's Arch.
Pharmacol. 335:508-512.
Kebabian JW and Calne DB. (1979) Multiple receptors for
dopamine. Nature 277:93-96.

173
Klein WL, Sullivan J, Skorupa A, and Aguilar JS. (1989)
Plasticity of neuronal receptors. FASEB J. 3:2132-2140.
Kobilka BK, Dixon RAF, Frielle T, Dohlman HG, Bolanowski MA,
Sigal IS, Yang-Feng TL, Francke V, Caron MD, and
Lefkowitz RJ. (1987) cDNA for the human P2-adrenergic
receptor: a protein with multiple membrane-spanning
domains and encoded by a gene whose chromosomal
location is shared with that of the receptor for
platelet-derived growth factor. PNAS 84:46-50.
Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, and
Lefkowitz RJ. (1988) Chimeric a 2-,P2-adrenergic
receptors: delineation of domains involved in effector
coupling and ligand binding specifity. Science
240:1310-1316.
Kohli JD and Goldberg LI. (1987) Dopamine receptors:a
classification based on physiological studies. Dopamine
Receptors. Alan R. Liss: New York. pp. 97-114.
Koob GF and Weiss F. (1990) Pharmacology of drug selfadministration. Alcohol 7:193-197.
Korpi ER, Sinclair JD, and Malminen o. (1987) Dopamine D2
receptor binding in striatal membranes of rat lines
selected for differences in alcohol-related behaviors.
Pharmacol. & Toxicol. 61:94-97.
Krupinski J, Caussen F, Bakalyar HA. (1989) Adenyl cyclase
amino acid sequence: possible channel- or
transporter-like structure. Science 244:1558-1564.
Kubo T, Fakuda K, Mikami A, Maeda A, Takahashi H, Mishina M,
Haga T, Haga K, Ichiyama A, Kangawa K, Kojima M, Matsuo
H, Hirose T, and Numa s. (1986) Cloning, sequencing and
expression of complemetary DNA encoding the muscarinic
acetylcholine receptor. Nature 323:411-416.
Lacey MG, Mercuri NB, and North RA. (1987) Dopamine acts on
D2 receptors to increase potassium conductance in
neurons of rat substantia nigra zona compacta. J.
Physiol. 392:397-416.
Laemmli UK. (1970} Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Nature
227:680-683.
Lai H, Carino MA, and Horita A. (1980) Effects of ethanol on
central dopamine functions. Life Sci. 27:299-304.

174
Lankford KL, De Mello FG, and Klein WL. (1988) D1-type
dopamine receptors inhibit growth cone motility in
cultured retina neurons: evidence that
neurotransmitters act as morphogenic growth regulators
in the developing central nervous system. PNAS
85:4567-4571.
Lasater EM and Dowling JE. (1985) Dopamine decreases
conductance of the electrical junctions between
cultured retinal horizontal cells. PNAS 82:3025-3029.
Leff SE, Hamblin MW, and Creese I. {1985) Interactions of
dopamine agonists with brain Dl receptors labelled by
3H-antagonists: evidence for the presence of high and
low affinity agonist binding states. Mel. Pharmacol.
27:171-183.
Lefkowitz RJ and Caron MG. (1988) Adrenergic receptors.
Model for the study of the receptors coupled to guanine
nucleotide regulatory proteins. J. Biol. Chem.
263:4993-4996.
Lehmann J, Briley M, and Langer SZ. {1983) Characterization
of dopamine autoreceptor and [ 3H]spiperone binding
sites in vitro with classical and novel dopamine
receptor agonists. Eur. J. Pharmacol. 88:11-26.
Leslie CA and Bennett JP. {1987) [ 3H]-Spiperone binds
selectively to rat striatal D2 dopamine receptors in
vivo: a kinetic and pharmacological analysis. Brain
Res. 407:253-262.
Lewis MJ and June HL. {1990) Neurobehavioral studies of
ethanol reward and activation. Alcohol 7:213-219.
Leyson JE, Gommerin W, and Laduron PM. (1978) Spiperone: a
ligand of choice for neuroleptic receptors. Biochem.
Pharmacol. 27:307-316.
Liljequist S, Berggren U, and Engel J. (1981) The effect of
catecholamine receptor antagonists on ethanol-induced
locomotor stimulation. J. Neural Trans. 50:57-67.
Lim DK, Yu ZJ, Haskins B, Rockhold RW, and HO IK. (1990)
Effects of acute and subacute cocaine administration on
the CNS dopaminergic system in Wister-Kyoto and
spontaneously hypertensive rats: II. Dopamine
Receptors. Neurochem. Res. 15:621-627.
Limbird LE. (1981) Activation and attenuation of adenylate
cyclase. The role of GTP-binding proteins as

175
macromolecular messengers in receptor cyclase coupling.
Biochem. J. 194:1-13.
Lindvall o, Bjorkland A, and Divac I. (1978) Organization of
catecholamine neurons projecting to frontal cortex in
rat brain. Brain Res. 142:1-24.
Lindvall o and Bjorkland A. (1979) Dopaminergic innervation
of the globus pallidus by collaterals from the
nigrostriatal pathway. Brain Res. 172:169-173.
List SJ and Seeman P. (1981) Resolution of dopamine and
serotonin receptor components of [ 3H)-spiperone binding
to rat brain regions. PNAS 78:2620-2624.
Llinas R, McGuinness TL, Leonard cs, Sugimori M, and
Greengard P. (1985) Intraterminal injection of synapsin
I or calcium/calmodulin-dependent protein kinase II
alters neurotransmitter release. PNAS 82:3035-3039.
Lochrie MA, Hurley JB, and Simon MI. (1985) Sequence of the
alpha subunit of photoreceptor G protein: homologies
between transducin, ras and elongation factors. Science
228:96-99.
Lovinger DM, White G, and Weight FF. (1989) Ethanol inhibits
NMDA-activated ion current in hippocampal neurons.
Science 243:1721-1724.
Lowry OH, Rosebrough NH, Farr AL, and Randall RJ. (1951)
Protein measurement with Folin phenol reagent. J. Biol.
Chem. 193:265- 275.
Lucchi L, Covelli v, Anthopoulou H, Spano PF, and Trabucchi
M. (1983) Effect of chronic ethanol treatment on
adenylate cyclase activity in rat striatum. Neurosci.
Lett. 40:187-192.
Lucchi L, Lupini M, Govoni s, Covelli V, Spano PF and
Trabucchi M. (1983) Ethanol and dopaminergic systems.
Pharmacol. Biochem. Behav. 18(Suppl 1):379-382.
Lucchi L, Moresco RM, Govoni s, and Trabucchi M. (1988)
Effect of chronic ethanol treatment on dopamine
receptor subtypes in rat striatum. Brain Res.
449:347-351.
Luthin GR and Tabakoff B. (1984) Activation of adenylate
cyclase by alcohols requires the nucleotide-binding
protein. J. Pharmacol. Exp. Ther. 228:579-587.
Lynch MA and Littleton JM. (1983) Possible association of

176
alcohol tolerance with increased synaptic calcium
sensitivity. Nature 303:175-176.
Lyness WH, Friedle NM, and Moore KE. (1979) Destruction of
dopaminergic nerve terminals in nucleus accumbens:
effect on D-amphetamine self-administration. Pharmacol.
Biochem. Behav. 11:553-556.
Lyon RC and Goldstein DB. (1983) Changes in synaptic
membrane order associated with chronic ethanol
treatmemt in mice. Mol. Pharmacol. 23:86-91.
Maguire PA and Druse MJ. (1989) The influence of cholesterol
on synaptic fluidity, dopamine Dl binding and dopaminestimulated adenylate cyclase. Brain Res. Bull. 23:6974.
Mahan LC, Burch RM, Monsma FJ, and Sibley DR. (1990)
Expression of striatal Dl dopamine receptors coupled to
inositol phosphate production and ca+ 2 mobilization in
Xenopus oocytes. PNAS 87:2196-2200.
Majchrowicz E. (1981) Reversal in central nervous system
function during chronic ethanol withdrawal in human and
experimental animals. Fed. Proc. 40:2065-2072.
Malgaroli AL, Vallar L, Elahi FR, Pozzan T, Spada A,and
Meldolesi J. (1987) Dopamine inhibits cystolic ca+ 2
increases in rat lactotroph cells: evidence of a dual
mechanism of action. J. Biol. Chem. 262:13920-13927.
Manik CP, Molinoff PB, and McGonigle P. (1988) Comparison of
[ 1 ~I)-SCH 23982 and [3H]-SCH 23390 as ligands for the
D-1 dopamine receptors. J. Neurochem. 51:391-397.
Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli o, Akil H,
and Watson SJ. (1990) Localization of dopamine D2
receptor mRNA and Dl and D2 binding in the rat brain
and pituitary: an in situ hybridization-receptor
autoradiographic analysis. J. Neurosci. 10:2587-2600.
Matthews RT and German DC. (1984) Electrophysiological
evidence for excitation of rat ventral tegmental area
dopamine neurons by morphine. Neurosci. 11:617-625.
Mazurski EJ and Beninger RJ. (1986) The effects of
(+)amphetamine and apomorphine on responding for a
conditioned reinforcer. Psychopharmacol. 90:239-243.
McBride WJ, Murphy JM, Lumeng L, anad Li T-K. (1990)
Serotonin, dopamine and GABA involvememt in alcohol

177
drinking of selective bred rats. Alcohol 7:199-205.
Medynski D, Sullivan K, Smith D, VanDop C, Chang F-H, Fung
BK-K, Seeburg PH, and Bourne HR. (1985) Amino acid
sequence of the a subunit of transducin deduced from
the cDNA sequence. PNAS 82:4311-4315.
Mereu G, Fadda F, and Gessa GL. (1984) Ethanol stimulates
the firing rate of nigral dopaminergic neurons in
unanesthetized rats. Brain Res. 292:63-69.
Mereu G and Gessa GL. (1985) Low doses of ethanol inhibit
the firing of neurons in the substantia nigra, pars
reticulata: a GABA-ergic effect? Brain Res.
360:325-330.
Messing RO, Carpenter CL, Diamond L, and Greenberg DA.
(1986) Ethanol regulates calcium channels in clonal
neural cells. PNAS 83:6213-6215.
Miller RJ, Kelly PH, and Neumeyer JL. (1976) Action of
aporphine alkaloids on dopaminergic mechanisms in rat
brain. Eur. J. Pharmacol. 35:77-83.
Miller R, Wickens JR, and Beninger RJ. (1990) Dopamine D-1
and D-2 receptors in relation to reward and
performance: a case for the D-1 receptor as a primary
site of therapeutic action of neuroleptic drugs. Prag.
Neurobiol. 34:143-183.
Mochly-Rosen D, Chang F, Cheever L, Diamond I, and Gordon
AS. (1988) Chronic ethanol causes heterologous
desensitization of receptors by reducing alpha S
messenger RNA. Nature 333:848-850.
Molloy AG and Waddington JC. (1985) Sniffing, rearing and
locomotor responses to the D-1 dopamine agonist R-SK &
F 38393 and to apomorphine: differential interactions
with the selective D-1 and D-2 antagonists SCH 23390
and metoclopramide. Eur. J. Pharmacol. 108:305-308.
Monsma FJ, Mahan LC, McVittie LD, Gerfen CR, and Sibley DR.
(1990) Molecular cloning and expression of a D1
dopamine receptor linked to adenylyl cyclase
activation. PNAS 87:6723-27.
Morelle G. (1989) A plasmid extraction procedure on a
miniprep scale. Focus 11.1:7-8.
Muller P, Britton RS, and Seeman P. (1980) The effects of
long term ethanol on brain receptors for dopamine,

178
acetylcholine, serotonin, and noradrenaline. Eur. J.
Pharmacol. 65:31-37.
Murphy JM, Waller MB, Gatto GJ, McBride WJ, Lumeng L, and Li
T-K. (1985) Monoamine uptake inhibitors attenuate
ethanol intake in alcohol-preferring (P) rats. Alcohol
2:349-352.
Murphy JM, McBride WJ, Lumeng L, and Li T-K. (1987) Contents
of monoamines in f orebrain regions of
alcohol-preferring (P) and -nonpreferring (NP) lines of
rats. Pharmacol. Biochem. Behav. 26:389-392.
Murphy JM, McBride WJ, Gatto GJ, Lumeng L, and Li T-K.
(1988) Effects of acute ethanol administration on
monoamine and metabolite content in forebrain regions
of ethanol-tolerant and -nontolerant alcohol-preferring
(P) rats. Pharmacol. Biochem. Behav. 29:169-174.
Nagy LE, Diamond I, and Gordon A. (1988) Cultured
lymphocytes from alcoholic subjects have altered cAMP
signal transduction. PNAS 85:6973-6976.
Nakajima s. (1989) Subtypes of dopamine receptors involved
in the mechanism of reinforcement. Neurosci. Behav.
Rev. 13:123-128.
Nathanson JA and Greengard P. (1981) Cyclic neucleotides and
synaptic transmission Basic Neurochemistry Little,
Braun & Co.: Boston, MA. pp. 297-310.
Nauta WJH, Smith GP, Faull RLM, and Domesick u. (1978)
Efferent connections and nigral afferents to the
nucleus accumbens septi in the rat. Neurosci.
3:385-401.
Nauta

w. (1986) Circuitous connections linking cerbral
cortex, limbic system, and corpus striatum. The Limbic
System:Functional Organization and Clinical Disorders.
Raven Press: New York. pp. 43-54.

Navan SE and Fung BKK. (1987) Characterization of transducin
from bovine retinal rod outer segments: participation
of the amino-terminal region of Ta in subunit
interaction. J. Biol. Chem. 262:15746-15751.
Nemeroff CB and Cain ST. (1985) Neurotensin-dopamine
interactions in the central nervous system. Trends
Pharmacol. Sci. 6:201-205.
Nestler EJ and Greengard P. (1989) Protein Phosphorylation
and the Regulation of Neuronal Function. Basic

179
Neurochemistry. Raven Press: New York. pp. 373-398.
Nicoll RA. (1987) Introduction to the Pharmacology of CNS
Drugs. Basic and Clinical Pharmacology. Appleton &
Lange:Norwalk, Conn. pp. 233-253.
Niznik HB, Grigoriadas DE, Otsuka NY, Dumbrille-Ross A, and
Seeman P. (1986) The dopamine D1 receptor:partial
purification of a digitonin-solubilized
receptor-guanine nucleotide binding complex. Biochem.
Pharmacol. 35:2974-2977.
Niznik HB, Fogel EL, Chen CJ, Brown EM, and Seeman P. (1988)
Dopamine Dl receptors of the calf parathyroid gland:
identification and characterization. Mol. Pharmacol.
34:29-36.
Niznik HB, Jarvie KR, Bzowej NH, Seeman P, Garlick RK,
Miller JJ, Baindur N, and Neumeyer JL. (1988)
Photoaffinity labeling of dopamine Dl receptors.
Biochemistry 27:7594-7599.
Niznik HB, Jarvie KR, and Brown EM. (1989) Dopamine Dl
receptors of the calf parathyroid gland:identification
of a ligand binding subunit with lower apparent
molecular weight but similar primary structure to
neuronal Dl receptors. Biochemistry 28:6925-6930.
Noronha AB and Druse MJ. (1982) Maternal ethanol consumption
and synaptic membrane glycoproteins in offspring. J.
Neurosci. Res. 8:83-97.
Northup JK, Smigel MD, Sternweis PC, and Gilman A. (1983)
The subunits of the stimulatory regulatory component of
adenylate cyclase: resolution of the activated
45,000-dalton (alpha) subunit. J. Biol. Chem.
258:11369-11376.
Northup JK. (1989) Regulation of cyclic nucleotides in the
nervous system. Basic Neurochemistry. Raven Press: New
York. pp. 349-363.
Oades Rd and Halliday GM. (1987) Ventral tegmental (AlO)
system: neurobiology, anatomy and connectivity. Brain
Res. Rev. 12:117-165.
O'Boyle KM and Waddington JL. (1984) Identification of the
enantiomers of SK & F 83566 as specific and
stereospecif ic antagonists at the striatal D1 dopamine
receptor: comparisons with the enantioselectivity of Ro
22-1319. Eur. J. Pharmacol. 106:219- 220.

180
O'Dowd BF, Hnatowich M, Regan JW, Leader WM, Caron MG, and
Lefkowitz RJ. (1988) Site-directed mutagenesis of the
cytoplasmic domains of the human P2-adrenergic
receptor: localization of regions involved in G
protein-receptor coupling. J. Biol. Chem.
263:15985-15992.
O'Malley KL, Mack KJ, Gandelman K-Y, and Todd RD. (1990)
Organization and expression of the rat D2A receptor
gene: identification of alternate transcript and a
variant donor splice site. Biochemistry 29:1367-1371.
Owens F, Cross AJ, Paulter M, and Waddington JL. (1979)
Change in the characteristics of 3H-spiperone binding
to rat striatal membranes after acute chlorpromazine
administration: effects of buffer washing of membranes.
Life Sci. 25:385-390.
Palkovits M and Brownstein MJ. (1988) Maps and Guide to
Microdissection of the Rat Brain. Elsevier:New York.
Pfaffinger PJ, Martin MJ, Hunter DD, Nathanson NM, and Hille
B. (1985) GTP-binding proteins couple cardiac
muscarinic receptors to a K+ channel. Nature
317:536-538.
Phillips AG and Fibiger HC. (1978) The role of dopamine in
maintaining intracranial self-stimulation in the
ventral tegmentum, nucleus accumbens, and medial
prefrontal cortex. Can. J. Psychol. 32:58-66.
Phillips AG, Lepaine FG, and Fibiger HC. (1982) Effects of
kainic acid lesions of the striatum on self-stimulation
in the substantia nigra and ventral tegmental area.
Behav. Brain Res. 5:297-310.
Phillips AG, Jakubovic A, and Fibiger HC. (1987) Increased
in vivo tyrosine hyroxylase activity in rat
telencephalon produced by self-stimulation of ventral
tegmental area. Brain Res. 402:109-116.
Porceddu ML, Giorgi o, Ongini E, Mile s, and Biggio G.
(1986) [ 3H] SCH 23390 binding sites in the rat
substantia nigra: evidence for a presynaptic
localization and innernation by dopamine. Life Sci.
39:321-328.
Rabin RA. (1985) Effect of ethanol on inhibition of striatal
adenylate cyclase activity. Biochem. Pharmacol.
34:4329-4331.
Rabin RA. (1990) Chronic ethanol exposure of PC 12 cells

181
alters adenylate cyclase activity and intracellular
cyclic AMP content. J. Pharmacol. Exp. Ther. 252:10211027.
Rabin RA and Molinoff PB. (1981) Activation of adenylate
cyclase by ethanol in mouse striatal tissue. J.
Pharmacol. Exp. Ther. 216:129-134.
Rabin RA and Molinoff PB. (1983) Multiple sites of action of
ethanol on adenylate cyclase. J. Pharmacol. Exp. Ther.
227:551-556.
Rabin RA, Bode DC, and Molinoff PB. (1986) Relationship
between ethanol-induced alterations in fluorescence
anistrophy and adenylate cyclase activity. Biochem.
Pharmacol. 35:2331-2335
Rabin RA, Baker RC, and Deitrich RA. (1987) Effects of
chronic ethanol exposure on adenylate cyclase
activities in rat. Pharmacol. Biochem. Behav.
26:693-697.
Rao DD, McKelvy J, Kebabian J, and MacKenzie RG. (1990) Two
forms of the rat D2 dopamine receptor as revealed by
the polymerase chain reaction. FEBS Lett. 263:18-22.
Richelson E, Stenstrom s, Forray c, Enloe L, and Pfenning M.
(1986) Effects of chronic exposure to ethanol on the
prostaglandin El receptor-mediated response and binding
in a murine neuroblastoma clone (N1E-115). J.
Pharmacol. Exp. Ther. 239:687-692.
Richfield EK, Young AB, and Penney JB. (1987) Comparative
distribution of dopamine D-1 and D-2 receptors in the
basal ganglia of turtles, pigeons, rats, cats, and
monkeys. J. Comp. Neurology 262:446-463.
Richfield EK, Penney JB, and Young DB. (1989) Anatomical and
affinity state comparisons between dopamine D1 and D2
receptors in the rat central nervous system. Neurosci.
30:767-777.
Roberts DCS and Koob GF. (1983) Disruption of cocaine selfadministration following 6-hydroxydopamine lesions of
the ventral tegmental area in rats. Pharmacol. Biochem.
Behav. 17:901-904.
Saffey K, Gillman MA, and Contrill RC. (1988) Chronic in
vivo ethanol administration alters the sensitivity of
adenylate cyclase coupling in homogenates of rat brain.
Neurosci. Lett. 84:317-322.

182
Saito T, Lee JM, and Tabakoff B. (1985) Ethanol's effects on
cortical adenylate cyclase activity. J. Neurochem.
44:1037-1044.
Saito T, Lee JM, Hoffman PL, and Tabakoff B. (1987) Effects
of chronic ethanol treatment on beta-adrenergic
receptor-coupled adenylate cyclase system of mouse
cerebral cortex. J. Neurochem. 48:1817-1822.
Samson HH, Tolliver GA, and Schwarz-Stevens K. (1990) Oral
ethanol self-administration:a behavioral
pharmacological approach to CNS control mechanisms.
Alcohol 7:187-191.
Schalling M, Djurfeldt M, Hokfelt T, Ehrlich M, Kurihara T,
and Greengard P. {1990) Distribution and cellular
localization of DARPP-32 mRNA in rat brain. Brain Res.
Mol. 7:139-149.
Schuckit MA, Li T-K, Cloninger CR, and Deitrich RA. {1985)
Genetics of alcoholism. Alcoholism: Clin. Exp. Res.
9:475-492.
Schulz DW, Wyrick SD, and Mailman RB. (1984) [ 3H]-SCH 23390
has the characteristics of a dopamine receptor ligand
in the rat central nervous system. Eur. J. Pharmacol.
106:211-212.
Schulz DW, Stanford EJ, Wyrick SW, and Mailman RB. (1985)
Binding of [ 3H]-SCH 23390 in rat brain: regional
distribution and effects of assay conditions and GTP
suggest interactions at a Dl-like dopamine receptor. J.
Neurochem. 45:1601-1611.
Seguela P, Watkins KC, and Descarries L. (1988)
Ultrastructural features of dopamine axon terminals in
the anteromedial and the superhinal cortex of adult
rat. Brain Res. 442:11-22.
Senogles SE, Spiegel AM, Padrell E, Iyengar R, and Caron MG.
{1990) Specificity of receptor-G protein interactions.
Discrimination of Gi subtypes by the D2 dopamine
receptor in a reconstituted system. J. Biol. Chem.
265:4507-4514.
Setler PE, Sarau HM, Zirkle CL, and Saunders HL. (1978) The
central effects of a novel dopamine agonist. Eur. J.
Pharmacol. 50:419-430.
Sibley DR, DeLean A, and Creese I. (1982) Anterior pituitary
dopamine receptors. Demonstration of interconvertible
high and low affinity states of the D-2 dopamine

183
receptor. J. Biol. Chem. 257:6351-6361.
Sibley DR, Peters JR, Nambi P, Caron MG, and Lefkowitz RJ.
(1984) Desensitization of turkey erythrocyte adenylate
cyclase. J. Biol. Chem. 259:9742-9749.
Sibley DR, Benovic JL, Caron MG, and Lefkowitz RJ. (1987)
Regulation of transmembrane signaling by receptor
phosphorylation. Cell 48:913-922.
Simmonds SH and Strange PG. (1985) Inhibition of inositol
phospholipid breakdown by D2 dopamine receptors in
dissociated bovine anterior pituitary cells. Neurosci.
Lett. 60:267-272.
Spiegel AM, Gierschik P, Levine MA, and Downs RW. (1985)
Clinical implication of guanine nucleotide-binding
proteins as receptor- effector couplers. New Engl. J.
Med. 312:26-33.
Stadel JM, Nambi P, Shorr RGL, Sawyer DF, Caron MG, and
Lefkowitz RJ. (1983) Catecholamine-induced
desensitization of turkey erythrocyte adenylate cyclase
is associated with phosphorylation of the B-adrenergic
receptor. PNAS 80:3173-3177.
Starr BS and Starr MS. (1986) Differential effects of
dopamine D-1 and D-2 agonists and antagonists on
velocity of movement, rearing and grooming in the
mouse. Neuropharmacol. 25:455-463.
Stein L. (1983) The chemistry of positive reward. Biological
Basis of Sensation Seeking, Impulsivity, and Anxiety.
Erlbaum: Hillside, N.J. pp. 151-176.
Steiner AL, Parter cw, and Kipnis DM. (1972)
Radioimmunoassay for cyclic nucleotides. I. Preparation
of antibodies and iodinated cyclic nucleotides. J.
Biol. Chem. 247:1106-1113.
Steiner AL, Pagliara AS, Chase LR, and Kipnis DM. (1972)
Radioimmunoassay for cyclic nucleotides. II. Adenosine
3'-5'-monophosphate and guanosine 3'-5'-monophosphate
in mammalian tissue and body fluids. J. Biol. Chem.
247:1114-1120.
Sternweis PC, Northup JK, Smigel MD, and Gilman AG.
The regulatory component of adenylate cyclase:
purification and properties. J. Biol. Chem.
256:11517-11526.
Stiles GL.

(1981)

(1989) Mechanisms of receptor activation in

184
adenylate cyclase systems. J. cardiovascular Physiol.
14(Suppl. 5):51-55.
Stockton GW and Smith ICP. (1976) A deuterium nuclear
magnetic resonance study of the condensing affect of
cholesterol on EGG phosphatidylcholine bilayer
membranes. I. Perdeuterated fatty acid probes. Chem.
Phys. Lipids 17:251-263.
Stoof JC and Verheijden PFHM. (1986) D-2 receptor
stimulatiom inhibits cyclic AMP formation brought about
by D-1 receptor stimulation in rat neostriatum but not
in nucleus accumbens. Eur. J. Pharmacol. 129:205-206.
Stoof JC, Verheijden PFHM, Leyson JE. (1987) Stimulation of
D2-receptors in rat nucleus accumbens slices inhibits
dopamine and acetylcholine release but not cyclic AMP
formation. Brain Res. 423:364-368.
Strader CD, Dixon RAF, Cheung AH, Candelore MR, Blake AD,
and Sigal IS. (1987) Mutations that uncouple the
P-adrenergic receptor from G1 and increase agonist
affinity. J. Biol. Chem. 262:16439-16443.
Strasser RH, Benovic JL, Caron MG, and Lefowitz RJ. (1986)
P-agonist- and prostaglandin E1-induced translocation
of the P-adrenergic receptor kinase: evidence that the
kinase may act on multiple adenylate cyclase-coupled
receptors. PNAS 83:6362-6366.
Strathmann M, Wilkie TM, and Simon MI. (1989) Diversity of
the G protein family: sequence from five additional a
subunits in the mouse. PNAS 86:7407-7409.
Sullivan KA, Miller RT, Masters SB, Beiderman B, Heideman W,
and Bourne HR. (1987) Identification of receptor
contact site involved in receptor-G protein coupling.
Nature 330:758-760.
Sun GY and Sun AY. (1985) Ethanol and membrane lipids.
Alcoholism: Clin. Exp. Res. 9:164-180.
Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR,
Kennedy JJ, Gelernter JE, Rozmahel R, Yang Y, Israel Y,
Seeman P, and O'Dowd BF. (1990). Human dopamine Dl
receptor encoded by an intronless gene on chromosome 5.
Nature 347:80-83.
syvalahti EKG, Hietala J, Roytta M, and Gronroos J. (1988)
Decrease in the number of rat brain dopamine and
muscarinic receptors after chronic alcohol intake.

185
Pharmacol. & Toxicol. 62:210-212.
Tabakoff B and Hoffman PL. (1978) Alterations in receptors
controlling dopamine synthesis after chronic ethanol
ingestion. J. Neurochem. 31:1223-1229.
Tabakoff B, Hoffman PL, and Ritzman RF. (1978) Dopamine
receptor function after chronic ingestion of ethanol.
Life Sci. 23:643-648.
Tabakoff B and Hoffman PL. (1979) Development of functional
dependence to ethanol in dopaminergic systems. J.
Pharmacol. Exp. Ther. 208:216-222.
Tabakoff B, Hoffman PL, Lee JM, Saito T, Willard B, and De
Leon-Jones F. (1988) Differences in platelet enzyme
activity between alcoholics and nonalcoholics. New
Engl. J. Med. 318:134-139.
Tabakoff B, Valverius P, Nhamburo PT, Rius RA, and Hoffman
PL. (1988) Region-specific effects of ethanol on G
proteins in mouse brain. Trans. Am. Soc. Neurochem.
19:144-153.
Taghzouti K, Simon H, Louilot A, Herman JP, and LeMoal M.
{1985) Behavioral study after local injection of
6-hydroxydopamine into the nucleus accumbens in the
rat. Brain Res. 44:9-20.
Tarter RE, Alterman AI, and Edwards KL. (1985) Vulnerability
to alcoholism in men: a behavior-genetic perspective.
J. Stud. Alcohol 46(4):329-356.
Titeler M and Seeman P. (1979) Selective labeling of
different dopamine receptors by a new agonist 3Hligand: 3H-N-propylnorapomorphine. Eur. J. Pharmacol.
56:291-292.
Titus RD, Kornfeld EC, Jones ND, Clemens JA, Smalstig EB,
Fuller RW, Hahn RA, Hynes MD, Mason NR, Wong DT, and
Foreman MM. (1983) Resolution and absolute confirmation
of an ergoline-related dopamine agonist,
trans-4,4a,5,6,7,8a,9-octahydro-5-propyl-1H(or
2H)-pyrazolo(3,4-g)quinoline. J. Med. Chem.
26:1112-1116.
Valverius P, Hoffman PL, and Tabakoff B. (1987) Effects of
ethanol on mouse cerebral cortical beta-adrenergic
receptors. Mel. Pharmacol. 32:217-222.
Valverius P, Hoffman PL, and Tabakoff B.

(1989) Hippocampal

186
and cerebellular beta-adrenergic receptors and
adenylate cyclase are differentially altered by chronic
ethanol ingestion. J. Neurochem. 52:492-497.
Van Natta P, Malin H, Bertolucci D, and Kaelber C. (1984)
The hidden influence of alcohol on mortality.
Epidemiologic Bulletin No. 6. Alcohol Health and
Research World 9:42-45.
Wang RY. (1981) Dopaminergic neurons in the rat ventral
tegmental area. II. Evidence for autoregulation. Brain
Res. Bull. 3:141-152.
Wolf ME and Roth RH. (1987) Dopamine neurons projecting to
the medial prefrontal cortex passess release-modulating
autoreceptors. Neuropharmacal. 26:1053-1059.
Weiner RI and Ganong WF. (1978) Role of brain monoamines and
histamine in regulation of anterior pituitary
secretion. Physiol. Rev. 58:905-976.
Weiss ER, Kelleher DJ, Woon cw, Soparkar s, Osawa s, Heasley
LE, and Johnson GL. (1988) Receptor activation of G
proteins. FASEB J. 2:2841-2844.
Wessling-Resnick M and Johnson GL. (1987) Allosteric
behavior in transducin activation mediated by
rhodopsin: initial rate analysis of guanine nucleotide
exchange. J. Biol. Chem. 262:3697-3705.
Wessling-Resnick M, Kelleher DJ, Weiss ER, and Johnson GL.
(1987) Enzymatic model for receptor activation of
GTP-binding regulatory proteins. Trends Biochem. Sci.
12:473-477.
Westernik BHC. (1983) Analysis of trace amounts of
catecholamines and related compounds in brain tissue: a
study near the detection limit of liquid chromatography
with electrochemical detection. J. Liquid Chromatogr.
6:2337-2351.
Wetherell JR, Fosbraey P, and French MC. (1989) A comparison
of the distribution of neurotransmitters in brain
regions of the rat and guinea-pig using a
chemiluminescent method and HPLC with electrochemical
detection. J. Neurochem. 53:1519-1526.
White FJ and Wang RY. (1984) AlO dopamine neurons: role of
autoreceptors in determining firing rate and
sensitivity to dopamine agonists. Life Sci. 34:11611170

187
White FJ and Wang RY. (1984) Pharmacological
characterization of dopamine autoreceptors in the rat
ventral tegmental area: microiontophoretic studies. J.
Pharmacol. Exp. Ther. 231:275-280.
White FJ and Wang RY. (1986) Electrophysiological evidence
for the existence of both D-1 and D-2 dopamine
receptors in the rat nucleus accumbens. J. Neurosci.
6:274-280.
Wickens J. (1990) Striatal dopamine in motor activation and
reward-mediated learning: steps towards a unifying
model. J. Neural Transm. 80:9-31.
Yatani A, Codina J, Imoto YI, Reeves JP, Birnbaumer L, and
Brown AM. (1987) A G-protein directly regulates
mammalian cardiac calcium channels. Science
238:1288-1292.
Yatani A, Mattera R, Codina J, Graf R, Okabe K, Padrell E,
Iyengar R, Brown AM, and Birnbaumer L. (1988) The G
protein-gated atrial K+ channel is stimulated by three
distinct Gia-subunits. Nature 336:680-682.
Yeagle PL. (1985) Cholesterol and the cell membrane.
Biochim. Biophys. Acta 822:267-287.
Zarevics P and Setler PE. (1979) Simultaneous
rate-independent and rate-dependent assessment of
intracranial self-stimulation: evidence for the direct
involvement of dopamine in brain reinforcement
mechanisms. Brain Res. 169:499-512.
Zhou Q-Y, Grandy DK, Thambi L, Kushner JA, Van Tol HHM, Cone
R, Pribnow D, Salon J, Bunzow JR, and Civelli o. (1990)
Cloning and expression of human and rat 0 1 dopamine
receptors. Nature 347:76-80.
Zucker RA and Gomberg ESC. (1986) Etiology of alcoholism
reconsidered: the case for a biopsychosocial process.
Am. Psychol. 41:783-793.

VITA

Susan Marie Pellegrino is the daughter of Chris and
Marie Pellegrino. She was born in Landsdowne, PA. Her
primary education was obtained at St. Charles Borromeo in
Drexel Hill, PA and her secondary education was obtained at
Cardinal O'Hara High School in Springfield, PA.
In September 1979, she entered the University of
Scranton in Scranton, PA and graduated May, 1983 with a B.S.
in Biology.
From October 1984 to July 1986,she was employed as a
chemical technician at ARCO Chemical Company in Newtown
Square, PA.
In August, 1986, she entered the Department of
Biochemistry at Loyola University of Chicago, Maywood, IL
with a Basic Science Fellowship from Loyola University.
In December, 1990, she began a postdoctoral fellowship
at the National Institutes of Health, NIAAA Section in
Rockville, MD.

ABSTRACTS
Pellegrino SM and Druse MJ. (1989) Brain D1 receptors in
rats chronically fed ethanol. Research Society of
Alcoholism Meeting. Alcoholism: Clinical and
Experimental Research 13:317.
Druse MJ and Pellegrino SM. (1990) Dopamine 02 receptors in
the nucleus accumbens and striatum of alcohol-fed rats.
Neuroscience Abs. 16:532.
PUBLICATIONS
Pellegrino SM and Druse MJ. The effects of chronic ethanol
exposure on the dopamine receptors in the rat brain.
(In preparation)
Pellegrino SM and Druse MJ. Effects of chronic ethanol
exposure on G proteins and adenylate cyclase activity.
(In preparation)

APPROVAL SHEET
The dissertation submitted by Susan Marie Pellegrino has
been read and approved by the following committee:
Dr. Mary Druse Manteuffel, Ph.D., Director
Professor, Molecular and Cellular Biochemistry
Loyola Stritch School of Medicine
Dr. Michael A. Collins, Ph.D.
Professor, Molecular and Cellular Biochemistry
Loyola stritch School of Medicine
Dr. Mark R. Kelley, Ph.D.
Assistant Professor, Molecular and Cellular
Biochemistry
Loyola Stritch School of Medicine
Dr. T. Celeste Napier, Ph.D.
Assistant Professor, Pharmacology
Loyola Stritch School of Medicine
Dr. George Battaglia, Ph.D.
Assistant Professor, Pharmacology
Loyola Stritch School of Medicine
The final copies have been examined by the director of the
dissertation and the signature which appears below verifies
the fact that any necessary changes have been incorporated
and that the dissertation is now given final approval by the
Committee with reference to content and form.
The dissertation is therefore accepted in partial
fulfillment of the requirements for the degree of Doctor of
Philosophy.
..__/'J!~/?~1-2_ L ,:::!._ '! I~]<!

Date

u

-/"'/JOk..,;--Lj ~U__.a:L "·/"'.Y)2u._.i4:_r..~/;:::~ /-'K_. 3
Director's Signature

.

